U.S. patent application number 12/345871 was filed with the patent office on 2009-05-07 for clostridial neurotoxin compositions and modified clostridial neurotoxins.
This patent application is currently assigned to Allergan, Inc.. Invention is credited to Kei Roger Aoki, Ester Fernandez-Salas, Todd M. Herrington, Lance E. Steward.
Application Number | 20090118475 12/345871 |
Document ID | / |
Family ID | 24487624 |
Filed Date | 2009-05-07 |
United States Patent
Application |
20090118475 |
Kind Code |
A1 |
Steward; Lance E. ; et
al. |
May 7, 2009 |
Clostridial Neurotoxin Compositions and Modified Clostridial
Neurotoxins
Abstract
Natural and modified neurotoxins and isolated neurotoxin
compositions are described. The neurotoxins may include one or more
structural modifications, wherein the structural modification(s)
alters the biological persistence, such as the biological half-life
and/or a biological activity of the modified neurotoxin relative to
an identical neurotoxin without the structural modification(s). In
one embodiment, methods of making the modified neurotoxin include
using recombinant techniques. In some embodiments, methods of using
the modified neurotoxin to treat conditions include treating
various disorders, neuromuscular ailments and pain.
Inventors: |
Steward; Lance E.; (Irvine,
CA) ; Fernandez-Salas; Ester; (Fullerton, CA)
; Herrington; Todd M.; (Brookline, MA) ; Aoki; Kei
Roger; (Coto de Caza, CA) |
Correspondence
Address: |
ALLERGAN, INC.
2525 DUPONT DRIVE, T2-7H
IRVINE
CA
92612-1599
US
|
Assignee: |
Allergan, Inc.
|
Family ID: |
24487624 |
Appl. No.: |
12/345871 |
Filed: |
December 30, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10757077 |
Jan 14, 2004 |
7491799 |
|
|
12345871 |
|
|
|
|
10163106 |
Jun 4, 2002 |
|
|
|
10757077 |
|
|
|
|
09910346 |
Jul 20, 2001 |
|
|
|
10163106 |
|
|
|
|
09620840 |
Jul 21, 2000 |
6903187 |
|
|
09910346 |
|
|
|
|
Current U.S.
Class: |
530/403 |
Current CPC
Class: |
A61K 38/00 20130101;
A61P 25/00 20180101; C07K 14/33 20130101; A61P 5/00 20180101; A61P
25/04 20180101; A61P 1/00 20180101; A61P 21/00 20180101; A61P 29/02
20180101; A61P 27/02 20180101; A61P 37/00 20180101; Y10S 530/825
20130101; A61P 27/00 20180101 |
Class at
Publication: |
530/403 |
International
Class: |
C07K 4/04 20060101
C07K004/04 |
Claims
1. A modified botulinum neurotoxin type A, wherein the modification
is one or more additional amino acid sequences comprising SEQ ID
NO: 27 within the N-terminal 30 amino acids of a wild-type
botulinum toxin type A light chain and one or more additional
leucine-based motifs within the C-terminal 50 amino acids of the
wild-type botulinum toxin type A light chain, wherein the one or
more additional leucine-based motifs is SEQ ID NO: 17, SEQ ID NO:
19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or
any combination thereof, wherein the additional amino acid sequence
comprising SEQ ID NO: 27 increases biological half-life of the
modified botulinum neurotoxin type A relative to an identical
botulinum neurotoxin type A without the additional amino acid
sequence comprising SEQ ID NO: 27, and wherein the additional
leucine-based motif increases biological half-life of the modified
botulinum neurotoxin type A relative to an identical botulinum
neurotoxin type A without the additional leucine-based motif.
2. The modified botulinum neurotoxin type A of claim 2, wherein the
additional leucine-based motif is SEQ ID NO: 2 or SEQ ID NO: 3.
3. The modified botulinum neurotoxin type A of claim 2, wherein the
additional leucine-based motif is SEQ ID NO: 5, SEQ ID NO: 7, SEQ
ID NO: 10, or SEQ ID NO: 12.
4. The modified botulinum neurotoxin type A of claim 2, wherein the
additional leucine-based motif is SEQ ID NO: 8.
5. The modified botulinum neurotoxin type A of claim 2, wherein the
additional leucine-based motif is SEQ ID NO: 9.
6. A modified botulinum neurotoxin type A, wherein the modification
is one or more additional amino acid sequences comprising SEQ ID
NO: 27 within the N-terminal 30 amino acids of a wild-type
botulinum toxin type A light chain and one or more additional
leucine-based motifs of SEQ ID NO: 11 within the C-terminal 50
amino acids of the wild-type botulinum toxin type A light chain,
wherein the additional amino acid sequence comprising SEQ ID NO: 27
increases biological half-life of the modified botulinum neurotoxin
type A relative to an identical botulinum neurotoxin type A without
the additional amino acid sequence comprising SEQ ID NO: 27, and
wherein the additional leucine-based motif of SEQ ID NO: 11
increases biological half-life of the modified botulinum neurotoxin
type A relative to an identical botulinum neurotoxin type A without
the additional leucine-based motif.
Description
CROSS REFERENCE
[0001] This application is a divisional and claims priority
pursuant to 35 U.S.C. 120 to U.S. patent application Ser. No.
10/757,077, filed Jan. 14, 2004, a continuation-in-part of U.S.
patent application Ser. No. 10/163,106, filed Jun. 4, 2003, which
is a continuation-in-part of U.S. patent application Ser. No.
09/910,346, filed Jul. 20, 2001, which is a continuation-in-part of
U.S. patent application Ser. No. 09/620,840, filed Jul. 21, 2000,
now U.S. Pat. No. 6,903,187. All prior applications are
incorporated herein by reference in their entireties.
BACKGROUND
[0002] The present invention relates to modified neurotoxins,
particularly modified Clostridial neurotoxins, and use thereof to
treat various conditions including conditions that have been
treated using naturally occurring botulinum toxins.
[0003] The present invention also relates to a composition
comprising an isolated or purified botulinum toxin light chain (or
a part thereof) and an intracellular structure, such as a component
of a mammalian plasma membrane.
[0004] Botulinum toxin, for example, botulinum toxin type A, has
been used in the treatment of numerous conditions including pain,
skeletal muscle conditions, smooth muscle conditions and glandular
conditions. Botulinum toxins are also used for cosmetic
purposes.
[0005] Numerous examples exist for treatment using botulinum toxin.
For examples of treating pain see Aoki, et al., U.S. Pat. No.
6,113,915 and Aoki, et al., U.S. Pat. No. 5,721,215. For an example
of treating a neuromuscular disorder, see U.S. Pat. No. 5,053,005,
which suggests treating curvature of the juvenile spine, i.e.,
scoliosis, with an acetylcholine release inhibitor, preferably
botulinum toxin A. For the treatment of strabismus with botulinum
toxin type A, see Elston, J. S., et al., British Journal of
Opthalmology, 1985, 69, 718-724 and 891-896. For the treatment of
blepharospasm with botulinum toxin type A, see Adenis, J. P., et
al., J. Fr. Opthalmol., 1990, 13 (5) at pages 259-264. For treating
spasmodic and oromandibular dystonia torticollis, see Jankovic et
al., Neurology, 1987, 37, 616-623. Spasmodic dysphonia has also
been treated with botulinum toxin type A. See Blitzer et al., Ann.
Otol. Rhino. Laryngol, 1985, 94, 591-594. Lingual dystonia was
treated with botulinum toxin type A according to Brin et al., Adv.
Neurol. (1987) 50, 599-608. Cohen et al., Neurology (1987) 37
(Suppl. 1), 123-4, discloses the treatment of writer's cramp with
botulinum toxin type A.
[0006] It would be beneficial to have botulinum toxins with altered
biological persistence and/or altered biological activity. For
example, a botulinum toxin can be used to immobilize muscles and
prevent limb movements after tendon surgery to facilitate recovery.
It would be beneficial to have a botulinum toxin (such as a
botulinum toxin type A) which exhibits a reduced period of
biological persistence so that a patient can regain muscle use and
mobility at about the time they recover from surgery. Furthermore,
a botulinum toxin with an altered biological activity, such as an
enhanced biological activity can have utility as a more efficient
toxin (i.e. more potent per unit amount of toxin), so that less
toxin can be used.
[0007] Additionally, there is a need for modified neurotoxins (such
as modified Clostridial toxins) which can exhibit an enhanced
period of biological persistence and modified neurotoxins (such as
modified Clostridial toxins) with reduced biological persistence
and/or biological activity and methods for preparing such
toxins.
[0008] Furthermore, there is a need for an isolated composition
comprising a botulinum toxin light chain component and an
intracellular structure component wherein the structure component
interacts with the light chain component in a manner effective to
facilitate substrate proteolysis within a cell, since such a
composition can have utility for research, diagnostic and
therapeutic purposes.
DEFINITIONS
[0009] Before proceeding to describe the present invention, the
following definitions are provided and apply herein.
[0010] "Heavy chain" means the heavy chain of a Clostridial
neurotoxin. It has a molecular weight of about 100 kDa and can be
referred to herein as Heavy chain or as H.
[0011] "H.sub.N" means a fragment (having a molecular weight of
about 50 kDa) derived from the Heavy chain of a Clostridial
neurotoxin which is approximately equivalent to the amino terminal
segment of the Heavy chain, or the portion corresponding to that
fragment in the intact Heavy chain. It is believed to contain the
portion of the natural or wild-type Clostridial neurotoxin involved
in the translocation of the light chain across an intracellular
endosomal membrane.
[0012] "H.sub.C" means a fragment (about 50 kDa) derived from the
Heavy chain of a Clostridial neurotoxin which is approximately
equivalent to the carboxyl terminal segment of the Heavy chain, or
the portion corresponding to that fragment in the intact Heavy
chain. It is believed to be immunogenic and to contain the portion
of the natural or wild-type Clostridial neurotoxin involved in high
affinity binding to various neurons (including motor neurons), and
other types of target cells.
[0013] "Light chain" means the light chain of a Clostridial
neurotoxin. It has a molecular weight of about 50 kDa, and can be
referred to as light chain, L or as the proteolytic domain (amino
acid sequence) of a Clostridial neurotoxin. The light chain is
believed to be effective as an inhibitor of exocytosis, including
as an inhibitor of neurotransmitter (i.e. acetylcholine) release
when the light chain is present in the cytoplasm of a target
cell.
[0014] "Neurotoxin" means a molecule that is capable of interfering
with the functions of a cell, including a neuron. The "neurotoxin"
can be naturally occurring or man-made. The interfered with
function can be exocytosis.
[0015] "Modified neurotoxin" means a neurotoxin which includes a
structural modification. In other words, a "modified neurotoxin" is
a neurotoxin which has been modified by a structural modification.
The structural modification changes the biological persistence,
such as the biological half-life (i.e. the duration of action of
the neurotoxin) and/or the biological activity of the modified
neurotoxin relative to the neurotoxin from which the modified
neurotoxin is made or derived. The modified neurotoxin is
structurally different from a naturally existing neurotoxin.
[0016] "Mutation" means a structural modification of a naturally
occurring protein or nucleic acid sequence. For example, in the
case of nucleic acid mutations, a mutation can be a deletion,
addition or substitution of one or more nucleotides in the DNA
sequence. In the case of a protein sequence mutation, the mutation
can be a deletion, addition or substitution of one or more amino
acids in a protein sequence. For example, a specific amino acid
comprising a protein sequence can be substituted for another amino
acid, for example, an amino acid selected from a group which
includes the amino acids alanine, aspargine, cysteine, aspartic
acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine,
lysine, leucine, methionine, proline, glutamine, arginine, serine,
threonine, valine, tryptophan, tyrosine or any other natural or
non-naturally occurring amino acid or chemically modified amino
acids. Mutations to a protein sequence can be the result of
mutations to DNA sequences that when transcribed, and the resulting
mRNA translated, produce the mutated protein sequence. Mutations to
a protein sequence can also be created by fusing a peptide sequence
containing the desired mutation to a desired protein sequence.
[0017] "Structural modification" means any change to a neurotoxin
that makes it physically or chemically different from an identical
neurotoxin without the structural modification.
[0018] "Biological persistence" or "persistence" means the time
duration of interference or influence caused by a neurotoxin or a
modified neurotoxin with a cellular (such as a neuronal) function,
including the temporal duration of an inhibition of exocytosis
(such as exocytosis of neurotransmitter, for example,
acetylcholine) from a cell, such as a neuron.
[0019] "Biological half-life" or "half-life" means the time that
the concentration of a neurotoxin or a modified neurotoxin,
preferably the active portion of the neurotoxin or modified
neurotoxin, for example, the light chain of Clostridial toxins, is
reduced to half of the original concentration in a mammalian cell,
such as in a mammalian neuron.
[0020] "Biological activity" or "activity" means the amount of
cellular exocytosis inhibited from a cell per unit of time, such as
exocytosis of a neurotransmitter from a neuron.
[0021] "Target cell" means a cell (including a neuron) with a
binding affinity for a neurotoxin or for a modified neurotoxin.
[0022] "PURE A" means a purified botulinum toxin type A, that is
the 150 kDa toxin molecule.
SUMMARY
[0023] New structurally modified neurotoxins have been discovered.
The present structurally modified neurotoxins can provide
substantial benefits, for example, enhanced or decreased biological
persistence and/or biological half-life and/or enhanced or
decreased biological activity as compared to the unmodified
neurotoxin.
[0024] In accordance with the present invention, there are provided
structurally modified neurotoxins, which include a neurotoxin and a
structural modification. The structural modification is effective
to alter a biological persistence of the structurally modified
neurotoxin relative to an identical neurotoxin without the
structural modification. Also, the structurally modified neurotoxin
is structurally different from a naturally existing neurotoxin.
[0025] The present invention also encompasses a modified neurotoxin
comprising a neurotoxin with a structural modification, wherein
said structural modification is effective to alter a biological
activity of said modified neurotoxin relative to an identical
neurotoxin without said structural modification, and wherein said
modified neurotoxin is structurally different from a naturally
existing neurotoxin. This structural modification can be effective
to reduce exocytosis from a target cell by more than the amount of
the exocytosis reduced from the target cell by an identical
neurotoxin without said structural modification. Alternately, the
structural modification can be effective to reduce an exocytosis
from a target cell by less than the amount of the exocytosis
reduced from the cell by an identical neurotoxin without said
structural modification. Significantly, the exocytosis can be
exocytosis of a neurotransmitter and the modified neurotoxin can
exhibit an altered biological activity without exhibiting an
altered biological persistence. The structural modification can
comprise a leucine-based motif. Additionally, the modified
neurotoxin can exhibits an altered biological activity as well as
an altered biological persistence. The present invention also
includes the circumstances where: (a) the modified neurotoxin
exhibits an increased biological activity as well as an increased
biological persistence; (b) the modified neurotoxin exhibits an
increased biological activity and a reduced biological persistence;
(c) the modified neurotoxin exhibits a decreased biological
activity and a decreased biological persistence, and; (d) the
modified neurotoxin exhibits an decreased biological activity and
an increased biological persistence.
[0026] Importantly, a unit amount (i.e. on a molar basis) of the
modified neurotoxin can be more efficient to reduce an exocytosis
from a cell than is a unit amount of the naturally existing
neurotoxin. In other words, a unit amount of a modified neurotoxin,
such as a modified botulinum toxin type A, can cleave its'
intracellular substrate (SNAP) in a manner such that a greater
inhibition of neurotransmitter exocytosis results (i.e. less
neurotransmitter is released from the cell), as compared to the
inhibition of neurotransmitter exocytosis exhibited by the
naturally occurring neurotoxin.
[0027] Further in accordance with the present invention, are
structurally modified neurotoxins, wherein a structural
modification is effective to enhance a biological persistence of
the modified neurotoxin. The enhanced biological persistence of the
structurally modified neurotoxin can be due, at least in part, to
an increased half-life and/or biological activity of the
structurally modified neurotoxin.
[0028] Still further in accordance with the present invention,
there are provided structurally modified neurotoxins wherein a
biological persistence of the structurally modified neurotoxin is
reduced relative to that of an identical neurotoxin without the
structural modification. This reduction in biological persistence
can be due, at least in part, to a decreased biological half-life
and/or activity of the structurally modified neurotoxins.
[0029] Still further in accordance with the present invention,
there are provided structurally modified neurotoxins wherein the
structural modification comprises a number of amino acids. For
example, the number of amino acids comprising the structural
modification can be 1 or more amino acids, from 1 to about 22 amino
acids, from 2 to about 10 amino acids, and from about 4 to about 7
amino acids.
[0030] In one embodiment, the structural modifications of the
structurally modified neurotoxins can comprise an amino acid. The
amino acid can comprise an R group containing a number of carbons.
For example, the number of carbon atoms in the amino acid can be 1
or more, from 1 to about 20 carbons, from 1 to about 12 carbons,
from 1 to about 9 carbons, from 2 to about 6 carbons, and about 4
carbons. R group as used in this application refers to amino acid
side chains. For example, the R group for alanine is CH.sub.3, and,
for example, the R group for serine is CH.sub.2OH.
[0031] In some embodiments, there are provided structurally
modified neurotoxins wherein the modification comprises an amino
acid. The amino acid can comprise an R group which is substantially
hydrocarbyl.
[0032] In still another embodiment, there are provided structurally
modified neurotoxins wherein the structural modification comprises
an amino acid. The amino acid further can comprise an R group that
includes at least one heteroatom.
[0033] Further in accordance with the present invention, there are
provided structurally modified neurotoxins wherein the structural
modification comprises, for example, a leucine-based motif, a
tyrosine-based motif, and/or an amino acid derivative. Examples of
an amino acid derivative that can comprise a structurally modified
neurotoxin are a myristylated amino acid, an N-glycosylated amino
acid, and a phosphorylated amino acid. The phosphorylated amino
acids can be phosphorylated by, for example, casein kinase II,
protein kinase C, and tyrosine kinase.
[0034] Still further in accordance with the present invention,
there are provided structurally modified neurotoxins which can
include a structural modification. The neurotoxin can comprise
three amino acid sequence regions. The first region can be
effective as a cellular binding moiety. This binding moiety can be
a binding moiety for a target cell, such as a neuron. The binding
moiety can be the carboxyl terminus of a botulinum toxin heavy
chain. It is well known that the carboxyl terminus of a botulinum
toxin heavy chain can be effective to bind, for example, receptors
found on certain cells, including certain nerve cells. In one
embodiment, the carboxyl terminus binds to receptors found on a
presynaptic membrane of a nerve cell. The second region can be
effective to translocate a structurally modified neurotoxin, or a
part of a structurally modified neurotoxin across an endosome
membrane. The third region can be effective to inhibit exocytosis
from a target cell. The inhibition of exocytosis can be inhibition
of neurotransmitter release, such as acetylcholine from a
presynaptic membrane. For example, it is well known that the
botulinum toxin light chain is effective to inhibit, for example,
acetylcholine (as well as other neurotransmitters) release from
various neuronal and non-neuronal cells.
[0035] At least one of the first, second or third regions can be
substantially derived from a Clostridial neurotoxin. The third
region can include the structural modification. In addition, the
modified neurotoxin can be structurally different from a naturally
existing neurotoxin. Also, the structural modification can be
effective to alter a biological persistence of the modified
neurotoxin relative to an identical neurotoxin without the
structural modification.
[0036] In one embodiment, there are provided structurally modified
neurotoxins, wherein the neurotoxin can be botulinum serotype A, B,
C.sub.1, C.sub.2, D, E, F, G, tetanus toxin and/or mixtures
thereof.
[0037] In some embodiments, there are provided structurally
modified neurotoxins where the third region can be derived from
botulinum toxin serotype A. In addition, there are provided
structurally modified neurotoxins wherein the third region cannot
be derived from botulinum serotype A.
[0038] In still another embodiment, there are provided structurally
modified neurotoxins wherein the structural modification includes a
biological persistence enhancing component effective to enhance the
biological persistence of the structurally modified neurotoxin. The
enhancing of the biological persistence can be at least in part due
to an increase in biological half-life and/or activity of the
structurally modified neurotoxin.
[0039] Further in accordance with the present invention, there are
provided structurally modified neurotoxins comprising a biological
persistence enhancing component, wherein the biological persistence
enhancing component can comprise a leucine-based motif. The
leucine-based motif can comprise a run of 7 amino acids, where a
quintet of amino acids and a duplet of amino acids can comprise the
leucine-based motif. The quintet of amino acids can define the
amino terminal end of the leucine-based motif. The duplet of amino
acids can define the carboxyl end of the leucine-based motif. There
are provided structurally modified neurotoxins wherein the quintet
of amino acids can comprise one or more acidic amino acids. For
example, the acidic amino acid can be glutamate or aspartate. The
quintet of amino acids can comprise a hydroxyl containing amino
acid. The hydroxyl containing amino acid can be, for example, a
serine, a threonine or a tyrosine. This hydroxyl containing amino
acid can be phosphorylated. At least one amino acid comprising the
duplet of amino acids can be a leucine, isoleucine, methionine,
alanine, phenylalanine, tryptophan, valine or tyrosine. In
addition, the duplet of amino acids in the leucine-based motif can
be leucine-leucine, leucine-isoleucine, isoleucine-leucine or
isoleucine-isoleucine, leucine-methionine. The leucine-based motif
can be an amino acid sequence of
phenylalanine-glutamate-phenylalanine-tyrosine-lysine-leucine-leucine.
[0040] In one embodiment, there are provided structurally modified
neurotoxins wherein the modification can be a tyrosine-based motif.
The tyrosine-based motif can comprise four amino acids. The amino
acid at the N-terminal end of the tyrosine-based motif can be a
tyrosine. The amino acid at the C-terminal end of the
tyrosine-based motif can be a hydrophobic amino acid.
[0041] Further in accordance with the present invention, the third
region can be derived from botulinum toxin serotype A or form one
of the other botulinum toxin serotypes.
[0042] Still further in accordance with the present invention,
there are provided structurally modified neurotoxins where the
biological persistence of the structurally modified neurotoxin can
be reduced relative to an identical neurotoxin without the
structural modification. The reduced biological persistence can be
in part due a decreased biological half-life and/or to a decrease
biological activity of the neurotoxin.
[0043] In one embodiment, there are provided structurally modified
neurotoxins, where the structural modification can include a
leucine-based motif with a mutation of one or more amino acids
comprising the leucine-based motif. The mutation can be a deletion
or substitution of one or more amino acids of the leucine-based
motif.
[0044] In some embodiments, there are provided structurally
modified neurotoxins, where the structural modification includes a
tyrosine-based motif with a mutation of one or more amino acids
comprising the tyrosine-based motif. For example, the mutation can
be a deletion or substitution of one or more amino acids of the
tyrosine-based motif.
[0045] In still another embodiment, there are provided structurally
modified neurotoxins, wherein the structural modification comprises
an amino acid derivative with a mutation of the amino acid
derivative or a mutation to a nucleotide or amino acid sequence
which codes for the derivativization of the amino acid. For
example, a deletion or substitution of the derivatized amino acid
or a nucleotide or amino acid sequence responsible for a
derivatization of the derivatized amino acid. The amino acid
derivative can be, for example, a myristylated amino acid, an
N-glycosylated amino acid, or a phosphorylated amino acid. The
phosphorylated amino acid can be produced by, for example, casein
kinase II, protein kinase C or tyrosine kinase.
[0046] In one embodiment of the present invention, there are
provided structurally modified neurotoxins, wherein the first,
second and/or third regions of the structurally modified
neurotoxins can be produced by recombinant DNA methodologies, i.e.
produced recombinantly.
[0047] In some embodiments of the present invention, there are
provided structurally modified neurotoxins, wherein the first,
second and/or third region of the neurotoxin is isolated from a
naturally existing Clostridial neurotoxin.
[0048] Another embodiment of the present invention provides a
modified neurotoxin comprising a botulinum toxin (such as a
botulinum toxin type A) which includes a structural modification
which is effective to alter a biological persistence of the
modified neurotoxin relative to an identical neurotoxin without the
structural modification. The structural modification can comprise a
deletion of amino acids 416 to 437 from a light chain of the
neurotoxin of SEQ ID NO: 29.
[0049] In still another embodiment of the present invention there
is provided a modified neurotoxin (such as a botulinum toxin type
A) which includes a structural modification which is effective to
alter a biological persistence of the modified neurotoxin relative
to an identical neurotoxin without the structural modification. The
structural modification can comprise a deletion of amino acids 1 to
8 from a light chain of the neurotoxin of SEQ ID NO: 29.
[0050] Still further in accordance with the present invention there
is provided a modified neurotoxin, such as a botulinum toxin type
A, which includes a structural modification which is effective to
alter a biological persistence of the modified neurotoxin relative
to an identical neurotoxin without the structural modification. The
structural modification may comprise, for example, a deletion of 2
or more amino acids from 1 to 20 and a deletion of 2 or more amino
acids from 398 to 437 from a light chain of the neurotoxin of SEQ
ID NO: 29. In one embodiment, the structural modification comprises
a deletion of amino acids 1 to 8 and 416 to 437 from a light chain
of the neurotoxin of SEQ ID NO: 29. In some embodiments, the
structural modification comprises a deletion of amino acids 1 to 9
and 416 to 437 from a light chain of the neurotoxin of SEQ ID NO:
29. With regard to deletion on either the 1-8 or 1-9 amino acids;
after synthesis the initial Methionine (M) of, for example, BoNT/A
is apparently posttranslationally removed within Clostridia. Amino
acids 1-8 do not include the initial Met residue. If one includes
the initial Met residue, then amino acids 1-9 are removed. Of
course a recombinant toxin would need a Met residue incorporated to
start protein synthesis. It may or may not be removed following
synthesis.
[0051] For example, a native synthesized BoNT/A can comprise:
MPFVNKQFNYKD (SEQ ID NO: 14), whereas a native processed BoNT/A can
comprise PFVNKQFNYKD (SEQ ID NO: 15). Thus a proposed 8 amino acid
deletion of SEQ ID NO: 27 would retain the YKD amino acid residues,
while a recombinantly produced deletion would retain the amino acid
residues NYKD at position numbers 9-12 of SEQ ID NO: 14.
[0052] Still further in accordance with the present invention,
there is provided a modified botulinum toxin, such as a modified
botulinum toxin type A, which includes a structural modification
effective to alter a biological persistence of the modified
neurotoxin relative to an identical neurotoxin without said
structural modification. The structural modification can comprise a
substitution of leucine at position 427 for an alanine and a
substitution of leucine at position 428 for an alanine in a light
chain of said neurotoxin of SEQ ID NO: 29.
[0053] Additionally, the scope of the present invention also
includes methods for enhancing the biological persistence and/or or
for enhancing the biological activity of a neurotoxin. In these
methods, a structural modification can be fused or added to the
neurotoxin, for example, the structural modification can be a
biological persistence enhancing component and/or a biological
activity enhancing component. Examples of structural modifications
that can be fused or added to the neurotoxin are a leucine-based
motif, a tyrosine-based motif and an amino acid derivative.
Examples of amino acid derivatives are a myristylated amino acid,
an N-glycosylated amino acid, and a phosphorylated amino acid. An
amino acid can be phosphorylated by, for example, protein kinase C,
caseine kinase II or tyrosine kinase.
[0054] Also in accordance with the present invention, there are
provided methods for reducing the biological persistence and/or for
reducing the biological activity of a neurotoxin. These methods can
comprise a step of mutating an amino acid of the neurotoxin. For
example, an amino acid of a leucine-based motif within the
neurotoxin can be mutated. Also, for example, one or more amino
acids within a tyrosine-based motif of the neurotoxin can be
mutated. Also, for example, an amino acid derivative for DNA or
amino acid sequence responsible for the derivatization of the amino
acid can be mutated. The derivatized amino acid can be a
myristylated amino acid, a N-glycosylated amino acid, or a
phosphorylated amino acid. The phosphorylated amino acid can be
produced by, for example, protein kinase C, caseine kinase II and
tyrosine kinase. These mutations can be, for example, amino acid
deletions or amino acids substitutions.
[0055] The present invention also includes methods for treating a
condition. The methods can comprise a step of administering an
effective dose of a structurally modified neurotoxin to a mammal to
treat a condition. The structurally modified neurotoxin can include
a structural modification. The structural modification is effective
to alter the biological persistence and/or the biological activity
of the neurotoxin. These methods for treating a condition can
utilize a neurotoxin that does not comprise a leucine-based motif.
Also, these methods for treating a condition can utilize a
neurotoxin, which includes a biological persistence enhancing
component and/or a biological activity enhancing component. The
biological persistence or activity enhancing component can
comprise, for example, a tyrosine-based motif, a leucine-based
motif or an amino acid derivative. The amino acid derivative can
be, for example, a myristylated amino acid, an N-glycosylated amino
acid or a phosphorylated amino acid. The phosphorylated amino acid
can be produced by, for example, protein kinase C, caseine kinase
II or tyrosine kinase. The condition treated can be a neuromuscular
disorder, an autonomic disorder or pain. The treatment of a
neuromuscular disorder can comprise a step of locally administering
an effective amount of a modified neurotoxin to a muscle or a group
of muscles. A method for treating an autonomic disorder can
comprise a step of locally administering an effective amount of a
modified neurotoxin to a gland or glands. A method for treating
pain can comprise a step of administering an effective amount of a
modified neurotoxin to the site of the pain. In addition, the
treatment of pain can comprise a step of administering an effective
amount of a modified neurotoxin to the spinal cord.
[0056] Still further in accordance with the present invention,
there are provided compositions and methods for treating with
modified neurotoxins conditions including spasmodic dysphonia,
laryngeal dystonia, oromandibular dysphonia, lingual dystonia,
cervical dystonia, focal hand dystonia, blepharospasm, strabismus,
hemifacial spasm, eyelid disorder, cerebral palsy, focal
spasticity, spasmodic colitis, neurogenic bladder, anismus, limb
spasticity, tics, tremors, bruxism, anal fissure, achalasia,
dysphagia, lacrimation, hyperhydrosis, excessive salivation,
excessive gastrointestinal secretions, pain from muscle spasms,
headache pain, brow furrows and skin wrinkles.
[0057] The present invention also provides for isolated
compositions which include a botulinum toxin light chain component
and an intracellular structure component. The structure component
interacts with the light chain component in a manner effective to
facilitate or alter substrate proteolysis within a cell. Such a
composition can have utility for research, diagnostic and
therapeutic purposes. It is believed that toxin light chain
localization is important for maintenance of the intracellular
activity of, at least, the LC of BoNT. Thus, it is believed that an
intracellular localization is an important factor in the long
biological half life of LC/A. For example, our invention indicates
that LC/A may be localized to the intracellular plasma membrane.
Our experiments indicate that the LC/A may not be actually inserted
into the plasma membrane, but may be instead directly associated
with proteins that reside at or near the plasma membrane.
[0058] Also provided are methods of producing an isolated
composition comprising a botulinum toxin light chain component and
an intracellular structure component wherein the structure
component interacts with the light chain component in a manner
effective to facilitate substrate proteolysis within a cell. The
methods may include the steps of: 1) interacting a botulinum toxin
light chain component with an intracellular structure component at
conditions effective to facilitate proteolysis of a substrate
within a cell; and 2) isolating the composition. Compositions which
include a modified botulinum toxin light chain and a structure
component may be isolated by these methods as well.
[0059] In one embodiment, the light chain component is a type A
toxin light chain component and the intracellular structure
component is a plasma membrane, for example a plasma membrane of a
mammalian cell.
[0060] In some embodiments, the light chain component is a type B
toxin light chain component and the intracellular structure
includes a cytoplasm component. The cytoplasm component may include
mitochondria, nucleus, endoplasmic reticulum, golgi apparatus,
lysosomes or secretory vesicles or combination thereof. The
cytoplasm component may include any portion of an organelle, for
example, the membrane of an organelle. Further, the cytoplasm
component may also include any substance which is included inside a
cell. In one embodiment, the cytoplasm component is from a
mammalian cell.
[0061] The structure component of the present invention may include
a cell membrane. The cell membrane may be a plasma membrane, for
example, a plasma membrane of a mammalian cell.
[0062] The structure component may include a protein complex. In
one embodiment, the protein complex includes a light chain
component. A protein complex may also include a substrate of the
light chain. In one embodiment, the substrate is an intracellular
component involved in exocytosis. For example, the substrate may be
SNAP-25. A protein complex may be between about 100 kDa and about
1000 kDa or more. In one embodiment, the protein complex is between
about 100 kDa and about 400 kDa. For example, the protein complex
may be about 110 kDa, about 140 kDa or about 170 kDa.
[0063] Our invention also includes an isolated composition
comprising a botulinum toxin light chain component and an
intracellular structure component wherein the structure component
interacts with the light chain component in a manner effective to
facilitate substrate proteolysis within a cell, where the light
chain component comprises a C-terminal portion of a botulinum toxin
light chain. Thus, our invention encompasses what can be referred
to as a "swapping of tails". For example our invention encompasses
a chimeric toxin protein where the C-terminal tail of LC/A and LC/E
are swapped or changed. Also included within the scope of our
invention is a modified or chimeric toxin molecule wherein the
N-terminus of the LC of one botulinum toxin serotype are swapped or
exchanged for the N-terminus of the LC of another botulinum toxin
serotype.
[0064] Without wishing to be bound by theory, it can be
hypothesized that toxin LC localization can provide a protective
role (i.e. protective from cellular proteases) and thereby provide
the LC of, for example, BoNT/A with it's extended duration of
action.
[0065] It is conceivable that a modified toxin could be cytosolic
with full enzymatic activity, and only the duration of action is
modified. Our invention encompasses a cytoplasmic botulinum toxin
light chain that does not interact with a intracellular structure
component. For example, upon removal of the targeting sequence of
BoNT/A it can accumulate in the cytosol and exhibit a shorter
duration of action, and not interact with an intracellular
structure component in a specific manner.
[0066] Thus, the presence of localizing signals and interaction
with cellular partners can be important for sequestration of LC/A
from cellular proteases. In this manner, sequestration or
protection of the LC may be responsible for the long duration of
action of BoNT/A by protection of the LC potentially extending the
enzymatic activity beyond that of a LC lacking any localization or
interacting signals.
[0067] In the present compositions, the light chain component may
include the light chain of botulinum toxin type A, B, C, D, E, F or
G or a portion thereof or a modified light chain thereof. In one
embodiment, the light chain component comprises a C-terminal
portion of a botulinum toxin light chain.
[0068] In one embodiment, a modified light chain is a light chain
with an added biological activity- or biological
persistence-enhancing component effective to enhance the
proteolytic activity of the light chain. For example, the enhancing
component may include a leucine based motif of SEQ ID No: 1.
[0069] In some embodiments, a modified light chain component is a
light chain with a mutation to one or more amino acids included in
the light chain to reduce the proteolytic activity of the light
chain. For example, the mutation may be in a biological
activity/persistence enhancing component of the light chain, for
example, in a leucine based motif of SEQ ID No: 1.
[0070] Any combination of features described herein are included
within the scope of the present invention provided that the
features included in any such combination are not mutually
inconsistent as will be apparent from the context, this
specification, and the knowledge of one of ordinary skill in the
art.
[0071] Additional advantages and aspects of the present invention
are apparent in the following detailed description and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0072] FIG. 1 shows localization of GFP-botulinum toxin A light
chain in (nerve growth factor) NGF-differentiated live PC12 cells
visualized on a fluorescence inverted microscope. The arrow
indicates that GFP-botulinum toxin A light chain localizes to the
plasma membrane.
[0073] FIG. 2 shows the localization of GFP-truncated botulinum
toxin A light chain in NGF-differentiated live PC12 cells
visualized on a fluorescence inverted microscope. The arrow
indicates that GFP-truncated botulinum toxin A light chain
localizes to punctate bodies inside the cytoplasm.
[0074] FIG. 3 shows the amino acid sequence for botulinum type A
light chain. The amino acid sequence of SEQ ID NO: 29 shown, minus
the underlined amino acids represents botulinum type A truncated
light chain. The overline labeled .DELTA.N8 indicates the eight
amino acids deleted from the amino terminus of the light chain, the
overline labeled .DELTA.C22 indicates the 22 amino acids deleted
from the carboxy terminus of the light chain. The double underline
indicates the leucine-based motif and the dotted lines indicate
tyrosine-based motifs.
[0075] FIG. 4 shows the localization of GFP-botulinum toxin A light
chain with LL to AA mutation at position 427 and 428 in
NGF-differentiated live PC12 cells visualized on a fluorescence
inverted microscope. The arrow indicates that GFP-botulinum toxin A
light chain with LL to AA mutation localizes to punctate bodies
inside the cytoplasm.
[0076] FIG. 5 shows localization of fluorescently labeled
anti-SNAP-25 visualized in horizontal confocal sections of
staurosporine-differentiated PC12 cells.
[0077] FIG. 6 shows an x-ray crystalographic structure of botulinum
toxin type A. The arrow indicates that SNAP-25 localizes to the
plasma membrane.
[0078] FIG. 7 shows localization of GFP-botulinum type B neurotoxin
light chain in NGF-differentiated live PC12 cells visualized on a
fluorescence inverted microscope. The arrow indicates that
GFP-botulinum toxin B light chain localizes to punctate bodies
inside the cytoplasm.
[0079] FIG. 8 shows sequence alignment and consensus sequence for
botulinum toxin type A Hall A light chain of SEQ ID NO: 29 and
botulinum toxin type B Danish I light chain of SEQ ID NO: 30.
[0080] FIG. 9 is a graph which illustrates the results of an in
vitro ELISA assay carried out by the inventors demonstrating that a
truncated LC/A in vitro cleaves substrate at a slower rate or less
efficiently than does non-truncated LC/A.
[0081] FIG. 10 shows a comparison of LC/A constructs expressed from
E. coli for in vitro analysis. The LC/A (WT) sequences shown are
amino acids 2-14 of SEQ ID NO: 29 (Amino terminus) and amino acids
412-438 of SEQ ID NO: 29 (Carboxyl Terminus). The LC/A
(.DELTA.N8/.DELTA.C22) sequences shown are SEQ ID NO: 25 (Amino
terminus) and SEQ ID NO: 26 (Carboxyl Terminus). The N-His LC/A
(WT) sequences shown are SEQ ID NO: 148 (Amino terminus) and amino
acids 412-438 of SEQ ID NO: 29 (Carboxyl Terminus).
[0082] FIG. 11 shows a ribbon diagram of LC/A with a Connolly
surface overlay. The coordinates were extracted from the holotoxin
x-ray structure (Protein Data Bank accession I.D. 3BTA) from Lacy
et al., Nat. Struct. Biol., 5, 898 (1998). Residues 1-430 are shown
in the structure, the 8 C-terminal amino acids were not resolved in
the holotoxin structure.
[0083] FIG. 12 shows the detection of GFP-LC fusion proteins
expressed in differentiated PC12 cells by western blot.
[0084] FIG. 13 is a western blot showing GFP-LC activity.
[0085] FIG. 14 shows the E. coli recombinant constructs for
expression of rLC/A and mutants.
[0086] FIG. 15 shows a SNAP-25 ELISA assay data showing in vitro
activity of E. coli expressed rLC/A and mutants.
[0087] FIG. 16 shows localization of GFP-LC/A at the plasma
membrane of PC12 cells by confocal microscopy. Images are from
slices at approximately the middle of the cell.
[0088] FIG. 17 shows PC12 cells transfected with plasmids encoding
GFP-LCA(.DELTA.N/.DELTA.C) and LCA(.DELTA.N/.DELTA.C)-GFP. The N-
and C-terminal truncated form of LC/A may be localized to an
internal structure or accumulated within the cell rather than at
the plasma membrane. Confocal microscope images are taken from
slices at approximately the middle of the cell.
[0089] FIG. 18. shows confocal images of GFP-LCA(LL-->AA)
expressed in PC12 cells. This construct shows a mixed pattern of
localization. Some cells seem to have protein localized to the
plasma membrane as well as the cytosol, other cells have primarily
cytosolic protein, while others are localized to near the plasma
membrane, but in a much more diffuse manner than GFP-LC/A (similar
to other reported dileucine mutants).
[0090] FIG. 19 shows the expression of transfected light chains in
differentiated PC12 cells.
[0091] FIG. 20 shows activity assessed by western blot of the
lysate of transfected cells. FIG. 20A shows the presence of the
SNAP-25.sub.197 BoNT/A cleavage product in lysates containing
GFP-LCA and GFP+LCA, but not GFP alone. FIG. 20B shows the presence
of the SNAP-25.sub.180 BoNT/E cleavage product in lysates
containing GFP-LCE, but not GFP alone.
[0092] FIG. 21 shows that light chain A localizes to the plasma
membrane. The top panel shows that GFP alone exhibits a diffuse
cytoplasmic localization. However, the bottom panel shows that
GFP-botulinum toxin A light chain localizes to the plasma
membrane.
[0093] FIG. 22 shows that light chain B localizes in the cytoplasm.
The top panel shows that GFP-botulinum toxin B light chain exhibits
a diffuse cytoplasmic localization. The bottom panel shows that
botulinum toxin B light chain-GFP localizes to punctate bodies
inside the cytoplasm.
[0094] FIG. 23 shows that Light Chain E also localizes primarily in
the cytoplasm. The top panel shows that GFP-botulinum toxin E light
chain exhibits a semi-diffuse cytoplasmic localization. The bottom
panel shows that botulinum toxin B light chain-GFP exhibits a
diffuse cytoplasmic localization.
[0095] FIG. 24 shows that expressed LCs inhibit exocytosis.
[0096] FIG. 25 shows localization of GFP in HeLa and HEK293T
cells.
[0097] FIG. 26 shows detection of GFP-LC fusion proteins expressed
in HeLa cells.
[0098] FIG. 27 shows localization of Light Chains in HeLa is
similar to PC12 Cells. The panel on the left shows that
GFP-botulinum toxin A light chain localizes to the plasma membrane.
The middle panel shows that GFP-botulinum toxin B light chain
exhibits a diffuse cytoplasmic localization. The panel on the right
shows that GFP-botulinum toxin E light chain exhibits a
semi-diffuse cytoplasmic localization.
[0099] FIG. 28 shows the detection of GFP-LC fusion proteins
expressed in HEK 293T cells.
[0100] FIG. 29 shows HEK293T cells transfected with plasmids
encoding GFP-LCA, GFP-LCE, GFP-LCB, and LCB-GFP. The panel on the
left shows that GFP-botulinum toxin A light chain localizes to the
plasma membrane. The middle panel shows that GFP-botulinum toxin B
light chain exhibits a diffuse cytoplasmic localization. The panel
on the right shows that GFP-botulinum toxin E light chain exhibits
a semi-diffuse cytoplasmic localization.
[0101] FIG. 30 shows western blots probed with a polyclonal
antibody to LCA to determine the size of the complex containing
GFP-LCA. PC-12 cells were treated with DPBT prior to lysis and the
samples were immunoprecipitated using a monoclonal antibody for
GFP. The western blot of the samples separated under reducing
conditions shows a 80 kDa protein corresponding to GFP-LCA (FIG.
30A). FIG. 30B shows the western blot of immunoprecipitated samples
separated under non-reducing conditions leaving the cross linking
agent uncleaved. Three different sized protein complexes containing
GFP-LCA were detected. The 120 kDa protein is not completely
defined. The 80 kDa protein is GFP-LCA.
[0102] FIG. 31 shows western Blots probed with a polyclonal
antibody to SNAP-25 to determine if the immuno-precipitated protein
complexes containing GFP-LCA (FIG. 30) also contain SNAP-25. FIG.
31A shows the western blot of the samples separated under reduced
conditions. A 25 kDa protein is detected in the GFP-LCA sample
corresponding to SNAP-25. FIG. 31B shows the western blot of
samples separated under non-reducing conditions. The three protein
bands detected with the antibody for SNAP-25 were detected with the
antibody for LCA. These data indicate LCA forms a complex with
SNAP-25 when transfected into PC-12 cells.
[0103] FIG. 32 is a graph showing the % of norepinephrine released
from PC-12 cells when placed in buffers containing various
concentrations of Ca.sup.2+/K.sup.+. The cells were untreated
(control), electroporated, or electroporated in the presence of 500
nM PURE-A (electroporation/Pure A). Norepinephrine secretion was
lower in PC-12 cells electroporated with 500 nM PURE-A. These
results indicate an inhibition of PC-12 exocytosis caused by BoNT-A
can be detected. The Y-axis shows the % of norepinephrine
released.
[0104] FIG. 33 is a graph showing the % norepinephrine released
from PC-12 cells exposed to 500 nM PURE A for up to three days.
Exocytosis was measured in cells placed in buffer containing 100 mM
KCl without (light shaded bar) or with 2.2 mM CaCl.sub.2 (Dark
Shaded Bar). Exposure to 500 nM PURE A for up to three days has no
effect on exocytosis by PC-12 cells. The Y-axis shows the % of
norepinephrine released.
[0105] FIG. 34 is a graph showing the % norepinephrine released
from PC-12 cells transfected with various plasmid constructs
containing GFP and light chain fusion proteins. Exocytosis was
measured in cells placed in buffer containing 100 mM KCl without
(light shaded bar) or with 2.2 mM CaCl.sub.2 (dark shaded bar). The
constructs containing the light chain inhibited exocytosis when
expressed in PC-12 cells. The Y-axis shows the % of norepinephrine
released.
[0106] FIG. 35. is a graph showing the amount of insulin secreted
by HIT-T15 cells placed in media containing high (25.2 mM) and low
concentrations (5.6 mM) of glucose. The cells were untreated
(control), electroporated, or electroporated in the presence of 500
nM PURE-A (electroporation/Pure A). PURE-A inhibited insulin
secretion in electroporated HIT-T15 cells. The Y-axis shows the
insulin released in ng/100,000 cells/hr.
[0107] FIG. 36 shows a western blot of a cell lysate of HIT-T15
cell treated with PURE A. The blot was probed with a polyclonal
antibody for the cleaved SNAP-25 produced by BoNT-A
(SNAP-25.sub.197). The cells were untreated (control)-lane 1,
electroporated-lane 2, or electroporated in the presence of 500 nM
PURE-A (electroporation/Pure A)-lane 3.
[0108] FIG. 37 is a graph showing the amount of insulin released
from HIT-T15 cells transfected with various plasmid constructs
containing GFP and light chain fusion proteins. Exocytosis was
measured in cells placed in media containing 5.6 mM glucose (light
shaded bar) or 25.6 mM glucose (dark shaded bar). The constructs
containing the light chain inhibited exocytosis when expressed in
PC-12 cells. The Y-axis shows the insulin released in ng/1,000,000
cells/hr.
DETAILED DESCRIPTION
[0109] The present invention is based upon the discovery that the
biological persistence and/or the biological activity of a
neurotoxin can be altered by structurally modifying the neurotoxin.
In other words, a modified neurotoxin with an altered biological
persistence and/or biological activity can be formed from a
neurotoxin containing or including a structural modification. In
one embodiment, the structural modification includes the fusing of
a biological persistence enhancing component to the primary
structure of a neurotoxin to enhance its biological persistence. In
a suitable embodiment, the biological persistence enhancing
component is a leucine-based motif. Even more preferably, the
biological half-life and/or the biological activity of the modified
neurotoxin is enhanced by about 100%. Generally speaking, the
modified neurotoxin has a biological persistence of about 20% to
300% more than an identical neurotoxin without the structural
modification. That is, for example, the modified neurotoxin
including the biological persistence enhancing component is able to
cause a substantial inhibition of neurotransmitter release for
example, acetylcholine from a nerve terminal for about 20% to about
300% longer than a neurotoxin that is not modified.
[0110] The present invention also includes within its scope a
modified neurotoxin with a biological activity altered as compared
to the biological activity of the native or unmodified neurotoxin.
For example, the modified neurotoxin can exhibit a reduced or an
enhanced inhibition of exocytosis (such as exocytosis of a
neurotransmitter) from a target cell with or without any alteration
in the biological persistence of the modified neurotoxin.
[0111] In a broad embodiment of the present invention, a
leucine-based motif is a run of seven amino acids. The run is
organized into two groups. The first five amino acids starting from
the amino terminal of the leucine-based motif form a "quintet of
amino acids." The two amino acids immediately following the quintet
of amino acids form a "duplet of amino acids." In a suitable
embodiment, the duplet of amino acids is located at the carboxyl
terminal region of the leucine-based motif. In a suitable
embodiment, the quintet of amino acids includes at least one acidic
amino acid selected from a group consisting of a glutamate and an
aspartate.
[0112] The duplet of amino acid includes at least one hydrophobic
amino acid, for example leucine, isoleucine, methionine, alanine,
phenylalanine, tryptophan, valine or tyrosine. Preferably, the
duplet of amino acid is a leucine-leucine, a leucine-isoleucine, an
isoleucine-leucine or an isoleucine-isoleucine, leucine-methionine.
Even more preferably, the duplet is a leucine-leucine.
[0113] In one embodiment, the leucine-based motif is xDxxxLL (SEQ
ID NO: 17), wherein x can be any amino acids. In another
embodiment, the leucine-based motif is xExxxLL (SEQ ID NO: 18),
wherein E is glutamic acid. In another embodiment, the duplet of
amino acids can include an isoleucine or a methionine, forming
xDxxxLI (SEQ ID NO: 19) or xDxxxLM (SEQ ID NO: 20), respectively.
Additionally, the aspartic acid, D, can be replaced by a glutamic
acid, E, to form xExxxLI (SEQ ID NO: 21), xExxxIL (SEQ ID NO: 22)
and xExxxLM (SEQ ID NO: 23). In a preferred embodiment, the
leucine-based motif is
phenylalanine-glutamate-phenylalanine-tyrosine-lysine-leucine-leucine,
SEQ ID NO: 1.
[0114] In some embodiments, the quintet of amino acids comprises at
least one hydroxyl containing amino acid, for example, a serine, a
threonine or a tyrosine. Preferably, the hydroxyl containing amino
acid can be phosphorylated. More preferably, the hydroxyl
containing amino acid is a serine which can be phosphorylated to
allow for the binding of adapter proteins.
[0115] Although non-modified amino acids are provided as examples,
a modified amino acid is also contemplated to be within the scope
of this invention. For example, leucine-based motif can include a
halogenated, preferably, fluorinated leucine.
[0116] Various leucine-based motif are found in various species. A
list of possible leucine-based motif derived from the various
species that can be used in accordance with this invention is shown
in Table 1. This list is not intended to be limiting.
TABLE-US-00001 TABLE 1 Species Sequence SEQ ID NO: Botulinum type A
FEFYKLL 1 Rat VMAT1 EEKRAIL 2 Rat VMAT2 EEKMAIL 3 Rat VAChT SERDVLL
4 Rat .delta. VDTQVLL 5 Mouse .delta. AEVQALL 6 Frog
.gamma./.delta. SDKQNLL 7 Chicken .gamma./.delta. SDRQNLI 8 Sheep
.delta. ADTQVLM 9 Human CD3.gamma. SDKQTLL 10 Human CD4 SQIKRLL 11
Human .delta. ADTQALL 12 S. cerevisiae NEQSPLL 13 Vam3p
[0117] VMAT is vesicular monoamine transporter; VACht is vesicular
acetylcholine transporter and S. cerevisiae Vam3p is a yeast
homologue of synaptobrevin. Italicized serine residues are
potential sites of phosphorylation.
[0118] The modified neurotoxin can be formed from any neurotoxin.
Also, the modified neurotoxin can be formed from a fragment of a
neurotoxin, for example, a botulinum toxin with a portion of the
light chain and/or heavy chain removed. Preferably, the neurotoxin
used is a Clostridial neurotoxin. A Clostridial neurotoxin
comprises a polypeptide having three amino acid sequence regions.
The first amino acid sequence region can include a target cell
(i.e. a neuron) binding moiety which is substantially completely
derived from a neurotoxin selected from a group consisting of
beratti toxin; butyricum toxin; tetanus toxin; botulinum type A, B,
C.sub.1, D, E, F, and G. Preferably, the first amino acid sequence
region is derived from the carboxyl terminal region of a toxin
heavy chain, H.sub.C. Also, the first amino acid sequence region
can comprise a targeting moiety which can comprise a molecule (such
as an amino acid sequence) that can bind to a receptor, such as a
cell surface protein or other biological component on a target
cell.
[0119] The second amino acid sequence region is effective to
translocate the polypeptide or a part thereof across an endosome
membrane into the cytoplasm of a neuron. In one embodiment, the
second amino acid sequence region of the polypeptide comprises an
amine terminal of a heavy chain, H.sub.N, derived from a neurotoxin
selected from a group consisting of beratti toxin; butyricum toxin;
tetanus toxin; botulinum type A, B, C.sub.1, D, E, F, and G.
[0120] The third amino acid sequence region has therapeutic
activity when it is released into the cytoplasm of a target cell,
such as a neuron. In one embodiment, the third amino acid sequence
region of the polypeptide comprises a toxin light chain, L, derived
from a neurotoxin selected from a group consisting of beratti
toxin; butyricum toxin; tetanus toxin; botulinum type A, B,
C.sub.1, D, E, F, and G.
[0121] The Clostridial neurotoxin can be a hybrid neurotoxin. For
example, each of the neurotoxin's amino acid sequence regions can
be derived from a different Clostridial neurotoxin serotype. For
example, in one embodiment, the polypeptide comprises a first amino
acid sequence region derived from the H.sub.C of the tetanus toxin,
a second amino acid sequence region derived from the H.sub.N of
botulinum type B, and a third amino acid sequence region derived
from the light chain of botulinum serotype E. All other possible
combinations are included within the scope of the present
invention.
[0122] Alternatively, all three of the amino acid sequence regions
of the Clostridial neurotoxin can be from the same species and same
serotype. If all three amino acid sequence regions of the
neurotoxin are from the same Clostridial neurotoxin species and
serotype, the neurotoxin will be referred to by the species and
serotype name. For example, a neurotoxin polypeptide can have its
first, second and third amino acid sequence regions derived from
Botulinum type E. In which case, the neurotoxin is referred as
Botulinum type E.
[0123] Additionally, each of the three amino acid sequence regions
can be modified from the naturally occurring sequence from which
they are derived. For example, the amino acid sequence region can
have at least one or more amino acids added or deleted as compared
to the naturally occurring sequence.
[0124] A biological persistence enhancing component or a biological
activity enhancing component, for example a leucine-based motif,
can be fused with any of the above described neurotoxins to form a
modified neurotoxin with an enhanced biological persistence and/or
an enhanced biological activity. "Fusing" as used in the context of
this invention includes covalently adding to or covalently
inserting in between a primary structure of a neurotoxin. For
example, a biological persistence enhancing component and/or a
biological activity enhancing component can be added to a
Clostridial neurotoxin which does not have a leucine-based motif in
its primary structure. In one embodiment, a leucine-based motif is
fused with a hybrid neurotoxin, wherein the third amino acid
sequence is derived from botulinum serotype A, B, C.sub.1, C.sub.2,
D, E, F, or G. In some embodiments, the leucine-based motif is
fused with a botulinum type E.
[0125] In some embodiments, a biological persistence enhancing
component and/or a biological activity enhancing component is added
to a neurotoxin by altering a cloned DNA sequence encoding the
neurotoxin. For example, a DNA sequence encoding a biological
persistence enhancing component and/or a biological activity
enhancing component is added to a cloned DNA sequence encoding the
neurotoxin into which the biological persistence enhancing
component and/or a biological activity enhancing component is to be
added. This can be done in a number of ways which are familiar to a
molecular biologist of ordinary skill. For example, site directed
mutagenesis or PCR cloning can be used to produce the desired
change to the neurotoxin encoding DNA sequence. The DNA sequence
can then be reintroduced into a native host strain. In the case of
botulinum toxins the native host strain would be a Clostridium
botulinum strain. Preferably, this host strain will be lacking the
native botulinum toxin gene. In an alternative method, the altered
DNA can be introduced into a heterologous host system such as E.
coli or other prokaryotes, yeast, insect cell lines or mammalian
cell lines. Once the altered DNA has been introduced into its host,
the recombinant toxin containing the added biological persistence
enhancing component and/or a biological activity enhancing
component can be produced by, for example, standard fermentation
methodologies.
[0126] Similarly, a biological persistence enhancing component can
be removed from a neurotoxin. For example, site directed
mutagenesis can be used to eliminate biological persistence
enhancing components, for example, a leucine-based motif.
[0127] Standard molecular biology techniques that can be used to
accomplish these and other genetic manipulations are found in
Sambrook et al. (1989) which is incorporated in its entirety herein
by reference.
[0128] In one embodiment, the leucine-based motif is fused with, or
added to, the third amino acid sequence region of the neurotoxin.
In a suitable embodiment, the leucine-based motif is fused with, or
added to, the region towards the carboxylic terminal of the third
amino acid sequence region. More preferably, the leucine-based
motif is fused with, or added to, the carboxylic terminal of the
third region of a neurotoxin. Even more preferably, the
leucine-based motif is fused with, or added to the carboxylic
terminal of the third region of botulinum type E. The third amino
acid sequence to which the leucine-based motif is fused or added
can be a component of a hybrid or chimeric modified neurotoxin. For
example, the leucine-based motif can be fused to or added to the
third amino acid sequence region (or a part thereof) of one
botulinum toxin type (i.e. a botulinum toxin type A), where the
leucine-based motif-third amino acid sequence region has itself
been fused to or conjugated to first and second amino acid sequence
regions from another type (or types) of a botulinum toxin (such as
botulinum toxin type B and/or E).
[0129] In some embodiments, a structural modification of a
neurotoxin which has a pre-existing biological persistence
enhancing component and/or a biological activity enhancing
component, for example, a leucine-based motif includes deleting or
substituting one or more amino acids of the leucine-based motif. In
addition, a modified neurotoxin includes a structural modification
which results in a neurotoxin with one or more amino acids deleted
or substituted in the leucine-based motif. The removal or
substitution of one or more amino acids from the preexisting
leucine-based motif is effective to reduce the biological
persistence and/or a biological activity of a modified neurotoxin.
For example, the deletion or substitution of one or more amino
acids of the leucine-based motif of botulinum type A reduces the
biological half-life and/or the biological activity of the modified
neurotoxin.
[0130] Amino acids that can be substituted for amino acids
contained in a biological persistence enhancing component include
alanine, aspargine, cysteine, aspartic acid, glutamic acid,
phenylalanine, glycine, histidine, isoleucine, lysine, leucine,
methionine, proline, glutamine, arginine, serine, threonine,
valine, tryptophan, tyrosine and other naturally occurring amino
acids as well as non-standard amino acids.
[0131] In the present invention the native botulinum type A light
chain has been shown to localize to differentiated PC12 cell
membranes in a characteristic pattern. Biological persistence
enhancing components are shown to substantially contribute to this
localization.
[0132] The data of the present invention demonstrates that when the
botulinum toxin type A light chain is truncated or when the
leucine-based motif is mutated, the light chain substantially loses
its ability to localize to the membrane in its characteristic
pattern. Localization to the cellular membrane is believed to be a
key factor in determining the biological persistence and/or the
biological activity of a botulinum toxin. This is because
localization to a cell membrane can protect the localized protein
from intracellular protein degradation.
[0133] FIGS. 1 and 2 show that deletion of the leucine-based motif
from the light chain of botulinum type A can change membrane
localization of the type A light chain. FIG. 1 shows localization
of GFP-light chain A fusion protein in differentiated PC12 cells.
The GFP fusion proteins were produced and visualized in
differentiated PC12 cells using methods well known to those skilled
in the art, for example, as described in Galli et al (1998) Mol
Biol Cell 9:1437-1448, incorporated in its entirety herein by
reference; also, for example, as described in Martinez-Arca et al
(2000) J Cell Biol 149:889-899, also incorporated in its entirety
herein by reference. Localization of a GFP-truncated light chain A
is shown in FIG. 2. Comparing FIGS. 1 and 2, it can be seen that
the pattern of localization is completely altered by the deletion
of the N-terminus and C-terminus comprising the leucine-based
motif. FIG. 3 shows the amino acid sequence of the botulinum type A
light chain. The underlined amino acid sequences indicate the amino
acids that were deleted in the truncated mutant. The leucine-based
motif is indicated by the asterisked bracket.
[0134] Further studies have been done in the present invention to
analyze the effect of specific amino acid substitutions within the
leucine-based motif. For example, in one study both leucine
residues contained in the leucine-based motif were substituted for
alanine residues. FIG. 4 shows the fluorescent image of
differentiated PC12 cells transfected with DNA encoding this
di-leucine to di-alanine substituted GFP-botulinum A light chain.
As can be seen, the substitution of alanine for leucine at
positions 427 and 428 in the botulinum type A light chain
substantially changes the localization characteristic of the light
chain.
[0135] It is within the scope of this invention that a
leucine-based motif, or any other persistence enhancing component
and/or a biological activity enhancing component present on a light
chain, can be used to protect the heavy chain as well. A random
coil belt extends from the botulinum type A translocation domain
and encircles the light chain. It is possible that this belt keeps
the two subunits in proximity to each other inside the cell while
the light chain is localized to the cell membrane. The structure of
native botulinum toxin type A is shown in FIG. 6.
[0136] In addition, the data of the present invention shows that
the leucine-based motif can be valuable in localizing the botulinum
A toxin in close proximity to the SNAP-25 substrate within the
cell. This can mean that the leucine-based motif is important not
only for determining the half-life of the toxin but for determining
the activity of the toxin as well. That is, the toxin will have a
greater activity if it is maintained in close proximity to the
SNAP-25 substrate inside the cell. FIG. 5 shows the localization of
SNAP-25 in horizontal confocal sections of differentiated PC12
cells (from Martinez-Arca et al (2000) J Cell Biol 149:889-899).
Similarity in the pattern of localization can be seen when
comparing localization of botulinum type A light chain as seen in
FIG. 1 to localization of SNAP-25 seen in FIG. 5.
[0137] The data of the present invention clearly shows that
truncation of the light chain, thereby deleting the leucine-based
motif, or amino acid substitution within the leucine-based motif
substantially changes membrane localization of the botulinum type A
light chain in nerve cells. In both truncation and substitution a
percentage of the altered light chain can localize to the cell
membrane in a pattern unlike that of the native type A light chain
(see FIGS. 1, 2 and 4). This data supports the presence of
biological persistence enhancing components other than a
leucine-based motif such as tyrosine motifs and amino acid
derivatives. Use of these other biological persistence enhancing
components and/or a biological activity enhancing components in
modified neurotoxins is also within the scope of the present
invention.
[0138] Also within the scope of the present invention is more than
one biological persistence enhancing component used in combination
in a modified neurotoxin to alter biological persistence of the
neurotoxin that is modified. The present invention also includes
use of more than one biological activity enhancing or biological
activity reducing components used in combination in a modified
neurotoxin to alter the biological activity of the neurotoxin that
is modified.
[0139] Tyrosine-based motifs are within the scope of the present
invention as biological persistence and/or a biological activity
altering components. Tyrosine-based motifs comprise the sequence
Y-X-X-Hy (SEQ ID NO: 24), where Y is tyrosine, X is any amino acid
and Hy is a hydrophobic amino acid. Tyrosine-based motifs can act
in a manner that is similar to that of leucine-based motifs. In
FIG. 3 some of tyrosine motifs found in the type A toxin light
chain are bracketed (SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33,
SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, and SEQ
ID NO: 38). In addition, a tyrosine-based motif is found within the
leucine-based motif which is indicated by an asterisked bracket in
FIG. 3.
[0140] Also within the scope of the present invention are modified
neurotoxins which comprise one or more biological persistence
altering components and/or a biological activity enhancing
components which occur naturally in both botulinum toxin types A
and B.
[0141] FIG. 7 shows localization of GFP-botulinum type B neurotoxin
light chain in live, differentiated PC12 cells. Localization of the
type B light chain appears to be to an intracellular organelle.
Similar localization pattern is seen for GFP-truncated botulinum
type A shown in FIG. 2. Localization of a botulinum toxin, or
botulinum toxin light chain, within the cell is believed to be a
key factor in determining biological persistence and/or biological
activity of the toxin. Therefore, these data appear to indicate
that there are biological persistence altering component(s), and/or
biological activity altering component(s), common to the type A and
type B botulinum toxins. These, and other biological persistence
altering components, and biological activity altering components,
are contemplated for use in accordance with the present
invention.
[0142] FIG. 8 shows a sequence alignment between type A and type B
light chains isolated from strains type A Hall A (SEQ ID NO: 29)
and type B Danish I (SEQ ID NO: 30) respectively. Light chains or
heavy chains isolated from other strains of botulinum toxin types A
and B can also be used for sequence comparison. The shaded amino
acids represent amino acid identities, or matches, between the
chains. Each of the shaded amino acids between amino acid position
10 and amino acid position 425 of the FIG. 8 consensus sequence,
alone or in combination with any other shaded amino acid or amino
acids, represents a biological persistence altering component that
is within the scope of the present invention. For example, amino
acids KAFK at positions 19 to 22 of SEQ ID NO: 29, LNK at positions
304 to 306 of SEQ ID NO: 29, L at position 228 of SEQ ID NO: 29 in
combination with KL at positions 95 and 96 of SEQ ID NO: 29, FDKLYK
at positions 346 to 351 of SEQ ID NO: 29, YL-T at positions 78 to
81 of SEQ ID NO: 29, YYD at positions 73 to 75 of SEQ ID NO: 29 in
combination with YL at positions 78 and 79 of SEQ ID NO: 29 in
combination with T a position 81 of SEQ ID NO: 29, F at position
297 of SEQ ID NO: 29 in combination with I at position 300 of SEQ
ID NO: 29 in combination with KL at positions 95 and 96 of SEQ ID
NO: 29 can be biological persistence altering components for use
within the scope of this invention. In addition, conserved regions
of charge, hydrophobicity, hydro-philicity and/or conserved
secondary, tertiary, or quaternary structures that may be
independent of conserved sequence are within the scope of the
present invention.
[0143] Amino acid derivatives are also within the scope of the
present invention as biological persistence enhancing components
and/or as biological activity enhancing components. Examples of
amino acid derivatives that act to effect biological persistence
and/or biological activity are phosphorylated amino acids. These
amino acids include, for example, amino acids phosphorylated by
tyrosine kinase, protein kinase C or casein kinase II. Other amino
acid derivatives within the scope of the present invention as
biological persistence enhancing components and/or as biological
activity enhancing components are myristylated amino acids and
N-glycosylated amino acids.
[0144] The present invention also contemplates compositions which
include a botulinum light chain component interacting with a
cellular structure component, for example, an intracellular
structure component. The structure component may include lipid,
carbohydrate, protein or nucleic acid or any combination
thereof.
[0145] The structure component may include a cell membrane, for
example, a plasma membrane. In certain embodiments, the structure
component comprises all or part of one or more organelles, for
example, the nucleus, endoplasmic reticulum, golgi apparatus,
mitochondria, lysosomes or secretory vesicles or combinations
thereof. The structure component may include any portion of an
organelle, for example, the membrane of an organelle. The structure
component may also include any substance which is included in the
cytoplasm of a cell.
[0146] The structure component may include one or more proteins. In
a suitable embodiment, the structure component includes one or more
cellular proteins. One or more of these cellular proteins may be
membrane associated proteins, for example, plasma membrane
associated proteins. In one embodiment of the invention, the
structure component includes adaptor proteins. Examples of adaptor
proteins are AP-1, AP-2 and AP-3. Adaptor proteins and their
characteristics are well known in the art and are discussed in, for
example, Darsow et al., J. Cell Bio., 142, 913 (1998) which is
incorporated in its entirety herein by reference. The one or more
proteins may also include the substrate which is cleaved by the
proteolytic domain of a botulinum toxin light chain component. For
example, a protein included in the structure component may be
SNAP-25.
[0147] The interaction between the light chain of botulinum type A
and the structure component may contribute to localization of the
toxin in a certain pattern. Therefore, the interaction may act to
facilitate proteolysis by, for example, increasing the biological
persistence and/or biological activity of the light chain.
[0148] A botulinum toxin heavy chain or portion thereof may also be
associated with the light chain component when the light chain is
interacting with the structure component.
[0149] In one embodiment, a botulinum toxin light chain component,
when interacting with the structure component in a cell, may
localize in the cell in a particular pattern. For example,
localization of a botulinum toxin type A light chain component may
be in a punctate or spotted pattern. For example, a botulinum type
A light chain component may be localized in a punctate pattern on a
cell membrane, for example, a plasma membrane. Botulinum type B
light chain may localize in the cytoplasm. Botulinum type E may
localize to the plasma membrane but to a lesser degree than type A.
Botulinum type E may also localize in the cytoplasm.
[0150] Methodologies to produce an isolated composition of the
invention are available to those skilled in the art. For example, a
composition may be isolated by isolating the plasma membrane from a
cell after introduction of a light chain component, for example,
light chain A, into a cell. The light chain may be introduced into
the cell by, for example, electroporation or by endocytosis. In the
case of introduction into the cell by endocytosis, a heavy chain
component may be included with the light chain component to
facilitate the endocytosis, for example, receptor mediated
endocytosis, of the light chain. In such preparation process, the
heavy chain component may also be isolated and be included in the
composition.
[0151] After introduction into the cell, the light chain component
associates or interacts with the substrate component forming a
composition. The composition may be isolated by purification of the
light chain component-structure component from the cell. Standard
purification techniques known to those skilled in the art may be
used to isolate a membrane and/or membrane associated protein(s)
which is included in the structure component which interacts with
the light chain component. Examples of conventional techniques for
isolation and purification of the light chain component/structure
component include immunoprecipitation and/or membrane purification
techniques.
[0152] The light chain component may be crosslinked to a portion of
the structure component before isolation. The technical procedures
for cross linking of biomolecules using agents such as DTBP are
well known to those skilled in the art.
[0153] In some embodiments, a composition of the invention may be
prepared by mixing together a purified or a partially purified
light chain component and a purified or a partially purified
intracellular structure component under conditions which are
effective to form the composition. Conditions important in forming
the composition may include pH, ionic concentration and
temperature.
[0154] The botulinum toxin light chain component of a composition,
may be a modified botulinum toxin light chain. Modifications may be
mutations and/or deletions as described elsewhere herein.
[0155] A modified light chain component may include a light chain A
modified to remove a leucine based motif or other structure(s)
which contributes to localization of the type A light chain to the
plasma membrane thereby resulting in a light chain with a reduced
ability to localize to a plasma membrane. This may result in a
reduction in the biological activity and/or biological persistence
of the light chain A. The biological persistence and/or activity of
the modified light chain may be about 10% to about 90% that of an
unmodified type A light chain.
[0156] Another modified light chain component may include a light
chain A modified by adding one or more leucine based motifs, or
other structure(s) which contributes to localization of the type A
light chain to the plasma membrane, thereby resulting in a light
chain with an increased ability to localize to a plasma membrane.
This may result in an increase in the biological activity and/or
biological persistence of the light chain A. The biological
persistence and/or activity of the modified light chain may be
about 1.5 to about 5 times that of an unmodified type A light
chain.
[0157] Another modified light chain component may include a light
chain B modified by adding one or more leucine based motifs, or
other structure(s) which contributes to localization of the type A
light chain to the plasma membrane, thereby resulting in a type B
light chain with a increased ability to localize to a plasma
membrane. This may result in an increase in the biological activity
and/or biological persistence of the light chain A. The biological
persistence and/or activity of the modified light chain may be
about 1.5 to about 10 times that of an unmodified type B light
chain.
[0158] A modified light chain component may include a light chain E
modified by adding one or more leucine based motifs, or other
structure(s) which contribute to localization of the type A light
chain to the plasma membrane, thereby resulting in a light chain
with an increased ability to localize to a plasma membrane. This
may result in an increase in the biological activity and/or
biological persistence of the light chain A. The biological
persistence and/or activity of the modified light chain may be
about 2 to about 20 times that of an unmodified type E light
chain.
[0159] Compositions of the invention have many uses and
applications, for example, in research science and medicine. Other
uses and applications will be readily apparent to those skilled in
the art.
[0160] In one broad aspect of the present invention, a method is
provided for treating a condition using a modified neurotoxin. The
conditions can include, for example, skeletal muscle conditions,
smooth muscle conditions, pain and glandular conditions. The
modified neurotoxin can also be used for cosmetics, for example, to
treat brow furrows.
[0161] The neuromuscular disorders and conditions that can be
treated with a modified neurotoxin include: for example, spasmodic
dysphonia, laryngeal dystonia, oromandibular and lingual dystonia,
cervical dystonia, focal hand dystonia, blepharospasm, strabismus,
hemifacial spasm, eyelid disorders, spasmodic torticolis, cerebral
palsy, focal spasticity and other voice disorders, spasmodic
colitis, neurogenic bladder, anismus, limb spasticity, tics,
tremors, bruxism, anal fissure, achalasia, dysphagia and other
muscle tone disorders and other disorders characterized by
involuntary movements of muscle groups can be treated using the
present methods of administration. Other examples of conditions
that can be treated using the present methods and compositions are
lacrimation, hyperhydrosis, excessive salivation and excessive
gastrointestinal secretions, as well as other secretory disorders.
In addition, the present invention can be used to treat
dermatological conditions, for example, reduction of brow furrows,
reduction of skin wrinkles. The present invention can also be used
in the treatment of sports injuries.
[0162] Borodic U.S. Pat. No. 5,053,005 discloses methods for
treating juvenile spinal curvature, i.e. scoliosis, using botulinum
type A. The disclosure of Borodic is incorporated in its entirety
herein by reference. In one embodiment, using substantially similar
methods as disclosed by Borodic, a modified neurotoxin can be
administered to a mammal, preferably a human, to treat spinal
curvature. In a suitable embodiment, a modified neurotoxin
comprising botulinum type E fused with a leucine-based motif is
administered. Even more preferably, a modified neurotoxin
comprising botulinum type A-E with a leucine-based motif fused to
the carboxyl terminal of its light chain is administered to the
mammal, preferably a human, to treat spinal curvature.
[0163] In addition, the modified neurotoxin can be administered to
treat other neuromuscular disorders using well known techniques
that are commonly performed with botulinum type A. For example, the
present invention can be used to treat pain, for example, headache
pain, pain from muscle spasms and various forms of inflammatory
pain. For example, Aoki U.S. Pat. No. 5,721,215 and Aoki U.S. Pat.
No. 6,113,915 disclose methods of using botulinum toxin type A for
treating pain. The disclosure of these two patents is incorporated
in its entirety herein by reference.
[0164] Autonomic nervous system disorders can also be treated with
a modified neurotoxin. For example, glandular malfunctioning is an
autonomic nervous system disorder. Glandular malfunctioning
includes excessive sweating and excessive salivation. Respiratory
malfunctioning is another example of an autonomic nervous system
disorder. Respiratory malfunctioning includes chronic obstructive
pulmonary disease and asthma. Sanders et al. disclose methods for
treating the autonomic nervous system; for example, treating
autonomic nervous system disorders such as excessive sweating,
excessive salivation, asthma, etc., using naturally existing
botulinum toxins. The disclosure of Sander et al. is incorporated
in its entirety by reference herein. In one embodiment,
substantially similar methods to that of Sanders et al. can be
employed, but using a modified neurotoxin, to treat autonomic
nervous system disorders such as the ones discussed above. For
example, a modified neurotoxin can be locally applied to the nasal
cavity of the mammal in an amount sufficient to degenerate
cholinergic neurons of the autonomic nervous system that control
the mucous secretion in the nasal cavity.
[0165] Pain that can be treated by a modified neurotoxin includes
pain caused by muscle tension, or spasm, or pain that is not
associated with muscle spasm. For example, Binder in U.S. Pat. No.
5,714,468 discloses that headache caused by vascular disturbances,
muscular tension, neuralgia and neuropathy can be treated with a
naturally occurring botulinum toxin, for example Botulinum type A.
The disclosures of Binder are incorporated in its entirety herein
by reference. In one embodiment, substantially similar methods to
that of Binder can be employed, but using a modified neurotoxin, to
treat headache, especially the ones caused by vascular
disturbances, muscular tension, neuralgia and neuropathy. Pain
caused by muscle spasm can also be treated by an administration of
a modified neurotoxin. For example, a botulinum type E fused with a
leucine-based motif, preferably at the carboxyl terminal of the
botulinum type E light chain, can be administered intramuscularly
at the pain/spasm location to alleviate pain.
[0166] Furthermore, a modified neurotoxin can be administered to a
mammal to treat pain that is not associated with a muscular
disorder, such as spasm. In one broad embodiment, methods of the
present invention to treat non-spasm related pain include central
administration or peripheral administration of the modified
neurotoxin.
[0167] For example, Foster et al. in U.S. Pat. No. 5,989,545
discloses that a botulinum toxin conjugated with a targeting moiety
can be administered centrally (intrathecally) to alleviate pain.
The disclosures of Foster et al. are incorporated in its entirety
by reference herein. In one embodiment, substantially similar
methods to that of Foster et al. can be employed, but using the
modified neurotoxin according to this invention, to treat pain. The
pain to be treated can be an acute pain, or preferably, chronic
pain.
[0168] An acute or chronic pain that is not associated with a
muscle spasm can also be alleviated with a local, peripheral
administration of the modified neurotoxin to an actual or a
perceived pain location on the mammal. In one embodiment, the
modified neurotoxin is administered subcutaneously at or near the
location of pain, for example, at or near a cut. In some
embodiments, the modified neurotoxin is administered
intramuscularly at or near the location of pain, for example, at or
near a bruise location on the mammal. In some embodiments, the
modified neurotoxin is injected directly into a joint of a mammal,
for treating or alleviating pain caused by arthritic conditions.
Also, frequent repeated injection or infusion of the modified
neurotoxin to a peripheral pain location is within the scope of the
present invention. However, given the long lasting therapeutic
effects of the present invention, frequent injection or infusion of
the neurotoxin can not be necessary. For example, practice of the
present invention can provide an analgesic effect, per injection,
for 2 months or longer, for example 27 months, in humans.
[0169] Without wishing to limit the invention to any mechanism or
theory of operation, it is believed that when the modified
neurotoxin is administered locally to a peripheral location, it
inhibits the release of Neuro-substances, for example substance P,
from the peripheral primary sensory terminal by inhibiting
SNARE-dependent exocytosis. Since the release of substance P by the
peripheral primary sensory terminal can cause or at least amplify
pain transmission process, inhibition of its release at the
peripheral primary sensory terminal will dampen the transmission of
pain signals from reaching the brain.
[0170] In addition to having pharmacologic actions at the
peripheral location, the modified neurotoxin of the present
invention can also have inhibitory effects in the central nervous
system, upon direct intrathecal administration, as set forth in
U.S. Pat. No. 6,113,915, or upon peripheral administration, where
presumably the modified toxin acts through retrograde transport via
a primary sensory afferent. This hypothesis of retrograde axonal
transport is supported by published data which shows that botulinum
type A can be retrograde transported to the dorsal horn when the
neurotoxin is injected peripherally. Thus, work by Weigand et al,
Nauny-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-165, and
Habermann, Nauny-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56,
showed that botulinum toxin is able to ascend to the spinal area by
retrograde transport. As such, a modified neurotoxin, for example
botulinum type A with one or more amino acids mutated from the
leucine-based motif, injected at a peripheral location, for example
intramuscularly, can be expected to be retrograde transported from
the peripheral primary sensory terminal to a central region.
[0171] The amount of the modified neurotoxin administered can vary
widely according to the particular disorder being treated, its
severity and other various patient variables including size,
weight, age, and responsiveness to therapy. Generally, the dose of
modified neurotoxin to be administered will vary with the age,
presenting condition and weight of the mammal, preferably a human,
to be treated. The potency of the modified neurotoxin will also be
considered.
[0172] Assuming a potency (for a botulinum toxin type A) which is
substantially equivalent to LD.sub.50=2,730 U in a human patient
and an average person is 75 kg, a lethal dose (for a botulinum
toxin type A) would be about 36 U/kg of a modified neurotoxin.
Therefore, when a modified neurotoxin with such an LD.sub.50 is
administered, it would be appropriate to administer less than 36
U/kg of the modified neurotoxin into human subjects. Preferably,
about 0.01 U/kg to 30 U/kg of the modified neurotoxin is
administered. More preferably, about 1 U/kg to about 15 U/kg of the
modified neurotoxin is administered. Even more preferably, about 5
U/kg to about 10 U/kg modified neurotoxin is administered.
Generally, the modified neurotoxin will be administered as a
composition at a dosage that is proportionally equivalent to about
2.5 cc/100 U. Those of ordinary skill in the art will know, or can
readily ascertain, how to adjust these dosages for neurotoxin of
greater or lesser potency. It is known that botulinum toxin type B
can be administered at a level about fifty times higher that that
used for a botulinum toxin type A for similar therapeutic effect.
Thus, the units amounts set forth above can be multiplied by a
factor of about fifty for a botulinum toxin type B.
[0173] Although examples of routes of administration and dosages
are provided, the appropriate route of administration and dosage
are generally determined on a case by case basis by the attending
physician. Such determinations are routine to one of ordinary skill
in the art (see for example, Harrison's Principles of Internal
Medicine (1998), edited by Anthony Fauci et al., 14.sup.th edition,
published by McGraw Hill). For example, the route and dosage for
administration of a modified neurotoxin according to the present
disclosed invention can be selected based upon criteria such as the
solubility characteristics of the modified neurotoxin chosen as
well as the types of disorder being treated.
[0174] The modified neurotoxin can be produced by chemically
linking the leucine-based motif to a neurotoxin using conventional
chemical methods well known in the art. For example, botulinum type
E can be obtained by establishing and growing cultures of
Clostridium botulinum in a fermenter, and then harvesting and
purifying the fermented mixture in accordance with known
procedures.
[0175] The modified neurotoxin can also be produced by recombinant
techniques. Recombinant techniques are preferable for producing a
neurotoxin having amino acid sequence regions from different
Clostridial species or having modified amino acid sequence regions.
Also, the recombinant technique is preferable in producing
botulinum type A with the leucine-based motif being modified by
deletion. The technique includes steps of obtaining genetic
materials from natural sources, or synthetic sources, which have
codes for a cellular binding moiety, an amino acid sequence
effective to translocate the neurotoxin or a part thereof, and an
amino acid sequence having therapeutic activity when released into
a cytoplasm of a target cell, preferably a neuron. In a suitable
embodiment, the genetic materials have codes for the biological
persistence enhancing component, preferably the leucine-based
motif, the H.sub.C, the H.sub.N and the light chain of the
Clostridial neurotoxins and fragments thereof. The genetic
constructs are incorporated into host cells for amplification by
first fusing the genetic constructs with a cloning vectors, such as
phages or plasmids. Then the cloning vectors are inserted into a
host, for example, Clostridium sp., E. coli or other prokaryotes,
yeast, insect cell line or mammalian cell lines. Following the
expressions of the recombinant genes in host cells, the resultant
proteins can be isolated using conventional techniques.
[0176] There are many advantages to producing these modified
neurotoxins recombinantly. For example, to form a modified
neurotoxin, a modifying fragment, or component must be attached or
inserted into a neurotoxin. The production of neurotoxin from
anaerobic Clostridium cultures is a cumbersome and time-consuming
process including a multi-step purification protocol involving
several protein precipitation steps and either prolonged and
repeated crystallization of the toxin or several stages of column
chromatography. Significantly, the high toxicity of the product
dictates that the procedure must be performed under strict
containment (BL-3). During the fermentation process, the folded
single-chain neurotoxins are activated by endogenous Clostridial
proteases through a process termed nicking to create a dichain.
Sometimes, the process of nicking involves the removal of
approximately 10 amino acid residues from the single-chain to
create the dichain form in which the two chains remain covalently
linked through the intrachain disulfide bond.
[0177] The nicked neurotoxin is much more active than the unnicked
form. The amount and precise location of nicking varies with the
serotypes of the bacteria producing the toxin. The differences in
single-chain neurotoxin activation and, hence, the yield of nicked
toxin, are due to variations in the serotype and amounts of
proteolytic activity produced by a given strain. For example,
greater than 99% of Clostridial botulinum serotype A single-chain
neurotoxin is activated by the Hall A Clostridial botulinum strain,
whereas serotype B and E strains produce toxins with lower amounts
of activation (0 to 75% depending upon the fermentation time).
Thus, the high toxicity of the mature neurotoxin plays a major part
in the commercial manufacture of neurotoxins as therapeutic
agents.
[0178] The degree of activation of engineered Clostridial toxins
is, therefore, an important consideration for manufacture of these
materials. It would be a major advantage if neurotoxins such as
botulinum toxin and tetanus toxin could be expressed,
recombinantly, in high yield in rapidly-growing bacteria (such as
heterologous E. coli cells) as relatively non-toxic single-chains
(or single chains having reduced toxic activity) which are safe,
easy to isolate and simple to convert to the fully-active form.
[0179] With safety being a prime concern, previous work has
concentrated on the expression in E. coli and purification of
individual H and light chains of tetanus and botulinum toxins;
these isolated chains are, by themselves, non-toxic; see Li et al.,
Biochemistry 33:7014-7020 (1994); Zhou et al., Biochemistry
34:15175-15181 (1995), hereby incorporated by reference herein.
Following the separate production of these peptide chains and under
strictly controlled conditions the H and light chains can be
combined by oxidative disulphide linkage to form the neuroparalytic
di-chains.
EXAMPLES
[0180] The following non-limiting examples provide those of
ordinary skill in the art with specific suitable methods to treat
non-spasm related pain within the scope of the present invention
and are not intended to limit the scope of the invention.
Example 1
Treatment of Pain Associated with Muscle Disorder
[0181] An unfortunate 36 year old woman has a 15 year history of
temporomandibular joint disease and chronic pain along the masseter
and temporalis muscles. Fifteen years prior to evaluation she noted
increased immobility of the jaw associated with pain and jaw
opening and closing and tenderness along each side of her face. The
left side is originally thought to be worse than the right. She is
diagnosed as having temporomandibular joint (TMJ) dysfunction with
subluxation of the joint and is treated with surgical orthoplasty
meniscusectomy and condyle resection.
[0182] She continues to have difficulty with opening and closing
her jaw after the surgical procedures and for this reason, several
years later, a surgical procedure to replace prosthetic joints on
both sides is performed. After the surgical procedure progressive
spasms and deviation of the jaw ensues. Further surgical revision
is performed subsequent to the original operation to correct
prosthetic joint loosening. The jaw continues to exhibit
considerable pain and immobility after these surgical procedures.
The TMJ remained tender as well as the muscle itself. There are
tender points over the temporomandibular joint as well as increased
tone in the entire muscle. She is diagnosed as having post-surgical
myofascial pain syndrome and is injected with the modified
neurotoxin into the masseter and temporalis muscles; the modified
neurotoxin is botulinum type E comprising a leucine-based motif.
The particular dose as well as the frequency of administrations
depends upon a variety of factors within the skill of the treating
physician.
[0183] Several days after the injections she noted substantial
improvement in her pain and reports that her jaw feels looser. This
gradually improves over a 2 to 3 week period in which she notes
increased ability to open the jaw and diminishing pain. The patient
states that the pain is better than at any time in the last 4
years. The improved condition persists for up to 27 months after
the original injection of the modified neurotoxin.
Example 2
Treatment of Pain Subsequent to Spinal Cord Injury
[0184] A patient, age 39, experiencing pain subsequent to spinal
cord injury is treated by intrathecal administration, for example,
by spinal tap or by catherization (for infusion) to the spinal
cord, with the modified neurotoxin; the modified neurotoxin is
botulinum type E comprising a leucine-based motif. The particular
toxin dose and site of injection, as well as the frequency of toxin
administrations, depend upon a variety of factors within the skill
of the treating physician, as previously set forth. Within about 1
to about 7 days after the modified neurotoxin administration, the
patient's pain is substantially reduced. The pain alleviation
persists for up to 27 months.
Example 3
Peripheral Administration of a Modified Neurotoxin to Treat
"Shoulder-Hand Syndrome"
[0185] Pain in the shoulder, arm, and hand can develop, with
muscular dystrophy, osteoporosis and fixation of joints. While most
common after coronary insufficiency, this syndrome can occur with
cervical osteoarthritis or localized shoulder disease, or after any
prolonged illness that requires the patient to remain in bed.
[0186] A 46 year old woman presents a shoulder-hand syndrome type
pain. The pain is particularly localized at the deltoid region. The
patient is treated by a bolus injection of a modified neurotoxin
subcutaneously to the shoulder; preferably the modified neurotoxin
is botulinum type E comprising a leucine-based motif. The modified
neurotoxin can also be, for example, modified botulinum type A, B,
C1, C2, D, E, F or G which comprise a leucine-based motif. The
particular dose as well as the frequency of administrations depends
upon a variety of factors within the skill of the treating
physician, as previously set forth. Within 1-7 days after modified
neurotoxin administration the patient's pain is substantially
alleviated. The duration of the pain alleviation is from about 7 to
about 27 months.
Example 4
Peripheral Administration of a Modified Neurotoxin to Treat
Postherapeutic Neuralgia
[0187] Postherapeutic neuralgia is one of the most intractable of
chronic pain problems. Patients suffering this excruciatingly
painful process often are elderly, have debilitating disease, and
are not suitable for major interventional procedures. The diagnosis
is readily made by the appearance of the healed lesions of herpes
and by the patient's history. The pain is intense and emotionally
distressing. Postherapeutic neuralgia can occur anywhere, but is
most often in the thorax.
[0188] A 76 year old man presents a postherapeutic type pain. The
pain is localized to the abdomen region. The patient is treated by
a bolus injection of a modified neurotoxin intradermally to the
abdomen; the modified neurotoxin is, for example, botulinum type A,
B, C1, C2, D, E, F and/or G. The modified neurotoxin comprises a
leucine-based motif and/or additional tyrosine-based motifs. The
particular dose as well as the frequency of administration depends
upon a variety of factors within the skill of the treating
physician, as previously set forth. Within 1-7 days after modified
neurotoxin administration the patient's pain is substantially
alleviated. The duration of the pain alleviation is from about 7 to
about 27 months.
Example 5
Peripheral Administration of a Modified Neurotoxin to Treat
Nasopharyngeal Tumor Pain
[0189] These tumors, most often squamous cell carcinomas, are
usually in the fossa of Rosenmuller and can invade the base of the
skull. Pain in the face is common. It is constant, dull-aching in
nature.
[0190] A 35 year old man presents a nasopharyngeal tumor type pain.
Pain is found at the lower left cheek. The patient is treated by a
bolus injection of a modified neurotoxin intramuscularly to the
cheek, preferably the modified neurotoxin is botulinum type A, B,
C1, C2, D, E, F or G comprising additional biological persistence
enhancing amino acid derivatives, for example, tyrosine
phosphorylations. The particular dose as well as the frequency of
administrations depends upon a variety of factors within the skill
of the treating physician. Within 1-7 days after modified
neurotoxin administration the patient's pain is substantially
alleviated. The duration of the pain alleviation is from about 7 to
about 27 months.
Example 6
Peripheral Administration of a Modified Neurotoxin to Treat
Inflammatory Pain
[0191] A patient, age 45, presents an inflammatory pain in the
chest region. The patient is treated by a bolus injection of a
modified neurotoxin intramuscularly to the chest, preferably the
modified neurotoxin is botulinum type A, B, C1, C2, D, E, F or G
comprising additional tyrosine-based motifs. The particular dose as
well as the frequency of administrations depends upon a variety of
factors within the skill of the treating physician, as previously
set forth. Within 1-7 days after modified neurotoxin administration
the patient's pain is substantially alleviated. The duration of the
pain alleviation is from about 7 to about 27 months.
Example 7
Treatment of Excessive Sweating
[0192] A male, age 65, with excessive unilateral sweating is
treated by administering a modified neurotoxin. The dose and
frequency of administration depends upon degree of desired effect.
Preferably, the modified neurotoxin is botulinum type A, B, C1, C2,
D, E, F and/or G. The modified neurotoxins comprise a leucine-based
motif. The administration is to the gland nerve plexus, ganglion,
spinal cord or central nervous system. The specific site of
administration is to be determined by the physician's knowledge of
the anatomy and physiology of the target glands and secretory
cells. In addition, the appropriate spinal cord level or brain area
can be injected with the toxin. The cessation of excessive sweating
after the modified neurotoxin treatment is up to 27 months.
Example 8
Post Surgical Treatments
[0193] A female, age 22, presents a torn shoulder tendon and
undergoes orthopedic surgery to repair the tendon. After the
surgery, the patient is administered intramuscularly with a
modified neurotoxin to the shoulder. The modified neurotoxin can
botulinum type A, B, C, D, E, F, and/or G wherein one or more amino
acids of a biological persistence enhancing component are deleted
from the toxin. For example, one or more leucine residues can be
deleted from and/or mutated from the leucine-based motif in
botulinum toxin serotype A. Alternatively, one or more amino acids
of the leucine-based motif can be substituted for other amino
acids. For example, the two leucines in the leucine-based motif can
be substituted for alanines. The particular dose as well as the
frequency of administrations depends upon a variety of factors
within the skill of the treating physician. The specific site of
administration is to be determined by the physician's knowledge of
the anatomy and physiology of the muscles. The administered
modified neurotoxin reduces movement of the arm to facilitate the
recovery from the surgery. The effect of the modified neurotoxin is
for about five weeks or less.
Example 9
Cloning, Expression and Purification of the Botulinum Neurotoxin
Light Chain Gene
[0194] This example describes methods to clone and express a DNA
nucleotide sequence encoding a botulinum toxin light chain and
purify the resulting protein product. A DNA sequence encoding the
botulinum toxin light chain can be amplified by PCR protocols which
employ synthetic oligonucleotides having sequences corresponding to
the 5' and 3' end regions of the light chain gene. Design of the
primers can allow for the introduction of restriction sites, for
example, Stu I and EcoR I restriction sites into the 5' and 3' ends
of the botulinum toxin light chain gene PCR product. These
restriction sites can be subsequently used to facilitate
unidirectional subcloning of the amplification products.
Additionally, these primers can introduce a stop codon at the
C-terminus of the light chain coding sequence. Chromosomal DNA from
C. botulinum, for example, strain HallA, can serve as a template in
the amplification reaction.
[0195] The PCR amplification can be performed in a 0.1 mL volume
containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM
of each deoxynucleotide triphosphate (dNTP), 50 pmol of each
primer, 200 ng of genomic DNA and 2.5 units of Taq DNA polymerase.
The reaction mixture can be subjected to 35 cycles of denaturation
(1 minute at 94.degree. C.), annealing (2 minutes at 55.degree. C.)
and polymerization (2 minutes at 72.degree. C.). Finally, the
reaction can be extended for an additional 5 minutes at 72.degree.
C.
[0196] The PCR amplification product can be digested with for
example, Stu I and EcoR I, to release the light chain encoding,
cloned, PCR DNA fragment. This fragment can then be purified by,
for example, agarose gel electrophoresis, and ligated into, for
example, a Sma I and EcoR I digested pBluescript II SK phagemid.
Bacterial transformants, for example, E. coli, harboring this
recombinant phagemid can be identified by standard procedures, such
as blue/white screening. Clones comprising the light chain encoding
DNA can be identified by DNA sequence analysis performed by
standard methods. The cloned sequences can be confirmed by
comparing the cloned sequences to published sequences for botulinum
light chains, for example, Binz, et al., in J. Biol. Chem. 265,
9153 (1990), Thompson et al., in Eur. J. Biochem. 189, 73 (1990)
and Minton, Clostridial Neurotoxins, The Molecular Pathogenesis of
Tetanus and Botulism p. 161-191, Edited by C. Motecucco (1995).
[0197] The light chain can be subcloned into an expression vector,
for example, pMal-P2. pMal-P2 harbors the malE gene encoding MBP
(maltose binding protein) which is controlled by a strongly
inducible promoter, P.sub.tac.
[0198] To verify expression of the botulinum toxin light chain, a
well isolated bacterial colony harboring the light chain gene
containing pMal-P2 can be used to inoculate L-broth containing 0.1
mg/ml ampicillin and 2% (w/v) glucose, and grown overnight with
shaking at 30.degree. C. The overnight cultures can be diluted 1:10
into fresh L-broth containing 0.1 mg/ml of ampicillin and incubated
for 2 hours. Fusion protein expression can be induced by addition
of IPTG to a final concentration of 0.1 mM. After an additional 4
hour incubation at 30.degree. C., bacteria can be collected by
centrifugation at 6,000.times.g for 10 minutes.
[0199] A small-scale SDS-PAGE analysis can confirm the presence of
a 90 kDa protein band in samples derived from IPTG-induced
bacteria. This MW would be consistent with the predicted size of a
fusion protein having MBP (.about.40 kDa) and botulinum toxin light
chain (.about.50 kDa) components.
[0200] The presence of the desired fusion proteins in IPTG-induced
bacterial extracts can be confirmed by western blotting using the
polyclonal anti-L chain probe described by Cenci di Bello et al.,
in Eur. J. Biochem. 219, 161 (1993). Reactive bands on PVDF
membranes (Pharmacia; Milton Keynes, UK) can be visualized using an
anti-rabbit immunoglobulin conjugated to horseradish peroxidase
(BioRad; Hemel Hempstead, UK) and the ECL detection system
(Amersham, UK). Western blotting results typically confirm the
presence of the dominant fusion protein together with several faint
bands corresponding to proteins of lower MW than the fully sized
fusion protein. This observation suggests that limited degradation
of the fusion protein occurred in the bacteria or during the
isolation procedure.
[0201] To produce the subcloned light chain, pellets from 1 liter
cultures of bacteria expressing the wild-type Botulinum neurotoxin
light chain proteins can be resuspended in column buffer [10 mM
Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EGTA and 1 mM DTT] containing
1 mM phenylmethanesulfonyl fluoride (PMSF) and 10 mM benzamidine,
and lysed by sonication. The lysates can be cleared by
centrifugation at 15,000.times.g for 15 minutes at 4.degree. C.
Supernatants can be applied to an amylose affinity column
[2.times.10 cm, 30 ml resin] (New England BioLabs; Hitchin, UK).
Unbound proteins can be washed from the resin with column buffer
until the eluate is free of protein as judged by a stable
absorbance reading at 280 nm. The bound MBP-L chain fusion protein
can be subsequently eluted with column buffer containing 10 mM
maltose. Fractions containing the fusion protein can be pooled and
dialyzed against 20 mM Tris-HCl (pH 8.0) supplemented with 150 mM
NaCl, 2 mM, CaCl2 and 1 mM DTT for 72 hours at 4.degree. C.
[0202] The MBP-L chain fusion proteins can be purified after
release from the host bacteria. Release from the bacteria can be
accomplished by enzymatically degrading or mechanically disrupting
the bacterial cell membrane. Amylose affinity chromatography can be
used for purification. Recombinant wild-type or mutant light chains
can be separated from the sugar binding domains of the fusion
proteins by site-specific cleavage with Factor Xa. This cleavage
procedure typically yields free MBP, free light chains and a small
amount of uncleaved fusion protein. While the resulting light
chains present in such mixtures can be shown to possess the desired
activities, an additional purification step can be employed. For
example, the mixture of cleavage products can be applied to a
second amylose affinity column which binds both the MBP and
uncleaved fusion protein. Free light chains can be isolated in the
flow through fraction.
Example 10
Reconstitution of Native Light Chain, Recombinant Wild-Type Light
Chain with Purified Heavy Chain
[0203] Native heavy and light chains can be dissociated from a BoNT
with 2 M urea, reduced with 100 mM DTT and then purified according
to established chromatographic procedures. For example, Kozaki et
al. (1981, Japan J. Med. Sci. Biol. 34, 61) and Maisey et al.
(1988, Eur. J. Biochem. 177, 683). A purified heavy chain can be
combined with an equimolar amount of either native light chain or a
recombinant light chain. Reconstitution can be carried out by
dialyzing the samples against a buffer consisting of 25 mM Tris (pH
8.0), 50 .mu.M zinc acetate and 150 mM NaCl over 4 days at
4.degree. C. Following dialysis, the association of the recombinant
light chain and native heavy chain to form disulfide linked 150 kDa
dichains is monitored by SDS-PAGE and/or quantified by
densitometric scanning.
Example 11
Production of a Modified Neurotoxin with an Enhanced Biological
Persistence
[0204] A modified neurotoxin can be produced by employing
recombinant techniques in conjunction with conventional chemical
techniques.
[0205] A neurotoxin chain, for example a botulinum light chain that
is to be fused with a biological persistence enhancing component to
form a modified neurotoxin can be produced recombinantly and
purified as described in example 9.
[0206] The recombinant neurotoxin chain derived from the
recombinant techniques can be covalently fused with (or coupled to)
a biological persistence enhancing component, for example a
leucine-based motif, a tyrosine-based motif and/or an amino acid
derivative. Peptide sequences comprising biological persistence
enhancing components can be synthesized by standard t-Boc/Fmoc
technologies in solution or solid phase as is known to those
skilled in the art. Similar synthesis techniques are also covered
by the scope of this invention, for example, methodologies employed
in Milton et al. (1992, Biochemistry 31, 8799-8809) and Swain et
al. (1993, Peptide Research 6, 147-154). One or more synthesized
biological persistence enhancing components can be fused to the
light chain of botulinum type A, B, C1, C2, D, E, F or G at, for
example, the carboxyl terminal end of the toxin. The fusion of the
biological persistence enhancing components is achieved by chemical
coupling using reagents and techniques known to those skilled in
the art, for example PDPH/EDAC and Traut's reagent chemistry.
[0207] Alternatively, a modified neurotoxin can be produced
recombinantly without the step of fusing the biological persistence
enhancing component to a recombinant botulinum toxin chain. For
example, a recombinant neurotoxin chain, for example, a botulinum
light chain, derived from the recombinant techniques of example 9
can be produced with a biological persistence enhancing component,
for example a leucine-based motif, a tyrosine-based motif and/or an
amino acid derivative. For example, one or more DNA sequences
encoding biological persistence enhancing components can be added
to the DNA sequence encoding the light chain of botulinum type A,
B, C1, C2, D, E, F or G. This addition can be done by any number of
methods used for site directed mutagenesis which are familiar to
those skilled in the art.
[0208] The recombinant modified light chain containing the fused or
added biological persistence enhancing component can be
reconstituted with a heavy chain of a neurotoxin by the method
described in example 10 thereby producing a complete modified
neurotoxin.
[0209] The modified neurotoxins produced according to this example
have an enhanced biological persistence. Preferably, the biological
persistence is enhanced by about 20% to about 300% relative to an
identical neurotoxin without the additional biological persistence
enhancing component(s).
Example 12
Production of a Modified Neurotoxin with a Reduced Biological
Persistence
[0210] A modified neurotoxin with a reduced biological persistence
can be produced by employing recombinant techniques. For example, a
botulinum light chain derived from the recombinant techniques of
example 9 can be produced without a biological persistence
enhancing component. For example, one or more leucine-based motifs,
tyrosine-based motifs and/or amino acid derivatives can be mutated.
For example, one or more DNA sequences encoding biological
persistence enhancing components can be removed from the DNA
sequence encoding the light chain of botulinum type A, B, C1, C2,
D, E, F or G. For example, the DNA sequence encoding the leucine
based motif can be removed from the DNA sequence encoding botulinum
type A light chain. Removal of the DNA sequences can be done by any
number of methods familiar to those skilled in the art.
[0211] The recombinant modified light chain with the deleted
biological persistence enhancing component can be reconstituted
with a heavy chain of a neurotoxin by the method described in
example 10 thereby producing a complete modified neurotoxin.
[0212] The modified neurotoxin produced according to this example
has a reduced biological persistence. Preferably, the biological
persistence is reduced by about 20% to about 300% relative to an
identical neurotoxin, for example botulinum type A, with the
leucine-based motif.
[0213] Although the present invention has been described in detail
with regard to certain suitable methods, other embodiments,
versions, and modifications within the scope of the present
invention are possible. For example, a wide variety of modified
neurotoxins can be effectively used in the methods of the present
invention in place of Clostridial neurotoxins. Also, the
corresponding genetic codes, i.e. DNA sequence, to the modified
neurotoxins are also considered to be part of this invention.
Additionally, the present invention includes peripheral
administration methods wherein two or more modified neurotoxins,
for example botulinum type E with a fused leucine-based motif and
botulinum type B comprising a leucine-based motif, are administered
concurrently or consecutively. While this invention has been
described with respect to various specific examples and
embodiments, it is to be understood that the invention is not
limited thereto and that it can be variously practiced with the
scope of the following claims.
Example 13
Production of a Modified Neurotoxin with a Reduced Biological
Persistence
[0214] Localization to the cellular membrane is likely a key factor
in determining the biological persistence of botulinum toxins. This
is because localization to a cell membrane can protect the
localized protein from intracellular protein degrading
complexes.
[0215] It is well known and generally accepted that the biological
persistence of botulinum type B neurotoxin is shorter than the
biological persistence of botulinum type A neurotoxin. In this
work, it was demonstrated that when the botulinum toxin type A
light chain is truncated, which comprises removing the
leucine-based motif, the light chain substantially loses its
ability to localize to the cellular membrane in its characteristic
pattern. In fact, truncated type A light chain localizes to the
cellular membrane in a pattern similar to that of botulinum toxin
type B light chain.
[0216] Therefore, it can be hypothesized that truncated botulinum
type A has a reduced biological persistence and/or a reduced
biological activity similar to that of botulinum toxin type B.
Example 14
Production of a Modified Neurotoxin with an Altered Biological
Persistence
[0217] Localization to the cellular membrane is likely a key factor
in determining the biological persistence of botulinum toxins. This
is because localization to a cell membrane can protect the
localized protein from intracellular protein degrading
complexes.
[0218] In this work, it was demonstrated that when the botulinum
toxin type A light chain is mutated, changing the two leucines at
positions 427 and 428 to alanines (FIG. 3), the light chain
substantially loses its ability to localize to the cellular
membrane in its characteristic pattern.
[0219] From this data it can be concluded that the mutated
botulinum type A has an altered biological persistence.
Example 15
In Vitro Cleavage of SNAP 25 by Truncated LC/A
[0220] As illustrated by FIG. 9, an in vitro ELISA assay was
carried out by the inventors demonstrating that a truncated LC/A in
vitro cleaves SNAP-25 substrate less efficiently than does
non-truncated LC/A. The data displayed is not a measure of
inhibition of exocytosis but a measure of the in vitro formation of
SNAP-25 cleavage. The assay was carried out as follows:
[0221] Materials: BirA-SNAP25.sub.128-206--this is a recombinant
substrate for LC/A, consisting of a BirA signal sequence fused to
the N-terminus of residues 128-206 of SNAP25. This fusion construct
was produced in E. coli and the BirA signal sequence was
biotinylated by the E. coli. Microtiter plates were coated with
streptavidin. The toxin used was BoNT/A complex or LC/A constructs.
The primary antibody was anti-SNAP25.sub.197 antibody. This
antibody recognizes the C-terminus of SNAP25 following cleavage by
Type A toxin (BirA-SNAP25.sub.128-197). The secondary antibody was
goat, anti-rabbit IgG conjugated to horseradish peroxidase. The
ImmunoPure TMB substrate was from Pierce, a colorimetric substrate
for horseradish peroxidase. The antibody that recognizes the
cleaved product SNAP25.sub.197 is specific for that cleaved product
and does not recognize the full length uncleaved substrate
SNAP25.sub.206.
[0222] Method: BirA-SNAP25.sub.128-206 was bound to streptavidin on
a microtiter plate. To the plates were added serial dilutions of
BoNT/A 900 kDa complex, His6-S-nativeLC/A, or
His6-S-truncLC/A-His6. All toxin samples were pre-incubated with
DTT (this is not required for the LC/A constructs, but they were
treated the same as the BoNT/A complex). The toxin samples were
incubated with the substrate for 90 minutes at 37.degree. C. The
toxin was removed and the bound substrate was incubated with
anti-SNAP25.sub.197 antibody. Unbound antibody was washed away and
the plates were then incubated with the secondary antibody
(anti-rabbit IgG conjugated to horseradish peroxidase). Unbound
antibody was again washed away and a colorimetric assay for
horseradish peroxidase was performed. The assay was quantified by
reading the absorbance at 450 nm.
[0223] In other work by the inventors disclosed herein the light
chain constructs that were expressed in the PC-12 cells were
expressed directly in the PC-12 cells and do not contain any tags.
The light chain constructs that have been expressed from E. coli
for these in vitro assays contain affinity tags for purification
purposes (these tags are not present on the proteins expressed in
the PC-12 cells, as disclosed herein). The LC/A expressed in PC12
was the fusion protein GFP-LC/A. Between the GFP and the LC/A there
is a set of Gly to separate both proteins.
[0224] An explanation of the various constructs follows:
[0225] Complex (red in the graph)--this is BoNT/A 900 kDa complex
isolated from C. botulinum
[0226] Truncated LC/A--a construct lacking 8 amino acids at the
N-terminus and 22 amino acids at the C-terminus. However, this
construct does contain a 6-histidine and an S-tag at the N-terminus
as well as a 6-histidine tag at the C-terminus.
[0227] Dialyzed Truncated LC/A--same as Truncated LC/A, but
imidazole resulting from the purification has been removed.
[0228] Full LC/A (dark green in graph)--native LC/A construct
(full-length), but containing the N-terminal 6-histidine and S-tag.
Does not have the C-terminal 6-histidine.
[0229] Dialyzed Full LC/A (light green in graph)--same as Full
LC/A, but imidazole resulting from the purification has been
removed.
[0230] To graphically depict these differences, FIG. 10 shows the
very N-terminus and the very C-terminus of these constructs (the
middle portion of the LC/A proteins is not shown). What is referred
to as Wildtype corresponds to the native LC/A that the inventors
had expressed directly in the PC-12 cells (this is construct that
the inventors demonstrated activity with via Western blot analysis
of the cleaved SNAP25 product). Truncated LC/A is the truncated
light chain containing the His and S-tags. N-His-LC/A is what was
referred to as Full LC/A in FIG. 9.
Example 16A
Intracellular Localization of Botulinum Toxin Type A Light
Chain
[0231] The sequences of LC/A, LC/B, and LC/E were analyzed for the
presence of localization signals. A putative dileucine motif was
identified at the C-terminus of LC/A and was unique to that
serotype. The role of the dileucine motif in LC/A activity as well
as localization was investigated. The inventors found that a LC/A
construct that lacks 8 N-terminal and 22 C-terminal amino acids
(including the dileucine motif) retains minimal activity and is
mislocalized when expressed in PC12 cells. The specific role of the
dileucine motif was elucidated by generating a LL-->AA double
mutant. The LL-->AA mutant has minimally reduced activity, but
is mislocalized when expressed in PC12 cells. The mislocalization
is similar to that recently reported for the LL-->AA mutant of
VAMP4. Localization and activity data are reported, supporting the
hypothesis that the dileucine motif is important for proper
intracellular localization of LC/A.
[0232] Materials and Methods: LC from BoNT/A (Allergan Hall A), N-
and C-terminal truncated LC/A, and double mutant LC/A (LL-->AA)
were cloned into pQBI25 (Qbiogene) as both N- and C-terminal GFP
fusion proteins: GFP-LCA, LCA-GFP; GFP-LCA(LL-->AA);
LCA(LL-->AA)-GFP; GFP-LCA(.DELTA.N/.DELTA.C);
LCA(.DELTA.N/.DELTA.C)-GFP.
[0233] Undifferentiated PC12 (rat pheochromocytoma) cells were
transfected with Lipofectamine2000 (Invitrogen) and then were
differentiated with NGF (Harlan).
[0234] Expression and integrity of the light chains were assessed
by immuno-precipitation with a GFP monoclonal antibody (3E6,
Qbiogene), followed by western blot with antibodies to GFP (pAb,
Santa Cruz) or LCA (pAb, Allergan).
[0235] Catalytic activity of PC12 expressed LC-GFP fusion proteins
was determined by western blot analysis with the following
antibodies: [0236] SMI-81 (Sternberger) and N-19 (Santa Cruz):
Recognize full-length SNAP-25 as well as SNAP25.sub.197 [0237] pAb
SNAP25.sub.197: Polyclonal antibody generated at Allergan [0238]
specific to the BoNT/A cleaved peptide.
[0239] In vitro activity of rLC's was determined by SNAP25 ELISA
assay. Recombinant LC (rLC/A), truncated LC
(trunLC/A(.DELTA.N8/.DELTA.C22)), and double mutant
LC/A(LL-->AA) were cloned into pET-30(+) vectors containing
polyHis affinity tags. The LC's were purified via Ni.sup.+2
affinity chromatography.
[0240] A biotinylated substrate corresponding to SNAP25(134-206)
was immobilized on a streptavidin-coated microtiter plate. The
appropriate LC constructs and 900 kDa BoNT/A complex were added to
substrate coated plates. Protease activity was determined by
quantitating the formation of SNAP(134-197) with a pAb (Allergan)
specific for the proteolysis product. The activity of 900 kDa
BoNT/A complex was determined as a control.
[0241] Localization of the GFP fusions in paraformaldehyde fixed
cells was determined by confocal microscopy (Leica). Cell slices
from the middle of the cell are shown in the images.
[0242] FIG. 3 shows LC/A sequence with the 8 N-terminal and 22
C-terminal amino acids that were deleted in the LC/A
(.DELTA.N8/.DELTA.C22) construct underlined. The dileucine motif is
bracketed from the top with an asterisk. The two leucine residues
that were mutated to alanines are the two leucines in the dileucine
motif. Mutation of LL-->AA has been demonstrated to disrupt
appropriate trafficking and localization of membrane associated
proteins.
[0243] FIG. 11 shows a ribbon diagram of LC/A with a Connolly
surface overlay from Lacy et al., Nat. Struct. Biol., 5, 898 (1998)
which is incorporated in its entirety herein by reference. The N-
and C-terminal regions of interest are yellow with amino acid
side-chains included. The dileucine motif is red and the Zn.sup.2+
atom is a silver sphere. The structure was extracted from the
holotoxin x-ray structure and includes residues 1-430 (the 17
C-terminal amino acids were not resolved in the structure).
[0244] FIGS. 12 and 13 show GFP-LC/A recombinant fusion constructs
that are expressed and active when transfected in PC12 cells. FIG.
12 shows the detection of GFP-LC fusion proteins expressed in
differentiated PC12 cells by western blot. GFP-LC Fusion Proteins
Detected in PC12 Lysates. Lanes: G, GFP; LC, GFP-LC/A; AA,
GFP-LC/A(LL-->AA); TA, GFP-LCA(.DELTA.N8/.DELTA.C22). Expression
and integrity of the fusion proteins was also assessed with a pAb
to LCA.
[0245] FIG. 13 shows expressed LC's are Active Proteases. PC12
cells transfected with and expressing the appropriate GFP-LC fusion
construct were collected and lysed. Activity was assessed by
western blot using either antibodies specific to the cleaved
product of LCA (SNAP25.sub.197) or to the N-terminus of SNAP25
(recognizes both cleaved and uncleaved SNAP25). Truncated LC/A is
expressed less efficiently and appears to be much less active than
LCA. LCA(AA) appears to be slightly less active than LC/A in PC12
cells. N-19 (Santa Cruz) SMI-81 (Sternberger) are antibodies to
N-terminus SNAP25.sub.206.
[0246] FIGS. 14 and 15 show E. coli expression and in vitro
activity of rLC/A and mutants. FIG. 14 shows E. coli expression of
rLC/A and mutants. * corresponds to the minimal essential domain of
LC/A reported in Kadkhodayan et al, Prot. Exp. Purif., 19, 125
(2000) which is incorporated in its entirety herein by
reference.
[0247] FIG. 15 shows a SNAP-25 ELISA assay showing in vitro
activity of E. coli expressed rLC/A and mutants. SNAP25(134-206)
was immobilized on a streptavidin-coated microtitre plate. The
formation of SNAP-25(134-197) was quantified with an Ab specific to
that product. As a control 900 kDa BoNT/A complex was included.
rLC/A(LL-->AA) is approximately 10 fold less active than rLC/A.
Truncated LC/A is approximately 1000 fold less active than
rLC/A.
[0248] FIG. 16 shows PC12 cells transfected with plasmids encoding
GFP-LCA. Confocal images were captured at approximately the middle
of the cell. Subcellular localization of the light chain in PC12
cells is shown. Localization of LC/A at the plasma membrane can
clearly be observed. LCA-GFP displays the same localization pattern
(data not shown).
[0249] FIG. 17 shows PC12 cells transfected with plasmids encoding
GFP-LCA(.DELTA.N/.DELTA.C) and LCA(.DELTA.N/.DELTA.C)-GFP (data not
shown). The N- and C-terminal truncated form of LC/A may be
localized to an internal structure rather than at the plasma
membrane.
[0250] FIG. 18 shows confocal images of GFP-LCA(LL-->AA)
expressed in PC12 cells. Mutation to the dileucine motif disrupts
LC/A localization of the plasma membrane. The dileucine mutant is
localized in a more diffuse pattern than GFP-LCA. The localization
pattern is similar to that seen for VAMP4 dileucine mutant as
reported in Penden et al, J. Biol. Chem., 276, 49183 (2001) which
is incorporated in its entirety herein by reference.
[0251] The results shown in at least FIGS. 3 and 11 to 18
demonstrate that the presence of a dileucine motif is critical for
the proper intracellular localization of LC/A and may be important
for the long duration of action of BoNT/A.
[0252] Additional studies showed that a GFP-LCA construct with the
eight amino acid residues of SEQ ID NO: 27 (PFVNKQFN) deleted from
the N-terminus (no C-terminus deletion) localized in PC12 cells a
very similar pattern to the localization in PC12 cells of a
truncated GFP-LCA construct with both the C and N terminus
deletions.
[0253] Further studies showed that a GFP-LCA construct with the
twenty two amino acid residues of SEQ ID NO: 28
(KNFTGLFEFYKLLCVRGIITSK) deleted from the C-terminus (no N-terminus
deletion) localized in PC12 cells in a very similar manner to that
of the GFP-LCA(LL-->AA) mutant.
[0254] A GFP-LCA construct with both the eight amino acid residues
of SEQ ID NO: 27 (PFVNKQFN) deleted from the N-terminus and the
twenty two amino acid residues of SEQ ID NO: 28
(KNFTGLFEFYKLLCVRGIITSK) deleted from the C-terminus accumulated
intracellularly.
Example 16B
[0255] The first 30 residues of the amino-terminus (N-term) and the
last 50 residues of the carboxyl-terminal (C-term) of the amino
acid sequences of botulinum toxin serotypes A through G light
chains (LC) are shown in Table 2.
TABLE-US-00002 TABLE 2 Toxin N-term (AAs 1-30) of LC SEQ ID NO:
C-term (last 50 AAs) of LC SEQ ID NO: BoNT/A MPFVNKQFNYKDPVNGVDI 39
GFNLRNTNLAANFNGQNTE 40 AYIKIPNAGQM INNMNFTKLKNFTGLFEFY KLLCVRGIITSK
BoNT/B MPVTINNFNYNDPIDNDNI 41 YTIEEGFNISDKNMGKEYR 42 IMMEPPFARGT
GQNKAINKQAYEEISKEHL AVYKIQMCKSVK BoNT/C.sub.1 MPITINNFNYSDPVDNKNI
43 NIPKSNLNVLFMGQNLSRN 44 LYLDTHLNTLA PALRKVNPENMLYLFTKFC
HKAIDGRSLYNK BoNT/D MTWPVKDFNYSDPVNDNDI 45 YTIRDGFNLTNKGFNIENS 46
LYLRIPQNKLI GQNIERNPALQKLSSESVV DLFTKVCLRLTK BoNT/E
MPKINSFNYNDPVNDRTIL 47 GYNINNLKVNFRGQNANLN 48 YIKPGGCQEFY
PRIITPITGRGLVKKIIRF CKNIVSVKGIRK BoNT/F MPVAINSFNYNDPVNDDTI 49
TVSEGFNIGNLAVNNRGQS 50 LYMQIPYEEKS IKLNPKIIDSIPDKGLVEK IVKFCKSVIPRK
BoNT/G MPVNIKNFNYNDPINNDDI 51 QNEGFNIASKNLKTEFNGQ 52 IMMEPFNDPGP
NKAVNKEAYEEISLEHLVI YRIAMCKPVMYK
[0256] Alterations in the amino acid sequence of these serotypes
can include amino acid substitutions, mutations, deletions, or
various combinations of these alterations. Such alterations can be
engineered in the first thirty amino acids (AAs) in the N-terminus
of the light chain and/or the last fifty AAs in the C-terminus of
the light chain using recombinant DNA technological methods that
are standard in the art.
[0257] Examples of amino acid sequence substitutions include the
replacement of one or more contiguous or non-contiguous amino acids
in the first 30 amino acids of the N-terminus and/or the last 50
amino acids of the C-terminus of the light chain with an equal
number and placement of amino acids that differ from the wild-type
sequence. Substitutions can be conservative or non-conservative of
the character of the amino acid. For example, the amino acid valine
at a specific position in the wild-type sequence can be replaced
with an alanine in the same position in the substituted sequence.
Furthermore, basic residues such as arginine or lysine can be
substituted for highly hydrophobic residues such as tryptophan. A
proline or histidine residue may be substituted in order to form or
disrupt a potentially important structural or catalytic element of
the protein. Some examples of amino acid substitutions are
indicated by bold underlined text in the sequences described in
Table 3.
TABLE-US-00003 TABLE 3 SEQ SEQ N-term ID C-term (last ID Toxin (AAs
1-30) of LC NO: 50 AAs) of LC NO: BoNT/A MPFANKQFNYKDPVNGVD 53
GFNLRNTNLAANFNGQNT 54 IAYIKIPNAGQM EINNMNRTKLKNFTGLFE
FYKLLCVRGIITSK BoNT/A MPFVNKQFNKKDPVNGVD 55 GFNLRNTNLAANFNGQNT 56
IAYIKIPNAGQM EINNMNFTKLKNAAGLFE FYKLLCVRGIITSK BoNT/A
MPFVNKQFNYKDPVNGVD 57 GFNLRNTNLAANHNGQNT 58 IARIKIPNAGQM
EINNMNFTKLKNFTGLFE FYKLLCVRGIITSK BoNT/A MPFVNKHFNYKDPVNGVD 59
GFNLRNTNLAANFNGQNT 60 IAYIKIPNAGQM EINNMNFTKLKNFTGLFE
FYKLLCARGIITSK BoNT/B MPATINNFNYNDPIDNDN 61 YTIEEGFNISDKNMGKEY 62
IIMMEPPFARGT RGQNKAINKQAYEEISKE HLAVYKIRMCKSVK BoNT/B
MPVTINNFNYNDPIDNDN 63 YTIEEGFNISDKNMGKEY 64 IIAAEPPFARGT
RGQNKAINKQAYEEISKE HLAVRKIQMCKSVK BoNT/B MPVTINNFNRNDPIDNDN 65
YTIEEGFNISDKNMGKEY 66 IIMMEPPFARGT RGQNKAINKQAKEEISKE
HLAVYKIQMCKSVK BoNT/C.sub.1 MPITINNKNYSDPVDNKN 67
NIPKSNLNVLFMGQNLSR 68 ILYLDTHLNTLA NPALRKVNPENMLYLFTK
FCEKAIDGRSLRNK BoNT/D MTWPAKDFNYSDPANDND 69 YTIRDGFNLTNKGFNIEN 70
ILYLRIPQNKLI SGQNIERNPALQKLSSES VVDLFTKACLRLTK BoNT/E
MPKINSFNYNDPANDRTI 71 GYNINNLKVNFRGQNANL 72 LYIKPGGCQEFY
NPRIITPITGRGHVKKII RFCKNIVSVKGIRK BoNT/E MPKINSRNYNDPVNDRTI 73
GYNINNLKVNFRGQNANL 74 LYIKPGGCQEFY NPRIITPITGRGLVKKII
RFCKNAASVKGIRK BoNT/E MPKINSFNYNDPVNDRTI 75 GYNINNLKVNFRGQNANL 76
LYIKPGGCQEFR NPRIITPITGRGLVKKII RFCKNIVSAKGIRK BoNT/F
MPAAINSFNYNDPVNDDT 77 TVSEGFNIGNLAVNNRGQ 78 ILYMQIPYEEKS
SIKLNPKIIDSIPDKGLV EKIVKFCKSAIPRK BoNT/G MPVNIKNHNYNDPINNDD 79
QNEGFNIASKNLKTEFNG 80 IIMMEPFNDPGP QNKAVNKEAYEEISLEHL
VIYRIAMCKPAMYK
[0258] Examples of amino acid sequence mutations include changes in
the first 30 amino acids of the N-terminus and/or the last 50 amino
acids of the C-terminus of the light chain sequence such that one
or several amino acids are added, substituted and/or deleted such
that the identity, number and position of amino acids in the
wild-type light chain sequence is not necessarily conserved in the
mutated light chain sequence. Some examples of amino acid sequence
mutations are described in Table 4, in which additions of amino
acids are shown in bold underlined text, and deletions are
indicated by dashes in the sequences shown.
TABLE-US-00004 TABLE 4 SEQ SEQ N-term ID C-term (last) ID Toxin
(AAs 1-30) of LC NO: 50 AAs) of LC NO: BoNT/A MPFVNKQFNYKDPVNGVD 81
GFNLRNTNLAANFNGQNT 82 IAYIKIPH---- EINNMNAAAAAAAAAA--
-----CVRGIITSK BoNT/A MAAA----NYKDPVNGVD 83 GKNLRNTNLAANFNGQNT 84
IAYIKIPNAGQM EINNMNFTKLKNFTGLFE FYK-CVRGIITSK BoNT/A
MPFVNKQFNYKDPVNGVD 85 GFNLRNTNLAA----HNT 86 IAR----NAGQM
EINNMNFTKLKNFTGLFE FYKLLCVRGIITSK BoNT/A MPKVNKQFN----VNGVD 87
GFNLRNTNLAANFNGQNT 88 IAYIKIPNAGQM EINNMNFTKLKNFTGLFE
FRR--------TSK BoNT/B MPVTINNFNYNDPIDNDN 89 YTIPPGFNISDKNMGKEY 90
IIAAAAAAARGT RGQNKAINKQAYEEISK EH------------- BoNT/B
MPA----FNYNDPIDNDN 91 YTIEEGFNISDKNMGKEY 92 IIMMEPPFARGT
RGQNKAAAAAAAEEISKE HLAVYKIQMCKSVK BoNT/B MPVTINNFNR-------- 93
YTIEEGFNISDKNMGKEY 94 --MMEPPFARGT RGQNKAINKQAY------
AAAAAAIQMCKSVK BoNT/C.sub.1 M---------SDPVDNKN 95
NIPKSNLNVLFMGQNLSR 96 ILYLDTHLNTLA NPALRKVNPENMLAAA--
-CHKAIDGRSLYNK BoNT/D MTRPVKD----DPVNDND 97 YTIRDGFNLTNKGFNIEN 98
ILYLRIPQNKLI SGQNIERNPALQKL---- --DLPPKVCLRLTK BoNT/E
MPKINSPPNYNDPVNDRT 99 GYNINNLKVNFRGQNANL 100 ILYIKPGGCQEFY
NPRIITPITGRGLVKKAA AACKNIVSVKGIRK BoNT/E MPKINSFNYNDPAAAAND 101
GYNINNLKVNFRGQNANL 102 RTILYIKPGGCQEFY NPRIITPITGRGLV---H
RFCKNIVSVKGIRK BoNT/E MPKINSFNYNDPVNDRTI 103 GYNINNLKVNFRGQNANL 104
LKIKPGGCKEFY NPRIITPITGRGLPP--- -------------- BoNT/F
MP------NYNDPVNDDT 105 TVSEGFNIGNLAVNNRGQ 106 ILYMQIPYEEKS
SIKLNPKIIDSIPDKGAA AAAA--CKSVIPRK BoNT/G MPVNIPP----DPINNDD 107
QNEGFNIASKNLKTEFNG 108 IIMMEPFNDPGP QNKAVNKEAY--------
-------AAAAAAA
[0259] Examples of amino acid sequence deletions include the
removal of one or more contiguous or non-contiguous amino acids
from the first 30 amino acids of the N-terminus and/or the last 50
amino acids of the C-terminus of the light chain sequence. Some
examples of amino acid sequence deletions are indicated by dashes
in the sequences shown in Table 5.
TABLE-US-00005 TABLE 5 SEQ SEQ N-term ID C-term (last) ID Toxin
(AAs 1-30) of LC NO: 50 AAs) of LC NO: BoNT/A M--------YKDPVNGVD
109 GFNLRNTNLAANFNGQNT 110 IAYIKIPNAGQM EINNMNFTKLKNFTGLFE
FYK----------- BoNT/A MPFVNKQ------VNGVD 111 GFNLRNTNLAANFNGQNT 112
IAYIKIPNAGQM EINNMNFTKLK------- ---LLCVRGIITSK BoNT/A
MPFVNKQFNYKDP----- 113 GFNLRNTNLAANFNGQNT 114 -AYIKIPNAGQM
EINNMN--------GLFE FYKLLCVRGIITSK BoNT/A MPFVNKQFNYKDPVNGVD 115
GFNLRN----------NT 116 IA---------- EINNMNFTKLKNFTGLFE
FYKLLCVRGIITSK BoNT/B MPVTINNFNYNDPIDNDN 117 YTI-----ISDKNMGKEY 118
IIMME------- RGQNKAINKQAYEEISKE ELAVYKIQMCKSVK BoNT/B
MPVTINNFNYND------ 119 YTIEEGFNISD------- 120 ----EPPFARGT
-GQNKAINKQAYEEISKE HLAVYKIQMCKSVK BoNT/B MP--------NDPIDNDN 121
YTIEEGFNISDKNMGKEY 122 IIMMEPPFARGT RGQNKAINKQA-------
-----KIQMCKSVK BoNT/C1 MPI-------SDPVDNKN 123 NIPKSNLNVLFMGQNLSR
124 ILYLDTHLNTLA NPALRKV----------K FCHKAIDGRSLYNK BoNT/D
MTW----------VNDND 125 YTIRDGFNLTNKGFNIEN 126 ILYLRIPQNKLI
SGQNIERNPA-------- --DLFTKVCLRLTK BoNT/E MP--------DPVNDRTI 127
GYNINNLKVNFRGQNANL 128 LYIKPGGCQEFY NPRIITPI----------
RFCKNIVSVKGIRK BoNT/E MPKINSFNYN-------- 129 GYNINN------GQNANL 130
--IKPGGCQEFY NPRIITPITGRGLVKKII RFCKNIVSVKGIRK BoNT/E
MPKINSFNYNDPVNDRTI 131 GYNINNLKVNFRGQNANL 132 LYIK--------
NPRIITPITGRGLVKKII R--------KGIRK BoNT/F MPVAINSFNYNDPVNDDT 133
TVSEGFNIGNLAVNNRGQ 134 ILYMQIP----- SIKLNPKIIDSIPD----
----KFCKSVIPRK BoNT/G M----------------- -- QNEGFNIASKNLKTEFNG 135
------------ QNKAVNKEA--------- ---RIAMCKPVMYK
Example 16C
[0260] In some embodiments of the present invention, the biological
persistence and/or the enzymatic activity of a toxin can be altered
by structurally modifying the toxin. In some embodiments, the
structural modification includes the substitution, mutation or
deletion of amino acids within the toxin. In a suitable embodiment,
the structural modification includes a chimeric fusion construct in
which a biological persistence-enhancing component or an enzymatic
activity-enhancing component may be fused to, swapped for, or
incorporated within a terminal end of the light chain of a
botulinum toxin. In some embodiments, the structural modification
includes a chimeric fusion construct in which a biological
persistence-reducing component or an enzymatic activity-reducing
component may be fused to, swapped for, or incorporated within a
terminal end of the light chain of a botulinum toxin. In a suitable
embodiment, the persistence- or activity-enhancing or persistence-
or activity-reducing component is an N-terminal region including
the first 30 amino acids of a light chain of a botulinum toxin, or
a C-terminal region including the last 50 amino acids of a light
chain of a botulinum toxin. This biological persistence- or
enzymatic activity-enhancing component or biological persistence-
or enzymatic activity-reducing component is swapped for, fused to,
or incorporated within an N- and/or C-terminus of a light chain of
a botulinum toxin to enhance or reduce its biological persistence
and/or enzymatic activity.
[0261] In some embodiments, the fusion of, addition to, or swapping
of the N-terminal region of the light chain of BoNT/A into a
chimeric construct results in an increase in biological persistance
and/or enzymatic activity. In some embodiments, a substituted,
mutated, or deleted N-terminal region of the light chain of BoNT/A
within a chimeric construct results in a decrease in biological
persistance and/or enzymatic activity. In some embodiments, the
fusion of, addition to, or swapping of the C-terminal region of the
light chain of BoNT/A into a chimeric construct results in an
increase in biological persistance and/or enzymatic activity. In
some embodiments, a substituted, mutated, or deleted C-terminal
region of the light chain of BoNT/A within a chimeric construct
results in a decrease in biological persistance and/or enzymatic
activity.
[0262] Generally, it is suitable that the chimeric toxin has a
biological persistence of about 20% to 300% greater than an
identical toxin without the structural modification. The biological
persistence of the chimeric toxin may be enhanced by about 100%.
That is, for example, the modified botulinum neurotoxin including
the biological persistence-enhancing component is able to cause a
substantial inhibition of neurotransmitter release (for example,
acetylcholine) from a nerve terminal for about 20% to about 300%
longer than a neurotoxin without the structural modification.
[0263] Similarly, it is suitable that the chimeric botulinum toxin
light chain has an altered enzymatic activity. For example, the
chimeric toxin can exhibit a reduced or an enhanced inhibition of
exocytosis (such as exocytosis of a neurotransmitter) from a target
cell with or without any alteration in the biological persistence
of the modified neurotoxin. Altered enzymatic activities include
increased or decreased efficiency or potency, increased or
decreased localization to the plasma membrane, increased or
decreased substrate specificity, and/or increased or decreased rate
of proteolysis of SNAP/SNARE proteins. An increase in enzymatic
activity can be from 1.5 to 5 times greater than the biological
activity of the native or unmodified light chain. For example, the
chimeric botulinum neurotoxin including the enzymatic
activity-enhancing component is able to cause a substantial
inhibition of neurotransmitter release (for example, acetylcholine)
from a nerve terminal due to an increased rate of proteolysis of
the SNAP-25 substrate as compared to a neurotoxin without the
structural modification.
[0264] It has been observed that a recombinant construct with both
the eight amino acid residues of SEQ ID NO: 27 (PFVNKQFN) deleted
from the N-terminus and the twenty-two amino acid residues of SEQ
ID NO: 28 (KNFTGLFEFYKLLCVRGIITSK) deleted from the C-terminus of
the light chain of botulinum toxin A exhibits a reduced activity
such that the effective concentration (EC.sub.50) required to
cleave the SNAP-25 substrate is nearly ten-fold greater than that
of a similar construct with only the C-terminal twenty-two amino
acid deletion (EC.sub.50 .DELTA.N8.DELTA.C22=4663 pM vs.
EC.sub.50.DELTA. C22=566 pM). The recombinant light chain of
botulinum toxin A was used as a control (EC.sub.50 rLC/A=7 pM),
and, therefore, as compared to the rLC/A construct, a 666-fold
greater concentration of the .DELTA.N.DELTA.8C22 construct is
required. A recombinant light chain construct with the dileucine
motif mutated to dialanine [rLC/A(LL-->AA)] also exhibits
reduced activity (EC.sub.50 rLC/A(LL-->AA)=184 pM); however, the
effective concentration of the .DELTA.N8.DELTA.C22 construct is
twenty-five fold greater than the rLC/A(LL-->AA) construct.
[0265] A modified light chain may include a light chain from
botulinum toxins A, B, C1, D, E, F or G. One or multiple domains at
the N- and/or C-terminus may be modified by addition, deletion or
substitution. For example, a modified chimeric light chain
component may include a light chain from BoNT/E modified by adding
or replacing/substituting one or more N- and/or C-terminal end
sequences derived from the BoNT/A light chain, thereby resulting in
a chimeric BoNT/E-BoNT/A chimeric light chain with one or both
terminal ends having one or more sequences which convey an
increased or decreased ability to localize to a plasma membrane,
increased or decreased biological persistence and/or an increased
or decreased enzymatic activity.
[0266] A chimeric botulinum toxin can be constructed such that a
C-terminal portion of the light chain of one botulinum toxin
serotype replaces a similar C-terminal portion within the light
chain of another botulinum toxin serotype. For example, the last
twenty two amino acid residues bearing the dileucine motif from the
C-terminus of the light chain of BoNT/A can replace the last twenty
two amino acid residues of the C-terminus of the light chain of
BoNT/E. The amino acid sequence of the entire light chain of such a
chimeric construct is shown below:
TABLE-US-00006 SEQ ID NO: 136
MPKINSFNYNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGT
TPQDFHPPTSLKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRINNNLSG
GILLEELSKANPYLGNDNTPDNQFHIGDASAVEIKFSNGSQDILLPNVII
MGAEPDLFETNSSNISLRNNYMPSNHGFGSIAIVTFSPEYSFRFNDNSMN
EFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQKQNPLITNIRGTNIE
EFLTFGGTDLNIITSAQSNDIYTNLLADYKKIASKLSKVQVSNPLLNPYK
DVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLATKFQVKCRQT
YIGQYKYFKLSNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIITPIT
GKNFTGLFEFYKLLCVRGIITSK
[0267] In the construct above, the majority of the amino acid
sequence is derived from BoNT/E serotype, and the amino acids shown
in bold underlined text are derived from the last twenty two amino
acid residues of the C-terminus of the light chain of BoNT/A which
bears the dileucine motif.
[0268] In a further example, the first thirty amino acid residues
from the N-terminus of the light chain of BoNT/A can replace the
first thirty amino acid residues of the N-terminus of the light
chain of BoNT/B. The amino acid sequence of the entire light chain
of such a chimeric construct is shown below:
TABLE-US-00007 SEQ ID NO: 137
MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMGRYYKAFKITDRIWIIPERY
TFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFFQTLIKLFNRIK
SKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVER
KKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYV
SVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIV
PNEKKFFMQSTDTIQAEELYTFGGQDPSIISPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFNKLYK
SLMLGFTEINIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNI
SDKNMGKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVK
[0269] In the construct above, the majority of the amino acid
sequence is derived from BoNT/B serotype, and the amino acids shown
in bold underlined text are derived from the first thirty amino
acid residues of the N-terminus of the light chain of BoNT/A.
[0270] Still further, the chimeric construct can have both
N-terminal and the C-terminal replacements. For example, the first
nine amino acid residues from the N-terminus of the light chain of
BoNT/A can replace the first nine amino acid residues of the
N-terminus of the light chain of BoNT/E. Additionally, in the same
construct, the last twenty-two amino acid residues from the
C-terminus of the light chain of BoNT/A can replace the last
twenty-two amino acid residues from the C-terminus of the light
chain of BoNT/E. The amino acid sequence of the entire light chain
of such a chimeric construct is shown below:
TABLE-US-00008 SEQ ID NO: 138
MPFVNKQFNNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGT
TPQDFHPPTSLKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRINNNLSG
GILLEELSKANPYLGNDNTPDNQFHIGDASAVEIKFSNGSQDILLPNVII
MGAEPDLFETNSSNISLRNNYMPSNHGFGSIAIVTFSPEYSFRFNDNSMN
EFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQKQNPLITNIRGTNIE
EFLTFGGTDLNIITSAQSNDIYTNLLADYKKIASKLSKVQVSNPLLNPYK
DVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLATKFQVKCRQT
YIGQYKYFKLSNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIITPIT
GKNFTGLFEFYKLLCVRGIITSK
[0271] In the construct above, the majority of the amino acid
sequence is derived from BoNT/E serotype, and the amino acids shown
in bold underlined text are derived from the first nine amino acid
residues of the N-terminus and the last twenty-two amino acid
residues of the C-terminus of the light chain of BoNT/A.
[0272] Similarly, the first nine amino acid residues from the
N-terminus of the light chain of BoNT/A can replace the first nine
amino acid residues of the N-terminus of the light chain of BoNT/B.
Additionally, in the same construct, the last twenty-two amino acid
residues from the C-terminus of the light chain of BoNT/A can
replace the last twenty-two amino acid residues from the C-terminus
of the light chain of BoNT/B. The amino acid sequence of the entire
light chain of such a chimeric construct is shown below:
TABLE-US-00009 SEQ ID NO: 139
MPFVNKQFNYNDPIDNDNIIMMEPPFARGTGRYYKAFKITDRIWIIPERY
TFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFFQTLIKLFNRIK
SKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVER
KKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYV
SVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIV
PNEKKFFMQSTDTIQAEELYTFGGQDPSIISPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFNKLYK
SLMLGFTEINIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNI
SDKNMGKEYRGQNKAINKQKNFTGLFEFYKLLCVRGIITSK
[0273] In the construct above, the majority of the amino acid
sequence is derived from BoNT/B serotype, and the amino acids shown
in bold underlined text are derived from the first nine amino acid
residues of the N-terminus and the last twenty-two amino acid
residues of the C-terminus of the light chain of BoNT/A.
[0274] Furthermore, the first nine amino acid residues from the
N-terminus of the light chain of BoNT/A can replace the first nine
amino acid residues of the N-terminus of the light chain of BoNT/F.
Additionally, in the same construct, the last twenty-two amino acid
residues from the C-terminus of the light chain of BoNT/A can
replace the last twenty-two amino acid residues from the C-terminus
of the light chain of BoNT/F. The amino acid sequence of the entire
light chain of such a chimeric construct is shown below:
TABLE-US-00010 SEQ ID NO: 140
MPFVNKQFNYNDPVNDDTILYMQIPYEEKSKKYYKAFEIMRNVWIIPERN
TIGTNPSDFDPPASLKNGSSAYYDPNYLTTDAEKDRYLKTTIKLFKRINS
NPAGKVLLQEISYAKPYLGNDHTPIDEFSPVTRTTSVNIKLSTNVESSML
LNLLVLGAGPDIFESCCYPVRKLIDPDVVYDPSNYGFGSINIVTFSPEYE
YTFNDISGGHNSSTESFIADPAISLAHELIHALHGLYGARGVTYEETIEV
KQAPLMIAEKPIRLEEFLTFGGQDLNIITSAMKEKIYNNLLANYEKIATR
LSEVNSAPPEYDINEYKDYFQWKYGLDKNADGSYTVNENKFNEIYKKLYS
FTESDLANKFKVKCRNTYFIKYEFLKVPNLLDDDIYTVSEGFNIGNLAVN
NRGQSIKLNPKIIDKNFTGLFEFYKLLCVRGIITSK
[0275] In the construct above, the majority of the amino acid
sequence is derived from BoNT/F serotype, and the amino acids shown
in bold underlined text are derived from the first nine amino acid
residues of the N-terminus and the last twenty-two amino acid
residues of the C-terminus of the light chain of BoNT/A.
[0276] In some embodiments, a light chain can be engineered such
that one or more segments of the light chain of one or more toxin
serotypes replace one or more segments of equal or unequal length
within the light chain of another toxin serotype. In a non-limiting
example of this kind of chimeric construct, fifty amino acid
residues from the N-terminus of the light chain of BoNT/A can
replace eight amino acid residues of the N-terminus of the light
chain of BoNT/B, resulting in a net gain of forty-two amino acids
in length in the N-terminal region of the light chain chimera. The
amino acid sequence of the entire light chain of such a chimeric
construct is shown below:
TABLE-US-00011 SEQ ID NO: 141
MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDT
FYNDPIDNDNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPED
FNKSSGIFNRDVCEYYDPDYLNTNDKKNIFFQTLIKLFNRIKSKPLGEKL
LEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANL
IIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQE
NKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFM
QSTDTIQAEELYTFGGQDPSIISPSTDKSIYDKVLQNFRGIVDRLNKVLV
CISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFNKLYKSLMLGFTE
INIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKNMGKE
YRGQNKAINKQAYEEISKEHLAVYKIQMCKSVK
[0277] In the construct above, the majority of the amino acid
sequence is derived from BoNT/B serotype, and the amino acids shown
in bold underlined text are derived from the first fifty amino acid
residues of the N-terminus of the light chain of BoNT/A.
[0278] In a non-limiting example of this kind of chimeric
construct, the last fifty amino acid residues from the C-terminus
of the light chain of BoNT/A can replace fifteen amino acid
residues within the C-terminus of the light chain of BoNT/E,
resulting in a net gain of thirty-five amino acids in the
C-terminal region of the light chain chimera. The amino acid
sequence of the entire light chain of such a chimeric construct is
shown below:
TABLE-US-00012 SEQ ID NO: 142
MPKINSFNYNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGT
TPQDFHPPTSLKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRINNNLSG
GILLEELSKANPYLGNDNTPDNQFHIGDASAVEIKFSNGSQDILLPNVII
MGAEPDLFETNSSNISLRNNYMPSNHGFGSIAIVTFSPEYSFRFNDNSMN
EFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQKQNPLITNIRGTNIE
EFLTFGGTDLNIITSAQSNDIYTNLLADYKKIASKLSKVQVSNPLLNPYK
DVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLATKFQVKCRQT
YIGQYKYFKLSNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIITPGF
NLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKNI VSVKGIRK
[0279] In the construct above, the majority of the amino acid
sequence is derived from BoNT/E serotype, and the amino acids shown
in bold underlined text are derived from the last fifty amino acid
residues of the C-terminus of the light chain of BoNT/A.
[0280] In a non-limiting example of this kind of chimeric
construct, thirty amino acid residues from the N-terminus of the
light chain of BoNT/A can replace ten amino acid residues of the
N-terminus of the light chain of BoNT/E, resulting in a net gain of
twenty amino acids in length in the N-terminal region of the
chimera. Additionally, in the same construct, the last fifty amino
acid residues from the C-terminus of the light chain of BoNT/A can
replace the last fifty amino acid residues from the C-terminus of
the light chain of BoNT/E. The amino acid sequence of the entire
light chain of such a chimeric construct is shown below:
TABLE-US-00013 SEQ ID NO: 143
MPKINSFNYMPFVNKQFNYKDPVNGVDIAYIKIPNAGQMYIKPGGCQEFY
KSFNIMKNIWIIPERNVIGTTPQDFHPPTSLKNGDSSYYDPNYLQSDEEK
DRFLKIVTKIFNRINNNLSGGILLEELSKANPYLGNDNTPDNQFHIGDAS
AVEIKFSNGSQDILLPNVIIMGAEPDLFETNSSNISLRNNYMPSNHGFGS
IAIVTFSPEYSFRFNDNSMNEFIQDPALTLMHELIHSLHGLYGAKGITTK
YTITQKQNPLITNIRGTNIEEFLTFGGTDLNIITSAQSNDIYTNLLADYK
KIASKLSKVQVSNPLLNPYKDVFEAKYGLDKDASGIYSVNINKFNDIFKK
LYSFTEFDLATKFQVKCRQTYIGQYKYFKLSNLLNDSIYNISEGFNLRNT
NLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSK
[0281] In the construct above, the majority of the amino acid
sequence is derived from BoNT/E serotype, and the amino acids shown
in bold underlined text are derived from the thirty amino acid
residues of the N-terminus and the last fifty amino acid residues
of the C-terminus of the light chain of BoNT/A.
[0282] In a non-limiting example of this kind of chimeric
construct, thirty amino acid residues from the N-terminus of the
light chain of BoNT/A can replace ten amino acid residues of the
N-terminus of the light chain of BoNT/B, resulting in a net gain of
twenty amino acids in length in the N-terminal region of the
chimera. Additionally, in the same construct, the last fifty amino
acid residues from the C-terminus of the light chain of BoNT/A can
replace the last fifty amino acid residues from the C-terminus of
the light chain of BoNT/B. The amino acid sequence of the entire
light chain of such a chimeric construct is shown below:
TABLE-US-00014 SEQ ID NO: 144
MPVTINNFNMPFVNKQFNYKDPVNGVDIAYIKIPNAGQMIMMEPPFARGT
GRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLN
TNDKKNIFFQTLIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFN
TNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMH
ELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDTIQAEELYTFGGQDPSII
SPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKF
VEDSEGKYSIDVESFNKLYKSLMLGFTEINIAENYKIKTRASYFSDSLPP
VKIKNLLDNEIGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYK LLCVRGIITSK
[0283] In the construct above, the majority of the amino acid
sequence is derived from BoNT/B serotype, and the amino acids shown
in bold underlined text are derived from the thirty amino acid
residues of the N-terminus and the last fifty amino acid residues
of the C-terminus of the light chain of BoNT/A.
[0284] In a non-limiting example of this kind of chimeric
construct, thirty amino acid residues from the N-terminus of the
light chain of BoNT/A can replace ten amino acid residues of the
N-terminus of the light chain of BoNT/F, resulting in a net gain of
twenty amino acids in length in the N-terminal region of the
chimera. Additionally, in the same construct, the last fifty amino
acid residues from the C-terminus of the light chain of BoNT/A can
replace the last fifty amino acid residues from the C-terminus of
the light chain of BoNT/F. The amino acid sequence of the entire
light chain of such a chimeric construct is shown below:
TABLE-US-00015 SEQ ID NO: 145
MPVAINSFNMPFVNKQFNYKDPVNGVDIAYIKIPNAGQMLYMQIPYEEKS
KKYYKAFEIMRNVWIIPERNTIGTNPSDFDPPASLKNGSSAYYDPNYLTT
DAEKDRYLKTTIKLFKRINSNPAGKVLLQEISYAKPYLGNDHTPIDEFSP
VTRTTSVNIKLSTNVESSMLLNLLVLGAGPDIFESCCYPVRKLIDPDVVY
DPSNYGFGSINIVTFSPEYEYTFNDISGGHNSSTESFIADPAISLAHELI
HALHGLYGARGVTYEETIEVKQAPLMIAEKPIRLEEFLTFGGQDLNIITS
AMKEKIYNNLLANYEKIATRLSEVNSAPPEYDINEYKDYFQWKYGLDKNA
DGSYTVNENKFNEIYKKLYSFTESDLANKFKVKCRNTYFIKYEFLKVPNL
LDDDIYGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVR GIITSK
[0285] In the construct above, the majority of the amino acid
sequence is derived from BoNT/F serotype, and the amino acids shown
in bold underlined text are derived from the thirty amino acid
residues of the N-terminus and the last fifty amino acid residues
of the C-terminus of the light chain of BoNT/A.
[0286] In some embodiments, the swapped sequences can be derived
from two different serotypes, resulting in a chimera with regions
from three different serotypes in all. In this example, eight amino
acid residues from the N-terminus of the light chain of BoNT/B can
replace five amino acid residues of the N-terminus of the light
chain of BoNT/E, resulting in a net gain of three amino acids in
length in the N-terminal region of the chimera. Additionally, in
the same construct, 30 amino acid residues including the dileucine
repeat of the C-terminus of the light chain of BoNT/A can replace
ten amino acid residues within the C-terminus of the light chain of
BoNT/E, resulting in a net gain of 20 amino acids in the C-terminal
region of the chimera. The amino acid sequence of the entire light
chain of such a chimeric construct is shown below:
TABLE-US-00016 SEQ ID NO: 146 MPKINSFNYNDP
DRTILYIKPGGCQEFYKSFNIMKNIWIIPE
RNVIGTTPQDFHPPTSLKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRI
NNNLSGGILLEELSKANPYLGNDNTPDNQFHIGDASAVEIKFSNGSQDIL
LPNVIIMGAEPDLFETNSSNISLRNNYMPSNHGFGSIAIVTFSPEYSFRF
NDNSMNEFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQKQNPLITNI
RGTNIEEFLTFGGTDLNIITSAQSNDIYTNLLADYKKIASKLSKVQVSNP
LLNPYKDVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLATKFQ
VKCRQTYIGQYKYFKLSNLLNDSIYNISEGYNINNLKVNFRGQNANLNPR
IITPITGRGLVKKIIRFCKNNMNFTKLKNFTGLFEFYKLLCVRGIITSK
[0287] In the construct above, the majority of the amino acid
sequence is derived from BoNT/E serotype, and the amino acids shown
in bold italicized text are derived from eight amino acid residues
of the N-terminus of the light chain of BoNT/B and thirty amino
acid residues shown in bold underlined text are derived from thirty
amino acid residues of the C-terminus of the light chain of
BoNT/A.
[0288] In a non-limiting example, eight amino acid residues from
the N-terminus of the light chain of BoNT/B can replace five amino
acid residues of the N-terminus of the light chain of BoNT/F,
resulting in a net gain of three amino acids in length in the
N-terminal region of the chimera. Additionally, in the same
construct, 30 amino acid residues including the dileucine repeat of
the C-terminus of the light chain of BoNT/A can replace ten amino
acid residues within the C-terminus of the light chain of BoNT/F,
resulting in a net gain of 20 amino acids in the C-terminal region
of the chimera. The amino acid sequence of the entire light chain
of such a chimeric construct is shown below:
TABLE-US-00017 SEQ ID NO: 147 MPVAINSFNYND
TILYMQIPYEEKSKKYYKAFEIMRNVWIIP
ERNTIGTNPSDFDPPASLKNGSSAYYDPNYLTTDAEKDRYLKTTIKLFKR
INSNPAGKVLLQEISYAKPYLGNDHTPIDEFSPVTRTTSVNIKLSTNVES
SMLLNLLVLGAGPDIFESCCYPVRKLIDPDVVYDPSNYGFGSINIVTFSP
EYEYTFNDISGGHNSSTESFIADPAISLAHELIHALHGLYGARGVTYEET
IEVKQAPLMIAEKPIRLEEFLTFGGQDLNIITSAMKEKIYNNLLANYEKI
ATRLSEVNSAPPEYDINEYKDYFQWKYGLDKNADGSYTVNENKFNEIYKK
LYSFTESDLANKFKVKCRNTYFIKYEFLKVPNLLDDDIYTVSEGFNIGNL
AVNNRGQSIKLNPKIIDSIPDKGLVEKNNMNFTKLKNFTGLFEFYKLLCV RGIITSKRK
[0289] In the construct above, the majority of the amino acid
sequence is derived from BoNT/F serotype, and the amino acids shown
in bold italicized text are derived from eight amino acid residues
of the N-terminus of the light chain of BoNT/B and thirty amino
acid residues shown in bold underlined text are derived from thirty
amino acid residues of the C-terminus of the light chain of
BoNT/A.
Example 16D
[0290] The invention also provides for a light chain of a botulinum
toxin B, C1, D, E, F or G comprising about the first 30 amino acids
from the N-terminus of the light chain of botulinum toxin type A
and about the last 50 amino acids from the C-terminus of the light
chain of botulinum toxin type A. The first 30 amino acids of the
N-terminus of type A here may be all or part, for example 2-16
contiguous or non contiguous amino acids, of the 30 amino acids.
The last 50 amino acids here may be all or part, for example 5-43
contiguous or non-contiguous, amino acids of the 50 amino
acids.
[0291] In some embodiments, such a light chain comprises about the
first 20 amino acids from the N-terminus of the light chain of
botulinum toxin type A and about the last 30 amino acids from the
C-terminus of the light chain of botulinum toxin type A. The first
20 amino acids of the N-terminus of type A here may be all or part,
for example 2-16 contiguous or non contiguous amino acids, of the
20 amino acids. The last 30 amino acids here may be all or part,
for example 5-23 contiguous or non-contiguous, amino acids of the
30 amino acids.
[0292] In some embodiments, such a light chain comprises about the
first 4 to 8, e.g. the first 8, amino acids from the N-terminus of
the light chain of botulinum toxin type A and about the last 7 to
22, e.g. the last 22, amino acids from the C-terminus of the light
chain of botulinum toxin type A. The first 8 amino acids of the
N-terminus of type A here may be all or part, for example 2-7
contiguous or non contiguous amino acids, of the 7 amino acids. The
last 22 amino acids here may be all or part, for example 5-16
contiguous or non-contiguous, amino acids of the 20 amino
acids.
[0293] In some embodiments, the inclusion of about the first 30
amino acids from the N-terminus and about the last 50 amino acids
from the C-terminus of the light chain of type A replaces one or
more amino acids at the N- and C-termini, respectively, of the
light chain of botulinum toxin type B, C1, D, E, F or G. The first
30 amino acids of the N-terminus of type A here may be all or part,
for example 2-16 contiguous or non contiguous amino acids, of the
30 amino acids. The last 50 amino acids here may be all or part,
for example 5-43 contiguous or non-contiguous, amino acids of the
50 amino acids.
[0294] In some embodiments, the inclusion of about the 20 amino
acids from the N-terminus and about the 30 amino acids from the
C-terminus of the light chain of type A replaces one or more amino
acids at the N- and C-termini, respectively, of the light chain of
botulinum toxin type B, C1, D, E, F or G. The first 20 amino acids
of the N-terminus of type A here may be all or part, for example
2-16 contiguous or non contiguous amino acids, of the 20 amino
acids. The last 30 amino acids here may be all or part, for example
5-23 contiguous or non-contiguous, amino acids of the 30 amino
acids.
[0295] In some embodiments, the inclusion of about the first 4 to
8, for example the first 8, amino acids from the N-terminus and
about the last 7 to 22, for example the last 22, amino acids from
the C-terminus of the light chain of type A replaces one or more
amino acids at the N- and C-termini, respectively, of the light
chain of botulinum toxin type B, C1, D, E, F or G. The first 8
amino acids of the N-terminus of type A here may be all or part,
for example 2-7 contiguous or non contiguous amino acids, of the 7
amino acids. The last 22 amino acids here may be all or part, for
example 5-16 contiguous or non-contiguous, amino acids of the 20
amino acids.
[0296] The invention also provides for a modified botulinum toxin
comprising the light chain of described herein, including the ones
described in Example 16D.
Example 17
Intracellular Localization of Botulinum Toxin Types A, B and E
Light Chains in Neuronal and Non-Neuronal Cells
[0297] Clostridial neurotoxins inhibit neurotransmission by
cleavage of a SNARE protein; each serotype has a distinct
therapeutic profile regarding efficacy, safety, and duration of
action (BoNT/A>BoNT/B>>BoNT/E). After the toxin is
internalised, the catalytic light chain (LC) translocates into the
cytosol and cleaves one of the SNARE proteins. Differences in
subcellular localization may influence the pharmacology of
different serotypes. Constructs were generated encoding the LC from
serotypes A, B and E fused with green fluorescent protein (GFP) at
N- or C-terminus and transfected them into PC12 cells that were
differentiated after transfection. Expression and catalytic
activity of LC's were assessed by western blotting. Confocal
microscopy reveals that GFP-LCA and LCA-GFP are localized in a
punctate pattern on the plasma membrane and neurites, (very similar
to the localization of GFP-SNAP-25). GFP-LCE and LCE-GFP are
dispersed in the cytoplasm but their localization is markedly
different from that of GFP alone. GFP-LCB is also cytosolic but
different from GFP-LCE, while LCB-GFP is located in an internal
structure. Localization data demonstrated that LCB-GFP is
accumulated intracellularly (i.e. "localized" to the cytosol) and
Western blot analysis demonstrated that this protein construct is
being degraded in PC12 cells.
[0298] Thus, the LCB-GFP was noted to be in an extremely bright and
presumably high concentration of LCB-GFP in a tight area and it was
not cytosolic (was not diffuse throughout the cytosol). It may be
that the LCB-GFP was, for example, retained in the ER (as is the
case for some misfolded proteins), in a protein degradation
path/organelle, or in an aggregation and precipitation within the
cell (i.e. in an aggresome).
The inventors have shown that this pattern of localization is not
unique to neuronal cells. Two non-neuronal cell lines: HeLa
(adenocarcinoma of cervix) and HEK293T (human embryonic kidney)
were transfected with the above described constructs. The various
GFP-LC constructs expressed in HeLa cells displayed very similar
patterns of localization for all serotypes, compared to those
expressed in PC12 cells. Expression of the GFP-LC constructs in
HEK293T cells resulted in a mixed patterns of localization with
several constructs having similarities to LCB-GFP. Western blot
analysis of the expressed proteins demonstrated that all the LC's
were being degraded in HEK293T cells.
Materials and Methods:
[0299] The Light Chain genes from BoNT/A (Allergan Hall A), BoNT/B
(NCTC 7273 Beans) and BoNT/E (NCTC 11219) were amplified from
genomic DNA by PCR. The genes were cloned into pQBI25 plasmids
(Qbiogene) as fusion proteins with GFP at the N-terminus or
separately at the C-terminus:
[0300] GFP-LCA (GLCA), LCA-GFP; GFP-LCB (GLCB), LCB-GFP (LCBG);
GFP-LCE (GLCE), LCE-GFP (LCEG)
[0301] The cell lines used for transfection were:
[0302] PC12: rat pheochromocytoma (chromaffin cells). NGF induces
properties of sympathetic neurons.
[0303] HeLa cells: adenocarcinoma of cervix. Epithelial,
non-secretory, no SNAP25, no VAMP-2.
[0304] HEK293T cells: primary human embryonal kidney transformed
with SV40. No SNAP25, no VAMP-2 expression
[0305] Cell lines were transfected using Lipofectamine2000
(Invitrogen). PC12 cells were transfected under undifferentiated
conditions and were differentiated afterwards with NGF (Harlan).
Plasmids expressing GFP alone were used as a control in all
experiments.
[0306] Expression and integrity of the transfected GFP-Light Chain
fusions was assessed by immunoprecipitation using a GFP monoclonal
antibody (3E6, Qbiogene), followed by western blot with antibodies
probing for GFP (PolyAb, Santa Cruz) or LCA (PolyAb generated at
Allergan).
[0307] Catalytic activity of the expressed Light Chain fusion
proteins was determined by western blot using the following
antibodies:
[0308] SMI-81 (Sternberger) and N-19 (Santa Cruz): Recognize
cleaved (BoNT/A and BoNT/E) and full length SNAP 25.
[0309] PolyAb SNAP25.sub.197: Polyclonal antibody generated at
Allergan, specific to the BoNT/A cleaved peptide.
[0310] PolyAb SNAP25.sub.180: Polyclonal antibody generated at
Allergan, specific to the BoNT/E cleaved peptide.
[0311] Localization of the Light Chains was determined by confocal
microscopy (Leica). Cell slices were taken at several positions in
the transfected cells. Slices with the focal point at the middle of
the cell are shown.
[0312] Inhibition of exocytosis as a result of expressing GFP-LCs
was assessed by quantitation of .sup.3H-noradrenaline release
induced by K.sup.+/Ca.sup.2+ stimulation.
[0313] Cells were loaded for 4 hours with .sup.3H-noradrenaline at
0.042 mM in culture media, and then washed 3.times. with PBS.
Exocytosis was induced with K.sup.+ in a Ca.sup.2+ containing
buffer.
[0314] FIGS. 19 and 20 show the expression and activity of light
chains in differentiated PC12 cells.
[0315] FIG. 19 shows the detection of GFP-LC fusion proteins
expressed in differentiated PC12 cells. LCB-GFP is degraded in PC12
cells but not GFP-LCB. Expression and integrity of GFP-LCA was also
assessed by probing with polyclonal antibody to LCA.
[0316] FIG. 20 shows Western blots of lysates from cells
transfected with GFP, GFP-LCA, GFP-LCE, and GFP+LCA (each gene
transfected separately, not a fusion construct). Activity of the
light chains was assessed by probing with specific antibodies for
the LCA and LCE cleaved products of SNAP25, and to the N-terminus
of SNAP25 (recognizes both the cleaved and full-length SNAP25). The
data shows that the expressed light chains are active proteases.
Antibodies to SNAP-25.sub.197 and SNAP-25.sub.180 were produced at
Allergan.
Subcellular localization of light chains in PC12 cells is shown in
FIGS. 21 to 23.
[0317] FIG. 21 shows that GFP-fused light chain A localizes to the
plasma membrane. PC12 cells were transfected with plasmids encoding
GFP and full length GFP-LCA. Images were taken in a confocal
microscope, with the focal plane at the middle of the cell. A clear
localization at the plasma membrane can be observed. LCA-GFP
displayed the same plasma membrane localization pattern.
[0318] FIG. 22 shows that light chain B localizes in the cytoplasm.
PC12 cells were transfected with plasmids encoding LCB-GFP and
GFP-LCB. A different localization pattern was observed dependent on
fusion of GFP to the N- or C-terminus of LCB. The localization
pattern observed for LCB-GFP is likely due to degradation of the
protein. GFP-LCB localizes to the cytoplasm.
[0319] FIG. 23 shows that Light Chain E also localizes primarily in
the cytoplasm. PC12 cells expressing GFP-fusions of LCE do not
extend neurites even in the presence of NGF. PC 12 cells were
transfected with plasmids encoding GFP-LCE and LCE-GFP. The
localization of LCE is cytoplasmic for both fusion proteins.
Despite treatment with NGF, transfected cells were round, with very
few neurites.
[0320] FIG. 24 shows that expressed LCs inhibit exocytosis in PC12
cells. Exocytosis was measured in undifferentiated PC12 cells
expressing GFP, GFP-LCA, GFP-LCB, and GFP-LCE that were selected
for 3 days with G418. Release of .sup.3H-noradrenaline was induced
by incubating the cells with 100 mM K.sup.+ in the presence of
Ca.sup.2+. Inhibition of exocytosis was observed in cells
expressing the light chains. FIG. 24A shows norepinephrine release
by PC12 cells electroporated with PURE A. The Y-axis represents %
norepinephrine release. FIG. 24B shows the percentage of .sup.3H
norepinephrine released by non-differentiated PC12 cells
transfected with various GFP constructs. The Y-axis represents %
norepinephrine release.
[0321] FIG. 25 shows localization of GFP in HeLa and HEK293T cells.
HeLa and HEK293T cells were transfected with a plasmid encoding the
Green Fluorescent Protein (GFP). GFP fluorescence can be detected
throughout the entire cell, including the nuclei (middle of
cell).
[0322] FIGS. 26 and 27 show subcellular localization of GFP light
chain fusions in HeLa cells.
[0323] FIG. 26 shows detection of GFP-LC fusion proteins expressed
in HeLa cells, by probing Western blots with an antibody for GFP.
This was accomplished by immunoprecipitation with a monoclonal
antibody against GFP, followed with Western blot analysis probing
for GFP with a polyclonal antibody In this cell line, LCB-GFP but
not GFP-LCB is degraded, similar to PC12 cells. Expression and
integrity of GFP-LCA was also assessed by probing with a polyclonal
antibody to LCA. [Top: IP GFP(3E2)/WB GFP (PolyAb); Bottom: IP
GFP(3E2)/WB LCA (PolyAb)].
[0324] FIG. 27 shows that localization of GFP-fused Light Chains
expressed in HeLa cells is similar to PC12 Cells. HeLa cells were
transfected with plasmids encoding GFP-LCA, GFP-LCE, GFP-LCB, and
LCB-GFP. The pattern of localization for all Light Chains is
similar to that observed in PC12 cells. Confocal images were
acquired with the focal plane at the middle of the cells.
[0325] FIGS. 28 and 29 show subcellular localization of GFP light
chain fusions in HEK293T cells. FIG. 28 shows the detection of
GFP-LC fusion proteins expressed in HEK 293T cells. The fusion
proteins were immunoprecipitated with a monoclonal antibody for GFP
and the Western blots were probed with a polyclonal antibody for
GFP. IP: GFP(3E2)/WB: GFP (PolyAb) The Western blot analysis
revealed that all GFP-LC fusion proteins are being degraded in
HEK293T cells.
[0326] FIG. 29 shows localization of the GFP fusion proteins in
HEK293T cells transfected with plasmids encoding GFP-LCA, GFP-LCE,
GFP-LCB, and LCB-GFP. The pattern of localization for all Light
Chains is mixed with some resemblance to PC12 and HeLa cells but
with accumulation of fluorescence intracellularly. The GFP-LC
fusion proteins seem to accumulate similarly in all cell types when
it is degraded. Western blots revealed that that all GFP-LC fusion
proteins are degraded in HEK293T cells. Accumulation of the fusion
proteins within the cells appears to be indicative of protein
degradation.
[0327] The data shown in FIG. 19-29 demonstrates at least that: the
Light Chain of BoNT serotypes A, B and E displays a different
subcellular localization; GFP-LCA, GFP-LCB, and GFP-LCE fusion
proteins expressed in differentiated PC12 cells display protease
activity and inhibit exocytosis; LCA localizes near the plasma
membrane of PC12 and HeLa cells. Localization in HEK293T cells is
different, probably due to degradation; LCE localizes to the
cytoplasm in PC12 and HeLa cells; LCB-GFP is degraded in all cell
types; GFP-LCB has a cytoplasmic localization; and localization of
the Light Chains is similar in both neuronal and non-neuronal
exocytic cells (PC12 and HeLa cells, respectively), suggesting that
the signal(s) for subcellular localization are contained within the
Light Chain sequences.
[0328] Localization of the light chains from different serotypes of
botulinum toxin may play a role in the therapeutic profile and
duration of action of the neurotoxins.
Example 18
Botulinum Toxin Light Chain Constructs and Light
Chain-Intracellular Structure Compositions
[0329] Recombinant plasmids have been constructed to yield fusion
proteins containing the green fluorescent protein attached to the
light chain of botulinum neurotoxin (BoNT). These constructs are
designated GFP-LCA, GFP-LCB, and GFP-LCE depending on the serotype
of the constituent light chain. These light chains are
metalloproteases that cleave a specific protein of the SNARE
complex in neuronal cells inhibiting neurotransmitter release.
Specifically, LCA and LCE cleave SNAP-25 and LCB cleaves VAMP2.
[0330] The inventors have shown that the protein product GFP-LCA
localizes to the cytoplasmic side of the plasma membrane when
expressed in PC-12 cells. The basis for membrane localization and
identification of the compartment within the plasma membrane where
the LCA resides was completed by identifying the proteins
interacting with or in close proximity to GFP-LCA.
[0331] The inventors have also determined that the proteins
expressed from the GFP-light chain constructs are active proteases
with the ability to cleave specific SNARE proteins. The inventors
also have demonstrated that these fusion proteins can inhibit
exocytosis when expressed in secretory cell lines containing
SNAP-25 and VAMP-2.
Methods:
[0332] Crosslinking Studies: PC-12 cells were transfected with the
plasmid containing either GFP-LCA (experimental group) or GFP
(control group) and differentiated with neuronal growth factor
(NGF). The cells were treated with a primary amine reactive
crosslinking agent and subsequently lysed using T-X-100. The
protein crosslinking agent, DTBP, is a reducible 11.9 .ANG. chain,
which can be cleaved by strong reducing agents such as DTT. DTBP is
also water-soluble and membrane permeable.
[0333] The GFP-LCA was immunoprecipitated using a monoclonal
antibody to GFP. The goal was to precipitate the GFP-LCA along with
any interacting proteins attached via the cross-linking reagent.
(This method can be used to prepare an isolated composition made up
of a botulinum toxin light chain component and an intracellular
structure component [the interacting proteins]. It is believed that
the intracellular structure component interacts with the light
chain component in a manner effective to facilitate substrate
(SNARE) proteolysis within a cell.) These samples were subjected to
SDS-PAGE under reduced and non-reduced conditions and blotted to
PVDF. The blots were subsequently probed with antibodies specific
for LCA and the SNARE protein SNAP-25. The antibodies used to probe
are listed in the table below.
TABLE-US-00018 Type (polyclonal Antibody Target Source or
monoclonal) LCA Allergan Polyclonal SNAP-25 (recognizes cleaved
AB-CAM Polyclonal and uncleaved)
Results:
[0334] Crosslinking Studies: SNAP-25 immuno-precipitates with
GFP-LCA suggesting these proteins form a complex when GFP-LCA is
expressed in PC-12 cells. The inventors have also found that other
SNARE type proteins immuno-precipitate with this complex when the
cells are treated with a protein cross-linking agent prior to
lysis. The inventors show the total size of the complex containing
GFP-LCA and SNAP-25 using the cross-linking reagent.
[0335] FIG. 30 shows a western blot of GFP immuno-precipitated from
cells transfected with GFP (lane 1) or GFP-LCA (lane 2). The cells
were treated with a crosslinking agent DTBP prior to lysis. The
samples were subjected to SDS-PAGE (4-15% polyacrilamide), blotted
onto a PVDF membrane, and probed with an antibody for LCA. The
samples are analyzed under reduced (FIG. 30A) and non-reduced (FIG.
30B) conditions. The crosslinking agent used in this study remains
uncleaved in the non-reduced conditions. FIG. 30A shows that an 80
kDa protein is immuno-precipitated from PC-12 cells transfected
with GFP-LCA, which correlates with the size of GFP-LCA. FIG. 30B
shows three different protein complexes containing GFP-LCA are
detected in the non-reduced sample with sizes of 110, 140 and 170
kDa. There were no protein bands larger than 170 kDa and nothing
was detected in the wells of the gel. This result indicates sizes
of the cellular complexes that contain GFP-LCA.
[0336] The blot from FIG. 30 was reprobed using a polyclonal
antibody for SNAP-25 (FIG. 31). FIG. 31A shows a 25 kDa protein was
detected in the reduced sample, which corresponds to the size of
SNAP-25. This data confirms that SNAP-25 is immunoprecipitated with
GFP-LCA. FIG. 31B shows the blot of the non-reduced samples, and
the higher molecular weight proteins containing GFP-LCA were also
detected using an antibody for SNAP-25. These data suggests GFP-LCA
is in a complex that contains SNAP-25 when expressed in PC-12
cells.
Example 19
Proteins Expressed From the GFP-Light Chain Constructs Can Inhibit
Exocytosis When Expressed in Secretory Cell Lines
[0337] The inventors have determined that the proteins expressed
from the GFP-light chain constructs are active proteases with the
ability to cleave specific SNARE proteins. In this example, the
inventors also have demonstrated that these fusion proteins can
inhibit exocytosis when expressed in secretory cell lines
containing SNAP-25 and VAMP-2.
Methods:
[0338] Exocytosis Assay Exocytosis was measured using
undifferentiated PC-12 cells exposed to tritium labeled
norepinephrine (noradrenaline--Amersham). The labeled PC-12 cells
were exposed to solutions containing various concentrations of
potassium chloride and calcium chloride. The goal was to depolarize
the PC-12 cells with potassium chloride and induce exocytosis via
vesicle fusion with the plasma membrane with calcium chloride. The
treated cells and the buffer containing the secreted
.sup.3H-noradrenline were collected separately and scintillation
counted. Exocytosis was determined by calculating the percent
norepinephrine released based on the formula below: % label
released=100*(number of dpm in buffer)/(number of dpm in
cell+number of dpm in buffer)
[0339] Exocytosis was also analyzed using HIT-T15 cells, a hamster
pancreatic cell line. This cell line is induced to secrete insulin
when placed in media containing high glucose concentrations.
HIT-T15 cells express SNAP-25 and their ability to secrete insulin
is sensitive to treatment with BoNT-A. Insulin secretion was
measured in HIT-T15 cells by placing the cells in DMEM containing
high glucose (25 mM) or low glucose (5.6 mM). After 1 hour
incubation at 37.degree. C., the secretion media is collected and
the amount of insulin secreted is determined using an insulin ELISA
(APLCO diagnostics). Exocytosis is expressed as the amount of
insulin secreted per 1.times.10.sup.5 cells per hour.
Results:
[0340] Exocytosis Assay: The inventors have demonstrated that the
GFP-light chain construct produce active enzymes capable of
inhibiting exocytosis when expressed in exocytotic cells.
[0341] The primary set of experiments was completed with PC-12
cells. The inventors detected a decrease in exocytosis by PC-12
cells treated with BoNT-A (FIG. 32). The cells were either
untreated (control) or permbealized via electroporation in the
presence or absence of 500 nM PURE A (purified botulinum toxin).
First, analysis of the data reveals the percent norepinephrine
released is significantly higher by PC-12 cells exposed to buffer
containing a high concentration of potassium chloride (100 mM). It
also appears the amount of .sup.3H-norepinephorine secreted is
lower in the PC-12 cells treated with 500 nM PURE A compared with
untreated cells. This is expected as PURE A cleaves SNAP-25 causing
an inhibition of exocytosis. These data confirm that an effect of
BoNT-A treatment on PC-12 cells can be measured using this
assay.
[0342] PC-12 cells are not known to express the receptor necessary
for BoNT-A binding and uptake. This was confirmed as follows.
Exocytosis in PC-12 cells exposed to 500 nM exogenous PURE A was
measured for up to three days. Exocytosis was induced by placing
cells in buffer containing 100 mM potassium chloride with or
without 2.2 mM calcium chloride. Cells placed in buffer containing
2.2 mM calcium chloride released a higher amount of norepinephrine.
These results indicate exocytosis can be induced when PC-12 cells
are placed in a buffer containing a high concentration of potassium
chloride supplemented with calcium chloride. The results in FIG. 33
also show no difference in exocytosis by cells exposed to exogenous
500 nM PURE A and untreated cells. These data confirm reported
results that PC-12 cells do not contain the necessary receptor for
the uptake of exogenous BoNT-A.
[0343] FIG. 34 shows the measurement of exocytosis by PC-12 cells
transfected with plasmids containing the various GFP-light chain
constructs. The cells containing the plasmid were selected by
adding G418 to the growth media for three days. The data from the
exocytosis assay shows the expressed fusion proteins inhibit
.sup.3H-norepinephrine release by PC-12 cells placed in 100 mM KCl
and 2.2 mM CaCl.sub.2. The inventors have shown that the GFP-LCA
and GFP-LCE fusion proteins cleave SNAP-25.sub.206 into
SNAP-25.sub.197 and SNAP-25.sub.180, respectively. These data
suggest the fusion proteins obtained from the expression of the
plasmid constructs are active proteases that can inhibit exocytosis
of PC-12 cells
[0344] A hamster pancreatic cell line, HIT-T15, was also used to
determine if active enzymes are produced by the various GFP-light
chain constructs. This is a non-neuronal cell line that secretes
insulin when placed in media containing high concentrations of
glucose. These cells contain SNAP-25 and their ability to secrete
insulin has been shown to be sensitive to BoNT-A. The inventors
confirmed that these cells secrete insulin in response to glucose,
and this exocytosis is inhibited by BoNT-A. FIG. 35 shows the
insulin secretion by HIT-T15 cells in response to high levels of
glucose. The amount of insulin secreted by these cells is greater
when placed in media containing high concentrations of glucose.
FIG. 35 also shows insulin secretion is inhibited in HIT-T15 cells
electroporated in the presence of 500 nM BoNT-A. The lysates from
the cells treated with BoNT-A were found to contain the cleaved
SNAP-25 produced by BoNT-A when analyzed via Western blots (FIG.
36). These data suggest insulin secretion in HIT-T15 is inhibited
by BoNT-A cleavage of SNAP-25.
[0345] FIG. 37 shows the measurement of insulin released by HIT-T15
cells transfected with plasmids containing the various GFP-light
chain fusion proteins. There was a decrease in the amount of
insulin secreted by cells transfected with the plasmids containing
light chain constructs when compared with untransfected cells and
cells transfected with the plasmid containing GFP. This inhibition
was especially seen when the cells were placed in media containing
high concentrations of glucose. These data provide additional
evidence the constructs produce active forms of the botulinum
neurotoxin light chain.
[0346] While this invention has been described with respect to
various specific examples and embodiments, it is to be understood
that the invention is not limited thereto and that it can be
variously practiced with the scope of the following claims. All
articles, references, publications, and patents set forth above are
incorporated herein by reference in their entireties.
Sequence CWU 1
1
14817PRTClostridium botulinum serotype A 1Phe Glu Phe Tyr Lys Leu
Leu1 527PRTRattus norvegicus 2Glu Glu Lys Arg Ala Ile Leu1
537PRTRattus norvegicus 3Glu Glu Lys Met Ala Ile Leu1 547PRTRattus
norvegicus 4Ser Glu Arg Asp Val Leu Leu1 557PRTRattus norvegicus
5Val Asp Thr Gln Val Leu Leu1 567PRTMus musculus 6Ala Glu Val Gln
Ala Leu Leu1 577PRTXenopus laevis 7Ser Asp Lys Gln Asn Leu Leu1
587PRTGallus gallus 8Ser Asp Arg Gln Asn Leu Ile1 597PRTOvis aries
9Ala Asp Thr Gln Val Leu Met1 5107PRTHomo sapiens 10Ser Asp Lys Asn
Thr Leu Leu1 5117PRTHomo sapiens 11Ser Gln Ile Lys Arg Leu Leu1
5127PRTHomo sapiens 12Ala Asp Thr Gln Ala Leu Leu1
5137PRTSaccharomyces cerevisiae 13Asn Glu Gln Ser Pro Leu Leu1
51412PRTClostridium botulinum serotype A 14Met Pro Phe Val Asn Lys
Gln Phe Asn Tyr Lys Asp1 5 101511PRTClostridium botulinum serotype
A 15Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp1 5
10164PRTClostridium botulinum serotype A 16Met Tyr Lys
Asp1177PRTArtificial SequenceSITE(1)...(7)Consensus sequence for
Leucine-based motif. 17Xaa Asp Xaa Xaa Xaa Leu Leu1
5187PRTArtificial SequenceSITE(1)...(7)Consensus sequence for
Leucine-based motif. 18Xaa Glu Xaa Xaa Xaa Leu Leu1
5197PRTArtificial SequenceSITE(1)...(7)Consensus sequence for
Leucine-based motif. 19Xaa Asp Xaa Xaa Xaa Leu Ile1
5207PRTArtificial SequenceSITE(1)...(7)Consensus sequence for
Leucine-based motif. 20Xaa Asp Xaa Xaa Xaa Leu Met1
5217PRTArtificial SequenceSITE(1)...(7)Consensus sequence for
Leucine-based motif. 21Xaa Glu Xaa Xaa Xaa Leu Ile1
5227PRTArtificial SequenceSITE(1)...(7)Consensus sequence for
Leucine-based motif. 22Xaa Glu Xaa Xaa Xaa Ile Leu1
5237PRTArtificial SequenceSITE(1)...(7)Consensus sequence for
Leucine-based motif. 23Xaa Glu Xaa Xaa Xaa Leu Met1
5244PRTArtificial SequenceSITE(1)...(4)Consensus sequence for
Tyrosine-based motif. 24Tyr Xaa Xaa Xaa12550PRTArtificial
SequencePEPTIDE(1)...(50)Peptide comprising a 6x His tag and S-tag
25Met His His His His His His Ser Ser Gly Leu Val Pro Arg Gly Ser1
5 10 15Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met
Asp 20 25 30Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met Tyr
Lys Asp 35 40 45Pro Val 502614PRTArtificial
SequencePEPTIDE(1)...(14)Peptide comprising a 6x His tag 26Asn Phe
Thr Lys Leu Thr Arg Ala His His His His His His1 5
10278PRTClostridium botulinum serotype A 27Pro Phe Val Asn Lys Gln
Phe Asn1 52822PRTClostridium botulinum sertotype A 28Lys Asn Phe
Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg1 5 10 15Gly Ile
Ile Thr Ser Lys 2029438PRTClostridium botulinum sertotype A 29Met
Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1 5 10
15Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro
20 25 30Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu
Arg 35 40 45Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
Pro Glu 50 55 60Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr
Leu Ser Thr65 70 75 80Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val
Thr Lys Leu Phe Glu 85 90 95Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met
Leu Leu Thr Ser Ile Val 100 105 110Arg Gly Ile Pro Phe Trp Gly Gly
Ser Thr Ile Asp Thr Glu Leu Lys 115 120 125Val Ile Asp Thr Asn Cys
Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140Arg Ser Glu Glu
Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile145 150 155 160Ile
Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170
175Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
180 185 190Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
Leu Leu 195 200 205Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr
Leu Ala His Glu 210 215 220Leu Ile His Ala Gly His Arg Leu Tyr Gly
Ile Ala Ile Asn Pro Asn225 230 235 240Arg Val Phe Lys Val Asn Thr
Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255Glu Val Ser Phe Glu
Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270Phe Ile Asp
Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285Lys
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295
300Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu
Lys305 310 315 320Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser
Val Asp Lys Leu 325 330 335Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr
Glu Ile Tyr Thr Glu Asp 340 345 350Asn Phe Val Lys Phe Phe Lys Val
Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365Phe Asp Lys Ala Val Phe
Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380Thr Ile Tyr Asp
Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn385 390 395 400Phe
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410
415Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
420 425 430Gly Ile Ile Thr Ser Lys 43530441PRTClostridium botulinum
sertotype B 30Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro
Ile Asp Asn1 5 10 15Asn Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg
Gly Thr Gly Arg 20 25 30Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile
Trp Ile Ile Pro Glu 35 40 45Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp
Phe Asn Lys Ser Ser Gly 50 55 60Ile Phe Asn Arg Asp Val Cys Glu Tyr
Tyr Asp Pro Asp Tyr Leu Asn65 70 75 80Thr Asn Asp Lys Lys Asn Ile
Phe Leu Gln Thr Met Ile Lys Leu Phe 85 90 95Asn Arg Ile Lys Ser Lys
Pro Leu Gly Glu Lys Leu Leu Glu Met Ile 100 105 110Ile Asn Gly Ile
Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125Phe Asn
Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn 130 135
140Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile
Ile145 150 155 160Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr
Ile Asp Ile Gly 165 170 175Ile Gln Asn His Phe Ala Ser Arg Glu Gly
Phe Gly Gly Ile Met Gln 180 185 190Met Lys Phe Cys Pro Glu Tyr Val
Ser Val Phe Asn Asn Val Gln Glu 195 200 205Asn Lys Gly Ala Ser Ile
Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220Ala Leu Ile Leu
Met His Glu Leu Ile His Val Leu His Gly Leu Tyr225 230 235 240Gly
Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe 245 250
255Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe
260 265 270Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys
Ser Ile 275 280 285Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val
Asp Arg Leu Asn 290 295 300Lys Val Leu Val Cys Ile Ser Asp Pro Asn
Ile Asn Ile Asn Ile Tyr305 310 315 320Lys Asn Lys Phe Lys Asp Lys
Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335Lys Tyr Ser Ile Asp
Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350Met Phe Gly
Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys 355 360 365Thr
Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys 370 375
380Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn
Ile385 390 395 400Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln
Asn Lys Ala Ile 405 410 415Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys
Glu His Leu Ala Val Tyr 420 425 430Lys Ile Gln Met Cys Lys Ser Val
Lys 435 440314PRTClostridium botulinum serotype
APHOSPHORYLATION(1)...(4)Tyrosine-based motif 31Tyr Ile Lys
Ile1324PRTClostridium botulinum serotype
APHOSPHORYLATION(1)...(4)Tyrosine-based motif 32Tyr Asp Ser
Thr1334PRTClostridium botulinum serotype
APHOSPHORYLATION(1)...(4)Tyrosine-based motif 33Tyr Gly Ser
Thr1344PRTClostridium botulinum serotype
APHOSPHORYLATION(1)...(4)Tyrosine-based motif 34Tyr Asn Lys
Phe1354PRTClostridium botulinum serotype
APHOSPHORYLATION(1)...(4)Tyrosine-based motif 35Tyr Met Lys
Asn1364PRTClostridium botulinum serotype
APHOSPHORYLATION(1)...(4)Tyrosine-based motif 36Tyr Leu Asn
Phe1374PRTClostridium botulinum serotype
APHOSPHORYLATION(1)...(4)Tyrosine-based motif 37Tyr Asp Gly
Phe1384PRTClostridium botulinum serotype
APHOSPHORYLATION(1)...(4)Tyrosine-based motif 38Tyr Lys Leu
Leu13930PRTClostridium botulinum serotype ADOMAIN(1)...(30)Amino
terminal 30 amino acids of light chain 39Met Pro Phe Val Asn Lys
Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1 5 10 15Val Asp Ile Ala Tyr
Ile Lys Ile Pro Asn Ala Gly Gln Met 20 25 304050PRTClostridium
botulinum serotype ADOMAIN(1)...(50)Carboxyl terminal 50 amino
acids of light chain 40Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala
Asn Phe Asn Gly Gln1 5 10 15Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
Lys Leu Lys Asn Phe Thr 20 25 30Gly Leu Phe Glu Phe Tyr Lys Leu Leu
Cys Val Arg Gly Ile Ile Thr 35 40 45Ser Lys 504130PRTClostridium
botulinum serotype BDOMAIN(13)...(30)Amino terminal 30 amino acids
of light chain 41Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp
Pro Ile Asp Asn1 5 10 15Asp Asn Ile Ile Met Met Glu Pro Pro Phe Ala
Arg Gly Thr 20 25 304250PRTClostridium botulinum serotype
BDOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
42Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser Asp Lys Asn Met Gly Lys1
5 10 15Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn Lys Gln Ala Tyr Glu
Glu 20 25 30Ile Ser Lys Glu His Leu Ala Val Tyr Lys Ile Gln Met Cys
Lys Ser 35 40 45Val Lys 504330PRTClostridium botulinum serotype
C1DOMAIN(1)...(30)Amino terminal 30 amino acids of light chain
43Met Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn1
5 10 15Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala 20
25 304450PRTClostridium botulinum serotype
C1DOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
44Asn Ile Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu1
5 10 15Ser Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu
Tyr 20 25 30Leu Phe Thr Lys Phe Cys His Lys Ala Ile Asp Gly Arg Ser
Leu Tyr 35 40 45Asn Lys 504530PRTClostridium botulinum serotype
DDOMAIN(1)...(30)Amino terminal 30 amino acids of light chain 45Met
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp1 5 10
15Asn Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile 20 25
304650PRTClostridium botulinum serotype DDOMAIN(1)...(50)Carboxyl
terminal 50 amino acids of light chain 46Tyr Thr Ile Arg Asp Gly
Phe Asn Leu Thr Asn Lys Gly Phe Asn Ile1 5 10 15Glu Asn Ser Gly Gln
Asn Ile Glu Arg Asn Pro Ala Leu Gln Lys Leu 20 25 30Ser Ser Glu Ser
Val Val Asp Leu Phe Thr Lys Val Cys Leu Arg Leu 35 40 45Thr Lys
504730PRTClostridium botulinum serotype EDOMAIN(1)...(30)Amino
terminal 30 amino acid of light chain 47Met Pro Lys Ile Asn Ser Phe
Asn Tyr Asn Asp Pro Val Asn Asp Arg1 5 10 15Thr Ile Leu Tyr Ile Lys
Pro Gly Gly Cys Gln Glu Phe Tyr 20 25 304850PRTClostridium
botulinum serotype EDOMAIN(1)...(50)Carboxyl terminal 50 amino
acids of light chain 48Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe
Arg Gly Gln Asn Ala1 5 10 15Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile
Thr Gly Arg Gly Leu Val 20 25 30Lys Lys Ile Ile Arg Phe Cys Lys Asn
Ile Val Ser Val Lys Gly Ile 35 40 45Arg Lys 504930PRTClostridium
botulinum serotype FDOMAIN(1)...(30)Amino terminal 30 amino acids
of light chain 49Met Pro Val Ala Ile Asn Ser Phe Asn Tyr Asn Asp
Pro Val Asn Asp1 5 10 15Asp Thr Ile Leu Tyr Met Gln Ile Pro Tyr Glu
Glu Lys Ser 20 25 305050PRTClostridium botulinum serotype
FDOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
50Thr Val Ser Glu Gly Phe Asn Ile Gly Asn Leu Ala Val Asn Asn Arg1
5 10 15Gly Gln Ser Ile Lys Leu Asn Pro Lys Ile Ile Asp Ser Ile Pro
Asp 20 25 30Lys Gly Leu Val Glu Lys Ile Val Lys Phe Cys Lys Ser Val
Ile Pro 35 40 45Arg Lys 505130PRTClostridium botulinum serotype
GDOMAIN(1)...(30)Amino terminal 30 amino acids of light chain 51Met
Pro Val Asn Ile Lys Asn Phe Asn Tyr Asn Asp Pro Ile Asn Asn1 5 10
15Asp Asp Ile Ile Met Met Glu Pro Phe Asn Asp Pro Gly Pro 20 25
305250PRTClostridium botulinum serotype GDOMAIN(1)...(50)Carboxyl
terminal 50 amino acids of light chain 52Gln Asn Glu Gly Phe Asn
Ile Ala Ser Lys Asn Leu Lys Thr Glu Phe1 5 10 15Asn Gly Gln Asn Lys
Ala Val Asn Lys Glu Ala Tyr Glu Glu Ile Ser 20 25 30Leu Glu His Leu
Val Ile Tyr Arg Ile Ala Met Cys Lys Pro Val Met 35 40 45Tyr Lys
505330PRTClostridium botulinum serotype ADOMAIN(1)...(30)Amino
terminal 30 amino acids of light chain 53Met Pro Phe Ala Asn Lys
Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1 5 10 15Val Asp Ile Ala Tyr
Ile Lys Ile Pro Asn Ala Gly Gln Met 20 25 305450PRTClostridium
botulinum serotype ADOMAIN(1)...(50)Carboxyl terminal 50 amino
acids of light chain 54Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala
Asn Phe Asn Gly Gln1 5 10 15Asn Thr Glu Ile Asn Asn Met Asn Arg Thr
Lys Leu Lys Asn Phe Thr 20 25 30Gly Leu Phe Glu Phe Tyr Lys Leu Leu
Cys Val Arg Gly Ile Ile Thr 35 40 45Ser Lys 505530PRTClostridium
botulinum serotype ADOMAIN(1)...(30)Amino terminal 30 amino acids
of light chain 55Met Pro Phe Val Asn Lys Gln Phe Asn Lys Lys Asp
Pro Val Asn Gly1 5 10 15Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala
Gly Gln Met 20 25 305650PRTClostridium botulinum serotype
ADOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
56Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln1
5 10 15Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Ala
Ala 20 25 30Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg Gly Ile
Ile Thr 35 40 45Ser Lys
505730PRTClostridium botulinum serotype ADOMAIN(1)...(30)Amino
terminal 30 amino acids of light chain 57Met Pro Phe Val Asn Lys
Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1 5 10 15Val Asp Ile Ala Arg
Ile Lys Ile Pro Asn Ala Gly Gln Met 20 25 305850PRTClostridium
botulinum serotype ADOMAIN(1)...(50)Carboxyl terminal 50 amino
acids of light chain 58Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala
Asn His Asn Gly Gln1 5 10 15Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
Lys Leu Lys Asn Phe Thr 20 25 30Gly Leu Phe Glu Phe Tyr Lys Leu Leu
Cys Val Arg Gly Ile Ile Thr 35 40 45Ser Lys 505930PRTClostridium
botulinum serotype ADOMAIN(1)...(30)Amino terminal 30 amino acids
of light chain 59Met Pro Phe Val Asn Lys His Phe Asn Tyr Lys Asp
Pro Val Asn Gly1 5 10 15Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala
Gly Gln Met 20 25 306050PRTClostridium botulinum serotype
ADOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
60Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln1
5 10 15Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe
Thr 20 25 30Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Ala Arg Gly Ile
Ile Thr 35 40 45Ser Lys 506130PRTClostridium botulinum serotype
BDOMAIN(1)...(30)Amino terminal 30 amino acids of light chain 61Met
Pro Ala Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn1 5 10
15Asp Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr 20 25
306250PRTClostridium botulinum serotype BDOMAIN(1)...(50)Carboxyl
terminal 50 amino acids of light chain 62Tyr Thr Ile Glu Glu Gly
Phe Asn Ile Ser Asp Lys Asn Met Gly Lys1 5 10 15Glu Tyr Arg Gly Gln
Asn Lys Ala Ile Asn Lys Gln Ala Tyr Glu Glu 20 25 30Ile Ser Lys Glu
His Leu Ala Val Tyr Lys Ile Arg Met Cys Lys Ser 35 40 45Val Lys
506330PRTClostridium botulinum serotype BDOMAIN(1)...(30)Amino
terminal 30 amino acids of light chain 63Met Pro Val Thr Ile Asn
Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn1 5 10 15Asp Asn Ile Ile Ala
Ala Glu Pro Pro Phe Ala Arg Gly Thr 20 25 306450PRTClostridium
botulinum serotype BDOMAIN(1)...(50)Carboxyl terminal 50 amino
acids of light chain 64Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser Asp
Lys Asn Met Gly Lys1 5 10 15Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn
Lys Gln Ala Tyr Glu Glu 20 25 30Ile Ser Lys Glu His Leu Ala Val Arg
Lys Ile Gln Met Cys Lys Ser 35 40 45Val Lys 506530PRTClostridium
botulinum serotype BDOMAIN(1)...(30)Amino terminal 30 amino acids
of light chain 65Met Pro Val Thr Ile Asn Asn Phe Asn Arg Asn Asp
Pro Ile Asp Asn1 5 10 15Asp Asn Ile Ile Met Met Glu Pro Pro Phe Ala
Arg Gly Thr 20 25 306650PRTClostridium botulinum serotype
BDOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
66Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser Asp Lys Asn Met Gly Lys1
5 10 15Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn Lys Gln Ala Lys Glu
Glu 20 25 30Ile Ser Lys Glu His Leu Ala Val Tyr Lys Ile Gln Met Cys
Lys Ser 35 40 45Val Lys 506730PRTClostridium botulinum serotype
C1DOMAIN(1)...(30)Amino terminal 30 amino acids of light chain
67Met Pro Ile Thr Ile Asn Asn Lys Asn Tyr Ser Asp Pro Val Asp Asn1
5 10 15Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala 20
25 306850PRTClostridium botulinum serotype
C1DOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
68Asn Ile Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu1
5 10 15Ser Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu
Tyr 20 25 30Leu Phe Thr Lys Phe Cys His Lys Ala Ile Asp Gly Arg Ser
Leu Arg 35 40 45Asn Lys 506930PRTClostridium botulinum serotype
DDOMAIN(1)...(30)Amino terminal 30 amino acids of light chain 69Met
Thr Trp Pro Ala Lys Asp Phe Asn Tyr Ser Asp Pro Ala Asn Asp1 5 10
15Asn Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile 20 25
307050PRTClostridium botulinum serotype DDOMAIN(1)...(50)Carboxyl
terminal 50 amino acids of light chain 70Tyr Thr Ile Arg Asp Gly
Phe Asn Leu Thr Asn Lys Gly Phe Asn Ile1 5 10 15Glu Asn Ser Gly Gln
Asn Ile Glu Arg Asn Pro Ala Leu Gln Lys Leu 20 25 30Ser Ser Glu Ser
Val Val Asp Leu Phe Thr Lys Ala Cys Leu Arg Leu 35 40 45Thr Lys
507130PRTClostridium botulinum serotype EDOMAIN(1)...(30)Amino
terminal 30 amino acids of light chain 71Met Pro Lys Ile Asn Ser
Phe Asn Tyr Asn Asp Pro Ala Asn Asp Arg1 5 10 15Thr Ile Leu Tyr Ile
Lys Pro Gly Gly Cys Gln Glu Phe Tyr 20 25 307250PRTClostridium
botulinum serotype EDOMAIN(1)...(50)Carboxyl terminal 50 amino
acids of light chain 72Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe
Arg Gly Gln Asn Ala1 5 10 15Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile
Thr Gly Arg Gly His Val 20 25 30Lys Lys Ile Ile Arg Phe Cys Lys Asn
Ile Val Ser Val Lys Gly Ile 35 40 45Arg Lys 507330PRTClostridium
botulinum serotype EDOMAIN(1)...(30)Amino terminal 30 amino acids
of light chain 73Met Pro Lys Ile Asn Ser Arg Asn Tyr Asn Asp Pro
Val Asn Asp Arg1 5 10 15Thr Ile Leu Tyr Ile Lys Pro Gly Gly Cys Gln
Glu Phe Tyr 20 25 307450PRTClostridium botulinum serotype
EDOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
74Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe Arg Gly Gln Asn Ala1
5 10 15Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr Gly Arg Gly Leu
Val 20 25 30Lys Lys Ile Ile Arg Phe Cys Lys Asn Ala Ala Ser Val Lys
Gly Ile 35 40 45Arg Lys 507530PRTClostridium botulinum serotype
EDOMAIN(1)...(30)Amino terminal 30 amino acids of light chain 75Met
Pro Lys Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp Arg1 5 10
15Thr Ile Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu Phe Arg 20 25
307650PRTClostridium botulinum serotype EDOMAIN(1)...(50)Carboxyl
terminal 50 amino acids of light chain 76Gly Tyr Asn Ile Asn Asn
Leu Lys Val Asn Phe Arg Gly Gln Asn Ala1 5 10 15Asn Leu Asn Pro Arg
Ile Ile Thr Pro Ile Thr Gly Arg Gly Leu Val 20 25 30Lys Lys Ile Ile
Arg Phe Cys Lys Asn Ile Val Ser Ala Lys Gly Ile 35 40 45Arg Lys
507730PRTClostridium botulinum serotype FDOMAIN(1)...(30)Amino
terminal 30 amino acids of light chain 77Met Pro Ala Ala Ile Asn
Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp1 5 10 15Asp Thr Ile Leu Tyr
Met Gln Ile Pro Tyr Glu Glu Lys Ser 20 25 307850PRTClostridium
botulinum serotype FDOMAIN(1)...(50)Carboxyl terminal 50 amino
acids of light chain 78Thr Val Ser Glu Gly Phe Asn Ile Gly Asn Leu
Ala Val Asn Asn Arg1 5 10 15Gly Gln Ser Ile Lys Leu Asn Pro Lys Ile
Ile Asp Ser Ile Pro Asp 20 25 30Lys Gly Leu Val Glu Lys Ile Val Lys
Phe Cys Lys Ser Ala Ile Pro 35 40 45Arg Lys 507930PRTClostridium
botulinum serotype GDOMAIN(1)...(30)Amino terminal 30 amino acids
of light chain 79Met Pro Val Asn Ile Lys Asn His Asn Tyr Asn Asp
Pro Ile Asn Asn1 5 10 15Asp Asp Ile Ile Met Met Glu Pro Phe Asn Asp
Pro Gly Pro 20 25 308050PRTClostridium botulinum serotype
GDOMAIN(1)...(50)Carboxyl terminal 50 amino acids of light chain
80Gln Asn Glu Gly Phe Asn Ile Ala Ser Lys Asn Leu Lys Thr Glu Phe1
5 10 15Asn Gly Gln Asn Lys Ala Val Asn Lys Glu Ala Tyr Glu Glu Ile
Ser 20 25 30Leu Glu His Leu Val Ile Tyr Arg Ile Ala Met Cys Lys Pro
Ala Met 35 40 45Tyr Lys 508126PRTClostridium botulinum serotype
AVARIANT(1)...(26)Variant of amino-terminal 30 amino acids of LC
81Met Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1
5 10 15Val Asp Ile Ala Tyr Ile Lys Ile Pro His 20
258243PRTClostridium botulinum serotype AVARIANT(1)...(43)Variant
of carboxyl-terminal 50 amino acids of LC 82Gly Phe Asn Leu Arg Asn
Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln1 5 10 15Asn Thr Glu Ile Asn
Asn Met Asn Ala Ala Ala Ala Ala Ala Ala Ala 20 25 30Ala Ala Cys Val
Arg Gly Ile Ile Thr Ser Lys 35 408326PRTClostridium botulinum
serotype AVARIANT(1)...(26)Variant of amino-terminal 30 amino acids
of LC 83Met Ala Ala Ala Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile
Ala1 5 10 15Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met 20
258448PRTClostridium botulinum serotype AVARIANT(1)...(48)Variant
of carboxyl-terminal 50 amino acids of LC 84Gly Lys Asn Leu Arg Asn
Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln1 5 10 15Asn Thr Glu Ile Asn
Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr 20 25 30Gly Leu Phe Glu
Phe Tyr Lys Cys Val Arg Gly Ile Ile Thr Ser Lys 35 40
458526PRTClostridium botulinum serotype AVARIANT(1)...(26)Variant
of amino-terminal 30 amino acids of LC 85Met Pro Phe Val Asn Lys
Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1 5 10 15Val Asp Ile Ala Arg
Asn Ala Gly Gln Met 20 258646PRTClostridium botulinum serotype
AVARIANT(1)...(46)Variant of carboxyl-terminal 50 amino acids of LC
86Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala His Asn Thr Glu Ile1
5 10 15Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe
Glu 20 25 30Phe Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser Lys
35 40 458726PRTClostridium botulinum serotype
AVARIANT(1)...(26)Variant of amino-terminal 30 amino acids of LC
87Met Pro Lys Val Asn Lys Gln Phe Asn Val Asn Gly Val Asp Ile Ala1
5 10 15Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met 20
258842PRTClostridium botulinum serotype AVARIANT(1)...(42)Variant
of carboxyl-terminal 50 amino acids of LC 88Gly Phe Asn Leu Arg Asn
Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln1 5 10 15Asn Thr Glu Ile Asn
Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr 20 25 30Gly Leu Phe Glu
Phe Arg Arg Thr Ser Lys 35 408930PRTClostridium botulinum serotype
BVARIANT(1)...(30)Variant of amino-terminal 30 amino acids of LC
89Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn1
5 10 15Asp Asn Ile Ile Ala Ala Ala Ala Ala Ala Ala Arg Gly Thr 20
25 309037PRTClostridium botulinum serotype
BVARIANT(1)...(37)Variant of carboxyl-terminal 50 amino acids of LC
90Tyr Thr Ile Pro Pro Gly Phe Asn Ile Ser Asp Lys Asn Met Gly Lys1
5 10 15Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn Lys Gln Ala Tyr Glu
Glu 20 25 30Ile Ser Lys Glu His 359126PRTClostridium botulinum
serotype BVARIANT(1)...(26)Variant of amino-terminal 30 amino acids
of LC 91Met Pro Ala Phe Asn Tyr Asn Asp Pro Ile Asp Asn Asp Asn Ile
Ile1 5 10 15Met Met Glu Pro Pro Phe Ala Arg Gly Thr 20
259250PRTClostridium botulinum serotype BVARIANT(1)...(50)Variant
of carboxyl-terminal 50 amino acids of LC 92Tyr Thr Ile Glu Glu Gly
Phe Asn Ile Ser Asp Lys Asn Met Gly Lys1 5 10 15Glu Tyr Arg Gly Gln
Asn Lys Ala Ala Ala Ala Ala Ala Ala Glu Glu 20 25 30Ile Ser Lys Glu
His Leu Ala Val Tyr Lys Ile Gln Met Cys Lys Ser 35 40 45Val Lys
509320PRTClostridium botulinum serotype BVARIANT(1)...(20)Variant
of amino-terminal 30 amino acids of LC 93Met Pro Val Thr Ile Asn
Asn Phe Asn Arg Met Met Glu Pro Pro Phe1 5 10 15Ala Arg Gly Thr
209444PRTClostridium botulinum serotype BVARIANT(1)...(44)Variant
of carboxyl-terminal 50 amino acids of LC 94Tyr Thr Ile Glu Glu Gly
Phe Asn Ile Ser Asp Lys Asn Met Gly Lys1 5 10 15Glu Tyr Arg Gly Gln
Asn Lys Ala Ile Asn Lys Gln Ala Tyr Ala Ala 20 25 30Ala Ala Ala Ala
Ile Gln Met Cys Lys Ser Val Lys 35 409521PRTClostridium botulinum
serotype C1VARIANT(1)...(21)Variant of amino-terminal 30 amino
acids of LC 95Met Ser Asp Pro Val Asp Asn Lys Asn Ile Leu Tyr Leu
Asp Thr His1 5 10 15Leu Asn Thr Leu Ala 209647PRTClostridium
botulinum serotype C1VARIANT(1)...(47)Variant of carboxyl-terminal
50 amino acids of LC 96Asn Ile Pro Lys Ser Asn Leu Asn Val Leu Phe
Met Gly Gln Asn Leu1 5 10 15Ser Arg Asn Pro Ala Leu Arg Lys Val Asn
Pro Glu Asn Met Leu Ala 20 25 30Ala Ala Cys His Lys Ala Ile Asp Gly
Arg Ser Leu Tyr Asn Lys 35 40 459726PRTClostridium botulinum
serotype DVARIANT(1)...(26)Variant of amino-terminal 30 amino acids
of LC 97Met Thr Arg Pro Val Lys Asp Asp Pro Val Asn Asp Asn Asp Ile
Leu1 5 10 15Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile 20
259844PRTClostridium botulinum serotype DVARIANT(1)...(44)Variant
of carboxyl-terminal 50 amino acids of LC 98Tyr Thr Ile Arg Asp Gly
Phe Asn Leu Thr Asn Lys Gly Phe Asn Ile1 5 10 15Glu Asn Ser Gly Gln
Asn Ile Glu Arg Asn Pro Ala Leu Gln Lys Leu 20 25 30Asp Leu Pro Pro
Lys Val Cys Leu Arg Leu Thr Lys 35 409931PRTClostridium botulinum
serotype EVARIANT(1)...(31)Variant of amino-terminal 30 amino acids
of LC 99Met Pro Lys Ile Asn Ser Pro Pro Asn Tyr Asn Asp Pro Val Asn
Asp1 5 10 15Arg Thr Ile Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu Phe
Tyr 20 25 3010050PRTClostridium botulinum serotype
EVARIANT(1)...(50)Variant of carboxyl-terminal 50 amino acids of LC
100Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe Arg Gly Gln Asn Ala1
5 10 15Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr Gly Arg Gly Leu
Val 20 25 30Lys Lys Ala Ala Ala Ala Cys Lys Asn Ile Val Ser Val Lys
Gly Ile 35 40 45Arg Lys 5010133PRTClostridium botulinum serotype
EVARIANT(1)...(33)Variant of amino-terminal 30 amino acids of LC
101Met Pro Lys Ile Asn Ser Phe Asn Tyr Asn Asp Pro Ala Ala Ala Ala1
5 10 15Asn Asp Arg Thr Ile Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu
Phe 20 25 30Tyr10247PRTClostridium botulinum serotype
EVARIANT(1)...(47)Variant of carboxyl-terminal 50 amino acids of LC
102Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe Arg Gly Gln Asn Ala1
5 10 15Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr Gly Arg Gly Leu
Val 20 25 30His Arg Phe Cys Lys Asn Ile Val Ser Val Lys Gly Ile Arg
Lys 35 40 4510330PRTClostridium botulinum serotype
EVARIANT(1)...(30)Variant of amino-terminal 30 amino acids of LC
103Met Pro Lys Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp Arg1
5 10 15Thr Ile Leu Lys Ile Lys Pro
Gly Gly Cys Lys Glu Phe Tyr 20 25 3010433PRTClostridium botulinum
serotype EVARIANT(1)...(33)Variant of carboxyl-terminal 50 amino
acids of LC 104Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe Arg Gly
Gln Asn Ala1 5 10 15Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr Gly
Arg Gly Leu Pro 20 25 30Pro10524PRTClostridium botulinum serotype
FVARIANT(1)...(24)Variant of amino-terminal 30 amino acids of LC
105Met Pro Asn Tyr Asn Asp Pro Val Asn Asp Asp Thr Ile Leu Tyr Met1
5 10 15Gln Ile Pro Tyr Glu Glu Lys Ser 2010648PRTClostridium
botulinum serotype FVARIANT(1)...(48)Variant of carboxyl-terminal
50 amino acids of LC 106Thr Val Ser Glu Gly Phe Asn Ile Gly Asn Leu
Ala Val Asn Asn Arg1 5 10 15Gly Gln Ser Ile Lys Leu Asn Pro Lys Ile
Ile Asp Ser Ile Pro Asp 20 25 30Lys Gly Ala Ala Ala Ala Ala Ala Cys
Lys Ser Val Ile Pro Arg Lys 35 40 4510726PRTClostridium botulinum
serotype GVARIANT(1)...(26)Variant of amino-terminal 30 amino acids
of LC 107Met Pro Val Asn Ile Pro Pro Asp Pro Ile Asn Asn Asp Asp
Ile Ile1 5 10 15Met Met Glu Pro Phe Asn Asp Pro Gly Pro 20
2510835PRTClostridium botulinum serotype GVARIANT(1)...(35)Variant
of carboxyl-terminal 50 amino acids of LC 108Gln Asn Glu Gly Phe
Asn Ile Ala Ser Lys Asn Leu Lys Thr Glu Phe1 5 10 15Asn Gly Gln Asn
Lys Ala Val Asn Lys Glu Ala Tyr Ala Ala Ala Ala 20 25 30Ala Ala Ala
3510922PRTClostridium botulinum serotype AVARIANT(1)...(22)Variant
of amino-terminal 30 amino acids of LC 109Met Tyr Lys Asp Pro Val
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile1 5 10 15Pro Asn Ala Gly Gln
Met 2011039PRTClostridium botulinum serotype
AVARIANT(1)...(39)Variant of carboxyl-terminal 50 amino acids of LC
110Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln1
5 10 15Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe
Thr 20 25 30Gly Leu Phe Glu Phe Tyr Lys 3511124PRTClostridium
botulinum serotype AVARIANT(1)...(24)Variant of amino-terminal 30
amino acids of LC 111Met Pro Phe Val Asn Lys Gln Val Asn Gly Val
Asp Ile Ala Tyr Ile1 5 10 15Lys Ile Pro Asn Ala Gly Gln Met
2011240PRTClostridium botulinum serotype AVARIANT(1)...(40)Variant
of carboxyl-terminal 50 amino acids of LC 112Gly Phe Asn Leu Arg
Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln1 5 10 15Asn Thr Glu Ile
Asn Asn Met Asn Phe Thr Lys Leu Lys Leu Leu Cys 20 25 30Val Arg Gly
Ile Ile Thr Ser Lys 35 4011324PRTClostridium botulinum serotype
AVARIANT(1)...(24)Variant of amino-terminal 30 amino acids of LC
113Met Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Ala Tyr Ile1
5 10 15Lys Ile Pro Asn Ala Gly Gln Met 2011442PRTClostridium
botulinum serotype AVARIANT(1)...(42)Variant of carboxyl-terminal
50 amino acids of LC 114Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala
Asn Phe Asn Gly Gln1 5 10 15Asn Thr Glu Ile Asn Asn Met Asn Gly Leu
Phe Glu Phe Tyr Lys Leu 20 25 30Leu Cys Val Arg Gly Ile Ile Thr Ser
Lys 35 4011520PRTClostridium botulinum serotype
AVARIANT(1)...(20)Variant of amino-terminal 30 amino acids of LC
115Met Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1
5 10 15Val Asp Ile Ala 2011640PRTClostridium botulinum serotype
AVARIANT(1)...(40)Variant of carboxyl-terminal 50 amino acids of LC
116Gly Phe Asn Leu Arg Asn Asn Thr Glu Ile Asn Asn Met Asn Phe Thr1
5 10 15Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu
Cys 20 25 30Val Arg Gly Ile Ile Thr Ser Lys 35
4011723PRTClostridium botulinum serotype BVARIANT(1)...(23)Variant
of amino-terminal 30 amino acids of LC 117Met Pro Val Thr Ile Asn
Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn1 5 10 15Asp Asn Ile Ile Met
Met Glu 2011845PRTClostridium botulinum serotype
BVARIANT(1)...(45)Variant of carboxyl-terminal 50 amino acids of LC
118Tyr Thr Ile Ile Ser Asp Lys Asn Met Gly Lys Glu Tyr Arg Gly Gln1
5 10 15Asn Lys Ala Ile Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu
His 20 25 30Leu Ala Val Tyr Lys Ile Gln Met Cys Lys Ser Val Lys 35
40 4511920PRTClostridium botulinum serotype
BVARIANT(1)...(20)Variant of amino-terminal 30 amino acids of LC
119Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Glu Pro Pro Phe1
5 10 15Ala Arg Gly Thr 2012042PRTClostridium botulinum serotype
BVARIANT(1)...(42)Variant of carboxyl-terminal 50 amino acids of LC
120Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser Asp Gly Gln Asn Lys Ala1
5 10 15Ile Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala
Val 20 25 30Tyr Lys Ile Gln Met Cys Lys Ser Val Lys 35
4012122PRTClostridium botulinum serotype BVARIANT(1)...(22)Variant
of amino-terminal 30 amino acids of LC 121Met Pro Asn Asp Pro Ile
Asp Asn Asp Asn Ile Ile Met Met Glu Pro1 5 10 15Pro Phe Ala Arg Gly
Thr 2012238PRTClostridium botulinum serotype
BVARIANT(1)...(38)Variant of carboxyl-terminal 50 amino acids of LC
122Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser Asp Lys Asn Met Gly Lys1
5 10 15Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn Lys Gln Ala Lys Ile
Gln 20 25 30Met Cys Lys Ser Val Lys 3512323PRTClostridium botulinum
serotype C1VARIANT(1)...(23)Variant of amino-terminal 30 amino
acids of LC 123Met Pro Ile Ser Asp Pro Val Asp Asn Lys Asn Ile Leu
Tyr Leu Asp1 5 10 15Thr His Leu Asn Thr Leu Ala
2012440PRTClostridium botulinum serotype C1VARIANT(1)...(40)Variant
of carboxyl-terminal 50 amino acids of LC 124Asn Ile Pro Lys Ser
Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu1 5 10 15Ser Arg Asn Pro
Ala Leu Arg Lys Val Lys Phe Cys His Lys Ala Ile 20 25 30Asp Gly Arg
Ser Leu Tyr Asn Lys 35 4012520PRTClostridium botulinum serotype
DVARIANT(1)...(20)Variant of amino-terminal 30 amino acids of LC
125Met Thr Trp Val Asn Asp Asn Asp Ile Leu Tyr Leu Arg Ile Pro Gln1
5 10 15Asn Lys Leu Ile 2012640PRTClostridium botulinum serotype
DVARIANT(1)...(40)Variant of carboxyl-terminal 50 amino acids of LC
126Tyr Thr Ile Arg Asp Gly Phe Asn Leu Thr Asn Lys Gly Phe Asn Ile1
5 10 15Glu Asn Ser Gly Gln Asn Ile Glu Arg Asn Pro Ala Asp Leu Phe
Thr 20 25 30Lys Val Cys Leu Arg Leu Thr Lys 35
4012722PRTClostridium botulinum serotype EVARIANT(1)...(22)Variant
of amino-terminal 30 amino acids of LC 127Met Pro Asp Pro Val Asn
Asp Arg Thr Ile Leu Tyr Ile Lys Pro Gly1 5 10 15Gly Cys Gln Glu Phe
Tyr 2012840PRTClostridium botulinum serotype EVARIANT(1)...(40)
Variant of carboxyl-terminal 50 amino acids of LC 128Gly Tyr Asn
Ile Asn Asn Leu Lys Val Asn Phe Arg Gly Gln Asn Ala1 5 10 15Asn Leu
Asn Pro Arg Ile Ile Thr Pro Ile Arg Phe Cys Lys Asn Ile 20 25 30Val
Ser Val Lys Gly Ile Arg Lys 35 4012920PRTClostridium botulinum
serotype EVARIANT(1)...(20)Variant of amino-terminal 30 amino acids
of LC 129Met Pro Lys Ile Asn Ser Phe Asn Tyr Asn Ile Lys Pro Gly
Gly Cys1 5 10 15Gln Glu Phe Tyr 2013044PRTClostridium botulinum
serotype EVARIANT(1)...(44)Variant of carboxyl-terminal 50 amino
acids of LC 130Gly Tyr Asn Ile Asn Asn Gly Gln Asn Ala Asn Leu Asn
Pro Arg Ile1 5 10 15Ile Thr Pro Ile Thr Gly Arg Gly Leu Val Lys Lys
Ile Ile Arg Phe 20 25 30Cys Lys Asn Ile Val Ser Val Lys Gly Ile Arg
Lys 35 4013122PRTClostridium botulinum serotype
EVARIANT(1)...(22)Variant of amino-terminal 30 amino acids of LC
131Met Pro Lys Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp Arg1
5 10 15Thr Ile Leu Tyr Ile Lys 2013242PRTClostridium botulinum
serotype EVARIANT(1)...(42)Variant of carboxyl-terminal 50 amino
acids of LC 132Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe Arg Gly
Gln Asn Ala1 5 10 15Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr Gly
Arg Gly Leu Val 20 25 30Lys Lys Ile Ile Arg Lys Gly Ile Arg Lys 35
4013325PRTClostridium botulinum serotype FVARIANT(1)...(25)Variant
of amino-terminal 30 amino acids of LC 133Met Pro Val Ala Ile Asn
Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp1 5 10 15Asp Thr Ile Leu Tyr
Met Gln Ile Pro 20 2513442PRTClostridium botulinum serotype
FVARIANT(1)...(42)Variant of carboxyl-terminal 50 amino acids of LC
134Thr Val Ser Glu Gly Phe Asn Ile Gly Asn Leu Ala Val Asn Asn Arg1
5 10 15Gly Gln Ser Ile Lys Leu Asn Pro Lys Ile Ile Asp Ser Ile Pro
Asp 20 25 30Lys Phe Cys Lys Ser Val Ile Pro Arg Lys 35
4013538PRTClostridium botulinum serotype GVARIANT(1)...(38)Variant
of carboxyl-terminal 50 amino acids of LC 135Gln Asn Glu Gly Phe
Asn Ile Ala Ser Lys Asn Leu Lys Thr Glu Phe1 5 10 15Asn Gly Gln Asn
Lys Ala Val Asn Lys Glu Ala Arg Ile Ala Met Cys 20 25 30Lys Pro Val
Met Tyr Lys 35136423PRTArtificial
SequenceDOMAIN(1)...(423)BoNT/A-BoNT/E chimeric LC 136Met Pro Lys
Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp Arg1 5 10 15Thr Ile
Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu Phe Tyr Lys Ser 20 25 30Phe
Asn Ile Met Lys Asn Ile Trp Ile Ile Pro Glu Arg Asn Val Ile 35 40
45Gly Thr Thr Pro Gln Asp Phe His Pro Pro Thr Ser Leu Lys Asn Gly
50 55 60Asp Ser Ser Tyr Tyr Asp Pro Asn Tyr Leu Gln Ser Asp Glu Glu
Lys65 70 75 80Asp Arg Phe Leu Lys Ile Val Thr Lys Ile Phe Asn Arg
Ile Asn Asn 85 90 95Asn Leu Ser Gly Gly Ile Leu Leu Glu Glu Leu Ser
Lys Ala Asn Pro 100 105 110Tyr Leu Gly Asn Asp Asn Thr Pro Asp Asn
Gln Phe His Ile Gly Asp 115 120 125Ala Ser Ala Val Glu Ile Lys Phe
Ser Asn Gly Ser Gln Asp Ile Leu 130 135 140Leu Pro Asn Val Ile Ile
Met Gly Ala Glu Pro Asp Leu Phe Glu Thr145 150 155 160Asn Ser Ser
Asn Ile Ser Leu Arg Asn Asn Tyr Met Pro Ser Asn His 165 170 175Gly
Phe Gly Ser Ile Ala Ile Val Thr Phe Ser Pro Glu Tyr Ser Phe 180 185
190Arg Phe Asn Asp Asn Ser Met Asn Glu Phe Ile Gln Asp Pro Ala Leu
195 200 205Thr Leu Met His Glu Leu Ile His Ser Leu His Gly Leu Tyr
Gly Ala 210 215 220Lys Gly Ile Thr Thr Lys Tyr Thr Ile Thr Gln Lys
Gln Asn Pro Leu225 230 235 240Ile Thr Asn Ile Arg Gly Thr Asn Ile
Glu Glu Phe Leu Thr Phe Gly 245 250 255Gly Thr Asp Leu Asn Ile Ile
Thr Ser Ala Gln Ser Asn Asp Ile Tyr 260 265 270Thr Asn Leu Leu Ala
Asp Tyr Lys Lys Ile Ala Ser Lys Leu Ser Lys 275 280 285Val Gln Val
Ser Asn Pro Leu Leu Asn Pro Tyr Lys Asp Val Phe Glu 290 295 300Ala
Lys Tyr Gly Leu Asp Lys Asp Ala Ser Gly Ile Tyr Ser Val Asn305 310
315 320Ile Asn Lys Phe Asn Asp Ile Phe Lys Lys Leu Tyr Ser Phe Thr
Glu 325 330 335Phe Asp Leu Ala Thr Lys Phe Gln Val Lys Cys Arg Gln
Thr Tyr Ile 340 345 350Gly Gln Tyr Lys Tyr Phe Lys Leu Ser Asn Leu
Leu Asn Asp Ser Ile 355 360 365Tyr Asn Ile Ser Glu Gly Tyr Asn Ile
Asn Asn Leu Lys Val Asn Phe 370 375 380Arg Gly Gln Asn Ala Asn Leu
Asn Pro Arg Ile Ile Thr Pro Ile Thr385 390 395 400Gly Lys Asn Phe
Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val 405 410 415Arg Gly
Ile Ile Thr Ser Lys 420137441PRTArtificial
SequenceDOMAIN(1)...(441)BoNT/A-BoNT/B chimeric LC 137Met Pro Phe
Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1 5 10 15Val Asp
Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gly Arg 20 25 30Tyr
Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu 35 40
45Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly
50 55 60Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu
Asn65 70 75 80Thr Asn Asp Lys Lys Asn Ile Phe Phe Gln Thr Leu Ile
Lys Leu Phe 85 90 95Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu
Leu Glu Met Ile 100 105 110Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg
Arg Val Pro Leu Glu Glu 115 120 125Phe Asn Thr Asn Ile Ala Ser Val
Thr Val Asn Lys Leu Ile Ser Asn 130 135 140Pro Gly Glu Val Glu Arg
Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile145 150 155 160Phe Gly Pro
Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly 165 170 175Ile
Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln 180 185
190Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu
195 200 205Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser
Asp Pro 210 215 220Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu
His Gly Leu Tyr225 230 235 240Gly Ile Lys Val Asp Asp Leu Pro Ile
Val Pro Asn Glu Lys Lys Phe 245 250 255Phe Met Gln Ser Thr Asp Thr
Ile Gln Ala Glu Glu Leu Tyr Thr Phe 260 265 270Gly Gly Gln Asp Pro
Ser Ile Ile Ser Pro Ser Thr Asp Lys Ser Ile 275 280 285Tyr Asp Lys
Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn 290 295 300Lys
Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr305 310
315 320Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu
Gly 325 330 335Lys Tyr Ser Ile Asp Val Glu Ser Phe Asn Lys Leu Tyr
Lys Ser Leu 340 345 350Met Leu Gly Phe Thr Glu Ile Asn Ile Ala Glu
Asn Tyr Lys Ile Lys 355 360 365Thr Arg Ala Ser Tyr Phe Ser Asp Ser
Leu Pro Pro Val Lys Ile Lys 370 375 380Asn Leu Leu Asp Asn Glu Ile
Tyr Thr Ile Glu Glu Gly Phe Asn Ile385 390 395 400Ser Asp Lys Asn
Met Gly Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile 405 410 415Asn Lys
Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr 420 425
430Lys Ile Gln Met Cys Lys Ser Val Lys 435 440138423PRTArtificial
SequenceDOMAIN(1)...(423)BoNT/A-BoNT/E chimeric LC 138Met Pro Phe
Val Asn Lys Gln Phe Asn Asn Asp Pro Val Asn Asp Arg1 5 10 15Thr Ile
Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu Phe Tyr Lys Ser 20 25
30Phe Asn Ile Met Lys Asn Ile Trp Ile Ile Pro Glu Arg Asn Val Ile
35 40 45Gly Thr Thr Pro Gln Asp Phe His Pro Pro Thr Ser Leu Lys Asn
Gly 50 55 60Asp Ser Ser Tyr Tyr Asp Pro Asn Tyr Leu Gln Ser Asp Glu
Glu Lys65 70 75 80Asp Arg Phe Leu Lys Ile Val Thr Lys Ile Phe Asn
Arg Ile Asn Asn 85 90 95Asn Leu Ser Gly Gly Ile Leu Leu Glu Glu Leu
Ser Lys Ala Asn Pro 100 105 110Tyr Leu Gly Asn Asp Asn Thr Pro Asp
Asn Gln Phe His Ile Gly Asp 115 120 125Ala Ser Ala Val Glu Ile Lys
Phe Ser Asn Gly Ser Gln Asp Ile Leu 130 135 140Leu Pro Asn Val Ile
Ile Met Gly Ala Glu Pro Asp Leu Phe Glu Thr145 150 155 160Asn Ser
Ser Asn Ile Ser Leu Arg Asn Asn Tyr Met Pro Ser Asn His 165 170
175Gly Phe Gly Ser Ile Ala Ile Val Thr Phe Ser Pro Glu Tyr Ser Phe
180 185 190Arg Phe Asn Asp Asn Ser Met Asn Glu Phe Ile Gln Asp Pro
Ala Leu 195 200 205Thr Leu Met His Glu Leu Ile His Ser Leu His Gly
Leu Tyr Gly Ala 210 215 220Lys Gly Ile Thr Thr Lys Tyr Thr Ile Thr
Gln Lys Gln Asn Pro Leu225 230 235 240Ile Thr Asn Ile Arg Gly Thr
Asn Ile Glu Glu Phe Leu Thr Phe Gly 245 250 255Gly Thr Asp Leu Asn
Ile Ile Thr Ser Ala Gln Ser Asn Asp Ile Tyr 260 265 270Thr Asn Leu
Leu Ala Asp Tyr Lys Lys Ile Ala Ser Lys Leu Ser Lys 275 280 285Val
Gln Val Ser Asn Pro Leu Leu Asn Pro Tyr Lys Asp Val Phe Glu 290 295
300Ala Lys Tyr Gly Leu Asp Lys Asp Ala Ser Gly Ile Tyr Ser Val
Asn305 310 315 320Ile Asn Lys Phe Asn Asp Ile Phe Lys Lys Leu Tyr
Ser Phe Thr Glu 325 330 335Phe Asp Leu Ala Thr Lys Phe Gln Val Lys
Cys Arg Gln Thr Tyr Ile 340 345 350Gly Gln Tyr Lys Tyr Phe Lys Leu
Ser Asn Leu Leu Asn Asp Ser Ile 355 360 365Tyr Asn Ile Ser Glu Gly
Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe 370 375 380Arg Gly Gln Asn
Ala Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr385 390 395 400Gly
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val 405 410
415Arg Gly Ile Ile Thr Ser Lys 420139441PRTArtificial
SequenceDOMAIN(1)...(441)BoNT/A-BoNT/B chimeric LC 139Met Pro Phe
Val Asn Lys Gln Phe Asn Tyr Asn Asp Pro Ile Asp Asn1 5 10 15Asp Asn
Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30Tyr
Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu 35 40
45Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly
50 55 60Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu
Asn65 70 75 80Thr Asn Asp Lys Lys Asn Ile Phe Phe Gln Thr Leu Ile
Lys Leu Phe 85 90 95Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu
Leu Glu Met Ile 100 105 110Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg
Arg Val Pro Leu Glu Glu 115 120 125Phe Asn Thr Asn Ile Ala Ser Val
Thr Val Asn Lys Leu Ile Ser Asn 130 135 140Pro Gly Glu Val Glu Arg
Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile145 150 155 160Phe Gly Pro
Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly 165 170 175Ile
Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln 180 185
190Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu
195 200 205Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser
Asp Pro 210 215 220Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu
His Gly Leu Tyr225 230 235 240Gly Ile Lys Val Asp Asp Leu Pro Ile
Val Pro Asn Glu Lys Lys Phe 245 250 255Phe Met Gln Ser Thr Asp Thr
Ile Gln Ala Glu Glu Leu Tyr Thr Phe 260 265 270Gly Gly Gln Asp Pro
Ser Ile Ile Ser Pro Ser Thr Asp Lys Ser Ile 275 280 285Tyr Asp Lys
Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn 290 295 300Lys
Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr305 310
315 320Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu
Gly 325 330 335Lys Tyr Ser Ile Asp Val Glu Ser Phe Asn Lys Leu Tyr
Lys Ser Leu 340 345 350Met Leu Gly Phe Thr Glu Ile Asn Ile Ala Glu
Asn Tyr Lys Ile Lys 355 360 365Thr Arg Ala Ser Tyr Phe Ser Asp Ser
Leu Pro Pro Val Lys Ile Lys 370 375 380Asn Leu Leu Asp Asn Glu Ile
Tyr Thr Ile Glu Glu Gly Phe Asn Ile385 390 395 400Ser Asp Lys Asn
Met Gly Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile 405 410 415Asn Lys
Gln Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu 420 425
430Cys Val Arg Gly Ile Ile Thr Ser Lys 435 440140436PRTArtificial
SequenceDOMAIN(1)...(436)BoNT/A-BoNT/F chimeric LC 140Met Pro Phe
Val Asn Lys Gln Phe Asn Tyr Asn Asp Pro Val Asn Asp1 5 10 15Asp Thr
Ile Leu Tyr Met Gln Ile Pro Tyr Glu Glu Lys Ser Lys Lys 20 25 30Tyr
Tyr Lys Ala Phe Glu Ile Met Arg Asn Val Trp Ile Ile Pro Glu 35 40
45Arg Asn Thr Ile Gly Thr Asn Pro Ser Asp Phe Asp Pro Pro Ala Ser
50 55 60Leu Lys Asn Gly Ser Ser Ala Tyr Tyr Asp Pro Asn Tyr Leu Thr
Thr65 70 75 80Asp Ala Glu Lys Asp Arg Tyr Leu Lys Thr Thr Ile Lys
Leu Phe Lys 85 90 95Arg Ile Asn Ser Asn Pro Ala Gly Lys Val Leu Leu
Gln Glu Ile Ser 100 105 110Tyr Ala Lys Pro Tyr Leu Gly Asn Asp His
Thr Pro Ile Asp Glu Phe 115 120 125Ser Pro Val Thr Arg Thr Thr Ser
Val Asn Ile Lys Leu Ser Thr Asn 130 135 140Val Glu Ser Ser Met Leu
Leu Asn Leu Leu Val Leu Gly Ala Gly Pro145 150 155 160Asp Ile Phe
Glu Ser Cys Cys Tyr Pro Val Arg Lys Leu Ile Asp Pro 165 170 175Asp
Val Val Tyr Asp Pro Ser Asn Tyr Gly Phe Gly Ser Ile Asn Ile 180 185
190Val Thr Phe Ser Pro Glu Tyr Glu Tyr Thr Phe Asn Asp Ile Ser Gly
195 200 205Gly His Asn Ser Ser Thr Glu Ser Phe Ile Ala Asp Pro Ala
Ile Ser 210 215 220Leu Ala His Glu Leu Ile His Ala Leu His Gly Leu
Tyr Gly Ala Arg225 230 235 240Gly Val Thr Tyr Glu Glu Thr Ile Glu
Val Lys Gln Ala Pro Leu Met 245 250 255Ile Ala Glu Lys Pro Ile Arg
Leu Glu Glu Phe Leu Thr Phe Gly Gly 260 265 270Gln Asp Leu Asn Ile
Ile Thr Ser Ala Met Lys Glu Lys Ile Tyr Asn 275 280 285Asn Leu Leu
Ala Asn Tyr Glu Lys Ile Ala Thr Arg Leu Ser Glu Val 290 295 300Asn
Ser Ala Pro Pro Glu Tyr Asp Ile Asn Glu Tyr Lys Asp Tyr Phe305 310
315 320Gln Trp Lys Tyr Gly Leu Asp Lys Asn Ala Asp Gly Ser Tyr Thr
Val 325 330 335Asn Glu Asn Lys Phe Asn Glu Ile Tyr Lys Lys Leu Tyr
Ser Phe Thr 340 345 350Glu Ser Asp Leu Ala Asn Lys Phe Lys Val Lys
Cys Arg Asn Thr Tyr 355 360 365Phe Ile Lys Tyr Glu Phe Leu Lys Val
Pro Asn Leu Leu Asp Asp Asp 370 375 380Ile Tyr Thr Val Ser Glu Gly
Phe Asn Ile Gly Asn Leu Ala Val Asn385 390 395 400Asn Arg Gly Gln
Ser Ile Lys Leu Asn Pro Lys Ile Ile Asp Lys Asn 405 410 415Phe Thr
Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg Gly Ile 420 425
430Ile Thr Ser Lys 435141483PRTArtificial
SequenceDOMAIN(1)...(483)BoNT/A-BoNT/B chimeric LC 141Met Pro Phe
Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1 5 10 15Val Asp
Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro 20 25 30Val
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40
45Asp Thr Phe Tyr Asn Asp Pro Ile Asp Asn Asp Asn Ile Ile Met Met
50 55 60Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg Tyr Tyr Lys Ala Phe
Lys65 70 75 80Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu Arg Tyr Thr
Phe Gly Tyr 85 90 95Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly Ile Phe
Asn Arg Asp Val 100 105 110Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn
Thr Asn Asp Lys Lys Asn 115 120 125Ile Phe Phe Gln Thr Leu Ile Lys
Leu Phe Asn Arg Ile Lys Ser Lys 130 135 140Pro Leu Gly Glu Lys Leu
Leu Glu Met Ile Ile Asn Gly Ile Pro Tyr145 150 155 160Leu Gly Asp
Arg Arg Val Pro Leu Glu Glu Phe Asn Thr Asn Ile Ala 165 170 175Ser
Val Thr Val Asn Lys Leu Ile Ser Asn Pro Gly Glu Val Glu Arg 180 185
190Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile Phe Gly Pro Gly Pro Val
195 200 205Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly Ile Gln Asn His
Phe Ala 210 215 220Ser Arg Glu Gly Phe Gly Gly Ile Met Gln Met Lys
Phe Cys Pro Glu225 230 235 240Tyr Val Ser Val Phe Asn Asn Val Gln
Glu Asn Lys Gly Ala Ser Ile 245 250 255Phe Asn Arg Arg Gly Tyr Phe
Ser Asp Pro Ala Leu Ile Leu Met His 260 265 270Glu Leu Ile His Val
Leu His Gly Leu Tyr Gly Ile Lys Val Asp Asp 275 280 285Leu Pro Ile
Val Pro Asn Glu Lys Lys Phe Phe Met Gln Ser Thr Asp 290 295 300Thr
Ile Gln Ala Glu Glu Leu Tyr Thr Phe Gly Gly Gln Asp Pro Ser305 310
315 320Ile Ile Ser Pro Ser Thr Asp Lys Ser Ile Tyr Asp Lys Val Leu
Gln 325 330 335Asn Phe Arg Gly Ile Val Asp Arg Leu Asn Lys Val Leu
Val Cys Ile 340 345 350Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr Lys
Asn Lys Phe Lys Asp 355 360 365Lys Tyr Lys Phe Val Glu Asp Ser Glu
Gly Lys Tyr Ser Ile Asp Val 370 375 380Glu Ser Phe Asn Lys Leu Tyr
Lys Ser Leu Met Leu Gly Phe Thr Glu385 390 395 400Ile Asn Ile Ala
Glu Asn Tyr Lys Ile Lys Thr Arg Ala Ser Tyr Phe 405 410 415Ser Asp
Ser Leu Pro Pro Val Lys Ile Lys Asn Leu Leu Asp Asn Glu 420 425
430Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser Asp Lys Asn Met Gly
435 440 445Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn Lys Gln Ala
Tyr Glu 450 455 460Glu Ile Ser Lys Glu His Leu Ala Val Tyr Lys Ile
Gln Met Cys Lys465 470 475 480Ser Val Lys142458PRTArtificial
SequenceDOMAIN(1)...(458)BoNT/A-BoNT/E chimeric LC 142Met Pro Lys
Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp Arg1 5 10 15Thr Ile
Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu Phe Tyr Lys Ser 20 25 30Phe
Asn Ile Met Lys Asn Ile Trp Ile Ile Pro Glu Arg Asn Val Ile 35 40
45Gly Thr Thr Pro Gln Asp Phe His Pro Pro Thr Ser Leu Lys Asn Gly
50 55 60Asp Ser Ser Tyr Tyr Asp Pro Asn Tyr Leu Gln Ser Asp Glu Glu
Lys65 70 75 80Asp Arg Phe Leu Lys Ile Val Thr Lys Ile Phe Asn Arg
Ile Asn Asn 85 90 95Asn Leu Ser Gly Gly Ile Leu Leu Glu Glu Leu Ser
Lys Ala Asn Pro 100 105 110Tyr Leu Gly Asn Asp Asn Thr Pro Asp Asn
Gln Phe His Ile Gly Asp 115 120 125Ala Ser Ala Val Glu Ile Lys Phe
Ser Asn Gly Ser Gln Asp Ile Leu 130 135 140Leu Pro Asn Val Ile Ile
Met Gly Ala Glu Pro Asp Leu Phe Glu Thr145 150 155 160Asn Ser Ser
Asn Ile Ser Leu Arg Asn Asn Tyr Met Pro Ser Asn His 165 170 175Gly
Phe Gly Ser Ile Ala Ile Val Thr Phe Ser Pro Glu Tyr Ser Phe 180 185
190Arg Phe Asn Asp Asn Ser Met Asn Glu Phe Ile Gln Asp Pro Ala Leu
195 200 205Thr Leu Met His Glu Leu Ile His Ser Leu His Gly Leu Tyr
Gly Ala 210 215 220Lys Gly Ile Thr Thr Lys Tyr Thr Ile Thr Gln Lys
Gln Asn Pro Leu225 230 235 240Ile Thr Asn Ile Arg Gly Thr Asn Ile
Glu Glu Phe Leu Thr Phe Gly 245 250 255Gly Thr Asp Leu Asn Ile Ile
Thr Ser Ala Gln Ser Asn Asp Ile Tyr 260 265 270Thr Asn Leu Leu Ala
Asp Tyr Lys Lys Ile Ala Ser Lys Leu Ser Lys 275 280 285Val Gln Val
Ser Asn Pro Leu Leu Asn Pro Tyr Lys Asp Val Phe Glu 290 295 300Ala
Lys Tyr Gly Leu Asp Lys Asp Ala Ser Gly Ile Tyr Ser Val Asn305 310
315 320Ile Asn Lys Phe Asn Asp Ile Phe Lys Lys Leu Tyr Ser Phe Thr
Glu 325 330 335Phe Asp Leu Ala Thr Lys Phe Gln Val Lys Cys Arg Gln
Thr Tyr Ile 340 345 350Gly Gln Tyr Lys Tyr Phe Lys Leu Ser Asn Leu
Leu Asn Asp Ser Ile 355 360 365Tyr Asn Ile Ser Glu Gly Tyr Asn Ile
Asn Asn Leu Lys Val Asn Phe 370 375 380Arg Gly Gln Asn Ala Asn Leu
Asn Pro Arg Ile Ile Thr Pro Gly Phe385 390 395 400Asn Leu Arg Asn
Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln Asn Thr 405 410 415Glu Ile
Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu 420 425
430Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser Lys
435 440 445Asn Ile Val Ser Val Lys Gly Ile Arg Lys 450
455143443PRTArtificial SequenceDOMAIN(1)...(443)BoNT/A-BoNT/E
chimeric LC 143Met Pro Lys Ile Asn Ser Phe Asn Tyr Met Pro Phe Val
Asn Lys Gln1 5 10 15Phe Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile
Ala Tyr Ile Lys 20 25 30Ile Pro Asn Ala Gly Gln Met Tyr Ile Lys Pro
Gly Gly Cys Gln Glu 35 40 45Phe Tyr Lys Ser Phe Asn Ile Met Lys Asn
Ile Trp Ile Ile Pro Glu 50 55 60Arg Asn Val Ile Gly Thr Thr Pro Gln
Asp Phe His Pro Pro Thr Ser65 70 75 80Leu Lys Asn Gly Asp Ser Ser
Tyr Tyr Asp Pro Asn Tyr Leu Gln Ser 85 90 95Asp Glu Glu Lys Asp Arg
Phe Leu Lys Ile Val Thr Lys Ile Phe Asn 100 105 110Arg Ile Asn Asn
Asn Leu Ser Gly Gly Ile Leu Leu Glu Glu Leu Ser 115 120 125Lys Ala
Asn Pro Tyr Leu Gly Asn Asp Asn Thr Pro Asp Asn Gln Phe 130 135
140His Ile Gly Asp Ala Ser Ala Val Glu Ile Lys Phe Ser Asn Gly
Ser145 150 155 160Gln Asp Ile Leu Leu Pro Asn Val Ile Ile Met Gly
Ala Glu Pro Asp 165 170 175Leu Phe Glu Thr Asn Ser Ser Asn Ile Ser
Leu Arg Asn Asn Tyr Met 180 185 190Pro Ser Asn His Gly Phe Gly Ser
Ile Ala Ile Val Thr Phe Ser Pro 195 200 205Glu Tyr Ser Phe Arg Phe
Asn Asp Asn Ser Met Asn Glu Phe Ile Gln 210
215 220Asp Pro Ala Leu Thr Leu Met His Glu Leu Ile His Ser Leu His
Gly225 230 235 240Leu Tyr Gly Ala Lys Gly Ile Thr Thr Lys Tyr Thr
Ile Thr Gln Lys 245 250 255Gln Asn Pro Leu Ile Thr Asn Ile Arg Gly
Thr Asn Ile Glu Glu Phe 260 265 270Leu Thr Phe Gly Gly Thr Asp Leu
Asn Ile Ile Thr Ser Ala Gln Ser 275 280 285Asn Asp Ile Tyr Thr Asn
Leu Leu Ala Asp Tyr Lys Lys Ile Ala Ser 290 295 300Lys Leu Ser Lys
Val Gln Val Ser Asn Pro Leu Leu Asn Pro Tyr Lys305 310 315 320Asp
Val Phe Glu Ala Lys Tyr Gly Leu Asp Lys Asp Ala Ser Gly Ile 325 330
335Tyr Ser Val Asn Ile Asn Lys Phe Asn Asp Ile Phe Lys Lys Leu Tyr
340 345 350Ser Phe Thr Glu Phe Asp Leu Ala Thr Lys Phe Gln Val Lys
Cys Arg 355 360 365Gln Thr Tyr Ile Gly Gln Tyr Lys Tyr Phe Lys Leu
Ser Asn Leu Leu 370 375 380Asn Asp Ser Ile Tyr Asn Ile Ser Glu Gly
Phe Asn Leu Arg Asn Thr385 390 395 400Asn Leu Ala Ala Asn Phe Asn
Gly Gln Asn Thr Glu Ile Asn Asn Met 405 410 415Asn Phe Thr Lys Leu
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys 420 425 430Leu Leu Cys
Val Arg Gly Ile Ile Thr Ser Lys 435 440144461PRTArtificial
SequenceDOMAIN(1)...(461)BoNT/A-BoNT/B chimeric LC 144Met Pro Val
Thr Ile Asn Asn Phe Asn Met Pro Phe Val Asn Lys Gln1 5 10 15Phe Asn
Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala Tyr Ile Lys 20 25 30Ile
Pro Asn Ala Gly Gln Met Ile Met Met Glu Pro Pro Phe Ala Arg 35 40
45Gly Thr Gly Arg Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp
50 55 60Ile Ile Pro Glu Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe
Asn65 70 75 80Lys Ser Ser Gly Ile Phe Asn Arg Asp Val Cys Glu Tyr
Tyr Asp Pro 85 90 95Asp Tyr Leu Asn Thr Asn Asp Lys Lys Asn Ile Phe
Phe Gln Thr Leu 100 105 110Ile Lys Leu Phe Asn Arg Ile Lys Ser Lys
Pro Leu Gly Glu Lys Leu 115 120 125Leu Glu Met Ile Ile Asn Gly Ile
Pro Tyr Leu Gly Asp Arg Arg Val 130 135 140Pro Leu Glu Glu Phe Asn
Thr Asn Ile Ala Ser Val Thr Val Asn Lys145 150 155 160Leu Ile Ser
Asn Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala 165 170 175Asn
Leu Ile Ile Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr 180 185
190Ile Asp Ile Gly Ile Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly
195 200 205Gly Ile Met Gln Met Lys Phe Cys Pro Glu Tyr Val Ser Val
Phe Asn 210 215 220Asn Val Gln Glu Asn Lys Gly Ala Ser Ile Phe Asn
Arg Arg Gly Tyr225 230 235 240Phe Ser Asp Pro Ala Leu Ile Leu Met
His Glu Leu Ile His Val Leu 245 250 255His Gly Leu Tyr Gly Ile Lys
Val Asp Asp Leu Pro Ile Val Pro Asn 260 265 270Glu Lys Lys Phe Phe
Met Gln Ser Thr Asp Thr Ile Gln Ala Glu Glu 275 280 285Leu Tyr Thr
Phe Gly Gly Gln Asp Pro Ser Ile Ile Ser Pro Ser Thr 290 295 300Asp
Lys Ser Ile Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val305 310
315 320Asp Arg Leu Asn Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile
Asn 325 330 335Ile Asn Ile Tyr Lys Asn Lys Phe Lys Asp Lys Tyr Lys
Phe Val Glu 340 345 350Asp Ser Glu Gly Lys Tyr Ser Ile Asp Val Glu
Ser Phe Asn Lys Leu 355 360 365Tyr Lys Ser Leu Met Leu Gly Phe Thr
Glu Ile Asn Ile Ala Glu Asn 370 375 380Tyr Lys Ile Lys Thr Arg Ala
Ser Tyr Phe Ser Asp Ser Leu Pro Pro385 390 395 400Val Lys Ile Lys
Asn Leu Leu Asp Asn Glu Ile Gly Phe Asn Leu Arg 405 410 415Asn Thr
Asn Leu Ala Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn 420 425
430Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe
435 440 445Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser Lys 450
455 460145456PRTArtificial SequenceDOMAIN(1)...(456)BoNT/A-BoNT/F
chimeric LC 145Met Pro Val Ala Ile Asn Ser Phe Asn Met Pro Phe Val
Asn Lys Gln1 5 10 15Phe Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile
Ala Tyr Ile Lys 20 25 30Ile Pro Asn Ala Gly Gln Met Leu Tyr Met Gln
Ile Pro Tyr Glu Glu 35 40 45Lys Ser Lys Lys Tyr Tyr Lys Ala Phe Glu
Ile Met Arg Asn Val Trp 50 55 60Ile Ile Pro Glu Arg Asn Thr Ile Gly
Thr Asn Pro Ser Asp Phe Asp65 70 75 80Pro Pro Ala Ser Leu Lys Asn
Gly Ser Ser Ala Tyr Tyr Asp Pro Asn 85 90 95Tyr Leu Thr Thr Asp Ala
Glu Lys Asp Arg Tyr Leu Lys Thr Thr Ile 100 105 110Lys Leu Phe Lys
Arg Ile Asn Ser Asn Pro Ala Gly Lys Val Leu Leu 115 120 125Gln Glu
Ile Ser Tyr Ala Lys Pro Tyr Leu Gly Asn Asp His Thr Pro 130 135
140Ile Asp Glu Phe Ser Pro Val Thr Arg Thr Thr Ser Val Asn Ile
Lys145 150 155 160Leu Ser Thr Asn Val Glu Ser Ser Met Leu Leu Asn
Leu Leu Val Leu 165 170 175Gly Ala Gly Pro Asp Ile Phe Glu Ser Cys
Cys Tyr Pro Val Arg Lys 180 185 190Leu Ile Asp Pro Asp Val Val Tyr
Asp Pro Ser Asn Tyr Gly Phe Gly 195 200 205Ser Ile Asn Ile Val Thr
Phe Ser Pro Glu Tyr Glu Tyr Thr Phe Asn 210 215 220Asp Ile Ser Gly
Gly His Asn Ser Ser Thr Glu Ser Phe Ile Ala Asp225 230 235 240Pro
Ala Ile Ser Leu Ala His Glu Leu Ile His Ala Leu His Gly Leu 245 250
255Tyr Gly Ala Arg Gly Val Thr Tyr Glu Glu Thr Ile Glu Val Lys Gln
260 265 270Ala Pro Leu Met Ile Ala Glu Lys Pro Ile Arg Leu Glu Glu
Phe Leu 275 280 285Thr Phe Gly Gly Gln Asp Leu Asn Ile Ile Thr Ser
Ala Met Lys Glu 290 295 300Lys Ile Tyr Asn Asn Leu Leu Ala Asn Tyr
Glu Lys Ile Ala Thr Arg305 310 315 320Leu Ser Glu Val Asn Ser Ala
Pro Pro Glu Tyr Asp Ile Asn Glu Tyr 325 330 335Lys Asp Tyr Phe Gln
Trp Lys Tyr Gly Leu Asp Lys Asn Ala Asp Gly 340 345 350Ser Tyr Thr
Val Asn Glu Asn Lys Phe Asn Glu Ile Tyr Lys Lys Leu 355 360 365Tyr
Ser Phe Thr Glu Ser Asp Leu Ala Asn Lys Phe Lys Val Lys Cys 370 375
380Arg Asn Thr Tyr Phe Ile Lys Tyr Glu Phe Leu Lys Val Pro Asn
Leu385 390 395 400Leu Asp Asp Asp Ile Tyr Gly Phe Asn Leu Arg Asn
Thr Asn Leu Ala 405 410 415Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile
Asn Asn Met Asn Phe Thr 420 425 430Lys Leu Lys Asn Phe Thr Gly Leu
Phe Glu Phe Tyr Lys Leu Leu Cys 435 440 445Val Arg Gly Ile Ile Thr
Ser Lys 450 455146449PRTArtificial
SequenceDOMAIN(1)...(449)BoNT/A-BoNT/E chimeric LC 146Met Pro Lys
Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Thr Ile Asn1 5 10 15Asn Phe
Asn Tyr Asp Arg Thr Ile Leu Tyr Ile Lys Pro Gly Gly Cys 20 25 30Gln
Glu Phe Tyr Lys Ser Phe Asn Ile Met Lys Asn Ile Trp Ile Ile 35 40
45Pro Glu Arg Asn Val Ile Gly Thr Thr Pro Gln Asp Phe His Pro Pro
50 55 60Thr Ser Leu Lys Asn Gly Asp Ser Ser Tyr Tyr Asp Pro Asn Tyr
Leu65 70 75 80Gln Ser Asp Glu Glu Lys Asp Arg Phe Leu Lys Ile Val
Thr Lys Ile 85 90 95Phe Asn Arg Ile Asn Asn Asn Leu Ser Gly Gly Ile
Leu Leu Glu Glu 100 105 110Leu Ser Lys Ala Asn Pro Tyr Leu Gly Asn
Asp Asn Thr Pro Asp Asn 115 120 125Gln Phe His Ile Gly Asp Ala Ser
Ala Val Glu Ile Lys Phe Ser Asn 130 135 140Gly Ser Gln Asp Ile Leu
Leu Pro Asn Val Ile Ile Met Gly Ala Glu145 150 155 160Pro Asp Leu
Phe Glu Thr Asn Ser Ser Asn Ile Ser Leu Arg Asn Asn 165 170 175Tyr
Met Pro Ser Asn His Gly Phe Gly Ser Ile Ala Ile Val Thr Phe 180 185
190Ser Pro Glu Tyr Ser Phe Arg Phe Asn Asp Asn Ser Met Asn Glu Phe
195 200 205Ile Gln Asp Pro Ala Leu Thr Leu Met His Glu Leu Ile His
Ser Leu 210 215 220His Gly Leu Tyr Gly Ala Lys Gly Ile Thr Thr Lys
Tyr Thr Ile Thr225 230 235 240Gln Lys Gln Asn Pro Leu Ile Thr Asn
Ile Arg Gly Thr Asn Ile Glu 245 250 255Glu Phe Leu Thr Phe Gly Gly
Thr Asp Leu Asn Ile Ile Thr Ser Ala 260 265 270Gln Ser Asn Asp Ile
Tyr Thr Asn Leu Leu Ala Asp Tyr Lys Lys Ile 275 280 285Ala Ser Lys
Leu Ser Lys Val Gln Val Ser Asn Pro Leu Leu Asn Pro 290 295 300Tyr
Lys Asp Val Phe Glu Ala Lys Tyr Gly Leu Asp Lys Asp Ala Ser305 310
315 320Gly Ile Tyr Ser Val Asn Ile Asn Lys Phe Asn Asp Ile Phe Lys
Lys 325 330 335Leu Tyr Ser Phe Thr Glu Phe Asp Leu Ala Thr Lys Phe
Gln Val Lys 340 345 350Cys Arg Gln Thr Tyr Ile Gly Gln Tyr Lys Tyr
Phe Lys Leu Ser Asn 355 360 365Leu Leu Asn Asp Ser Ile Tyr Asn Ile
Ser Glu Gly Tyr Asn Ile Asn 370 375 380Asn Leu Lys Val Asn Phe Arg
Gly Gln Asn Ala Asn Leu Asn Pro Arg385 390 395 400Ile Ile Thr Pro
Ile Thr Gly Arg Gly Leu Val Lys Lys Ile Ile Arg 405 410 415Phe Cys
Lys Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly 420 425
430Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser
435 440 445Lys 147459PRTArtificial
SequenceDOMAIN(1)...(459)BoNT/A-BoNT/B-BoNT/F chimeric LC 147Met
Pro Val Ala Ile Asn Ser Phe Asn Tyr Asn Asp Val Thr Ile Asn1 5 10
15Asn Phe Asn Tyr Thr Ile Leu Tyr Met Gln Ile Pro Tyr Glu Glu Lys
20 25 30Ser Lys Lys Tyr Tyr Lys Ala Phe Glu Ile Met Arg Asn Val Trp
Ile 35 40 45Ile Pro Glu Arg Asn Thr Ile Gly Thr Asn Pro Ser Asp Phe
Asp Pro 50 55 60Pro Ala Ser Leu Lys Asn Gly Ser Ser Ala Tyr Tyr Asp
Pro Asn Tyr65 70 75 80Leu Thr Thr Asp Ala Glu Lys Asp Arg Tyr Leu
Lys Thr Thr Ile Lys 85 90 95Leu Phe Lys Arg Ile Asn Ser Asn Pro Ala
Gly Lys Val Leu Leu Gln 100 105 110Glu Ile Ser Tyr Ala Lys Pro Tyr
Leu Gly Asn Asp His Thr Pro Ile 115 120 125Asp Glu Phe Ser Pro Val
Thr Arg Thr Thr Ser Val Asn Ile Lys Leu 130 135 140Ser Thr Asn Val
Glu Ser Ser Met Leu Leu Asn Leu Leu Val Leu Gly145 150 155 160Ala
Gly Pro Asp Ile Phe Glu Ser Cys Cys Tyr Pro Val Arg Lys Leu 165 170
175Ile Asp Pro Asp Val Val Tyr Asp Pro Ser Asn Tyr Gly Phe Gly Ser
180 185 190Ile Asn Ile Val Thr Phe Ser Pro Glu Tyr Glu Tyr Thr Phe
Asn Asp 195 200 205Ile Ser Gly Gly His Asn Ser Ser Thr Glu Ser Phe
Ile Ala Asp Pro 210 215 220Ala Ile Ser Leu Ala His Glu Leu Ile His
Ala Leu His Gly Leu Tyr225 230 235 240Gly Ala Arg Gly Val Thr Tyr
Glu Glu Thr Ile Glu Val Lys Gln Ala 245 250 255Pro Leu Met Ile Ala
Glu Lys Pro Ile Arg Leu Glu Glu Phe Leu Thr 260 265 270Phe Gly Gly
Gln Asp Leu Asn Ile Ile Thr Ser Ala Met Lys Glu Lys 275 280 285Ile
Tyr Asn Asn Leu Leu Ala Asn Tyr Glu Lys Ile Ala Thr Arg Leu 290 295
300Ser Glu Val Asn Ser Ala Pro Pro Glu Tyr Asp Ile Asn Glu Tyr
Lys305 310 315 320Asp Tyr Phe Gln Trp Lys Tyr Gly Leu Asp Lys Asn
Ala Asp Gly Ser 325 330 335Tyr Thr Val Asn Glu Asn Lys Phe Asn Glu
Ile Tyr Lys Lys Leu Tyr 340 345 350Ser Phe Thr Glu Ser Asp Leu Ala
Asn Lys Phe Lys Val Lys Cys Arg 355 360 365Asn Thr Tyr Phe Ile Lys
Tyr Glu Phe Leu Lys Val Pro Asn Leu Leu 370 375 380Asp Asp Asp Ile
Tyr Thr Val Ser Glu Gly Phe Asn Ile Gly Asn Leu385 390 395 400Ala
Val Asn Asn Arg Gly Gln Ser Ile Lys Leu Asn Pro Lys Ile Ile 405 410
415Asp Ser Ile Pro Asp Lys Gly Leu Val Glu Lys Asn Asn Met Asn Phe
420 425 430Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys
Leu Leu 435 440 445Cys Val Arg Gly Ile Ile Thr Ser Lys Arg Lys 450
45514859PRTArtificial SequencePEPTIDE(1)...(59)Peptide comprising a
6x His tag and S-tag 148Met His His His His His His Ser Ser Gly Leu
Val Pro Arg Gly Ser1 5 10 15Gly Met Lys Glu Thr Ala Ala Ala Lys Phe
Glu Arg Gln His Met Asp 20 25 30Ser Pro Asp Leu Gly Thr Asp Asp Asp
Asp Lys Ala Met Gly Ser Phe 35 40 45Val Asn Lys Gln Phe Asn Tyr Lys
Asp Pro Val 50 55
* * * * *